0001193125-23-115560 | S-4 | XBRL Viewer | GE Healthcare Technologies INC

Acquisition and disposition-related benefits (charges)

$ 2,861

$ 3,172

$ 2,981

Restructuring costs

$ (12)

(146)

(155)

(134)

(1)

(15)

(14)

Gain (loss) of business dispositions and divestments

(3)

Spin-Off and separation costs

(58)

(14)

(2)

Amortization of acquisition-related intangible assets

(31)

(33)

(121)

(90)

(83)

Investment revaluation gain (loss)

(8)

(31)

Interest and other financial charges – net

(136)

(4)

(77)

(40)

(66)

Non-operating benefit income (costs)

115

(3)

(5)

Income from continuing operations before income taxes

546

533

2,512

2,875

2,710

Operating Segments [Member]

Segment Reporting, Revenue Reconciling Item [Line Items]

Operating Segments [Member] | Imaging [Member]

664

599

Segment Reporting, Revenue Reconciling Item [Line Items]

Operating Segments [Member] | Ultrasound [Member]

191

206

1,100

1,240

1,182

Segment Reporting, Revenue Reconciling Item [Line Items]

Operating Segments [Member] | PCS [Member]

207

192

908

885

640

Segment Reporting, Revenue Reconciling Item [Line Items]

Operating Segments [Member] | PDx [Member]

109

341

356

698

Segment Reporting, Revenue Reconciling Item [Line Items]

Operating Segments [Member] | Other [Member]

155

138

520

693

504

Segment Reporting, Revenue Reconciling Item [Line Items]

Financial Instruments and Fair Value Measurements Disclosure [Abstract]

$ 2

$ (2)

$ (8)

^[1]

$ (2)

^[1]

$ (43)

^[1]

[1]	Financial information not presented within the reportable segments, shown within the Other category, represents the HFS business and certain other investments which do not meet the definition of an operating segment.

Acquisitions, Goodwill, And Other Intangible Assets - Schedule Of Estimated Intangible Pre-tax Amortization (Detail) $ in Millions	Dec. 31, 2022 USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2023	$ 357
2024	295
2025	248
2026	193
2027	$ 106

Financial Instruments And Fair Value Measurements

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Financial Instruments And Fair Value Measurements

NOTE 12. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

DERIVATIVES AND HEDGING.

Our primary objective in executing and holding derivatives is to reduce the earnings and cash flow volatility associated with fluctuations in foreign currency exchange rates and commodity prices and hedge the volatility associated with the translation of the assets and liabilities of subsidiaries with a different functional currency

than the U.S. Dollar (“USD”). These hedge contracts reduce, but do not entirely eliminate, the impact of foreign currency rate and commodity price movements. The Company does not enter into or hold derivative instruments for speculative trading purposes.

Cash Flow Hedges

The total amount in AOCI related to cash flow hedges of foreign currency-denominated forecasted transactions was a net $30 million loss as of March 31, 2023. We expect to reclassify $27 million of

pre-tax

net deferred losses associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the earnings effects of the related forecasted transactions.

Pre-tax

gains (losses) reclassified from AOCI into earnings were $33 million and $11 million, for the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the maximum length of time over which we are hedging our forecasted transactions was approximately two years.

Net Investment Hedges

As of March 31, 2023 and December 31, 2022, the Company had $2,176 million and $2,132 million notional, respectively, of receive-fixed USD,

pay-fixed

Euro (“EUR”) cross-currency swaps and designated each as the hedging instruments in net investment hedging relationships in order to mitigate the foreign currency risk attributable to the translation of its net investment in certain

EUR-functional

subsidiaries.

The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated:

Fair Value of Derivatives


	March 31, 2023						December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,226	$	25	$	62	$	1,240	$	32	$	53

Derivatives accounted for as cash flow hedges		1,226		25		62		1,240		32		53

Cross-currency swaps		2,176		21		167		2,132		—		111

Derivatives accounted for as net investment hedges		2,176		21		167		2,132		—		111

Foreign currency exchange contracts		4,690		38		22		4,456		9		20
Embedded derivatives		594		19		14		604		24		18
Equity contracts		231		15		3		8		—		6
Commodity derivatives		54		1		3		48		1		1

Derivatives not designated as hedges		5,569		73		42		5,116		34		45

Total derivatives	$	8,971	$	119	$	271	$	8,488	$	66	$	209

Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis on our Condensed Consolidated and Combined Statements of Financial Position and in the table above.

The fair value of the derivatives contracts are recognized within All other current assets, All other assets, All other current liabilities, and All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position based upon the contractual timing of settlements for these contracts.

As of March 31, 2023, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $56 million.

The table below presents the

pre-tax

gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges:

Pre-tax

Gains (Losses) Recognized in OCI Related to Cash flow and Net Investment Hedges


	For the three months ended March 31
	2023			2022
Cash flow hedges	$	(17	)	$	41
Net investment hedges		35			—

The table below presents the gains (losses) of our derivative financial instruments in the Condensed Consolidated and Combined Statements of Income:

Derivative Financial Instruments


	For the three months ended March 31, 2023									For the three months ended March 31, 2022
	Cost of products		Cost of services		Selling, general and administrative		Other (a)			Cost of products			Cost of services		Selling, general and administrative		Other (a)
Foreign currency exchange contracts	$	27	$	6	$	—	$	—		$	9		$	2	$	—	$	—

Effects of cash flow hedges		27		6		—		—			9			2		—		—

Cross-currency swaps		—		—		—		—			—			—		—		—

Effects of net investment hedges		—		—		—		—			—			—		—		—

Foreign currency exchange		7		2		—		1			(1	)		—		—		—
Embedded derivatives		—		—		—		(1	)		—			—		—		3
Equity contracts		—		—		15		3			—			—		—		—
Commodity derivatives		—		—		—		(2	)		—			—		—		10

Effect of derivatives not designated as hedges	$	7	$	2	$	15	$	1		$	(1	)	$	—	$	—	$	13

(a)	Amounts inclusive of Other income (expense) — net on the Condensed Consolidated and Combined Statements of Income.

FAIR VALUE MEASUREMENTS.

The following table represents financial assets and liabilities that are recorded and measured at fair value on a recurring basis:

Fair Value of Financial Assets and Liabilities


	March 31, 2023								December 31, 2022
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Investment securities	$	31	$	—	$	—	$	31	$	21	$	—	$	—	$	21
Derivatives		—		119		—		119		—		66		—		66
Liabilities:
Deferred compensation (a)		264		3		—		267		62		2		—		64
Derivatives		—		268		3		271		—		203		6		209
Contingent consideration		—		—		57		57		—		—		42		42

(a)	Certain deferred compensation plans whose value is derived from market-based securities values were transferred from GE as part of the Spin-Off.

Contingent Consideration

The contingent consideration liabilities as of March 31, 2023 and December 31, 2022 were recorded in connection with business acquisitions. Changes in the Level 3 fair value measurement of contingent consideration were not material during the three months ended March 31, 2023 and 2022.

Fair Value of Other Financial Instruments

The estimated fair value of long-term debt (including the current portion) as of March 31, 2023 and December 31, 2022, was $10,819 million and $8,512 million compared to a carrying value (which includes a reduction for amortized debt issuance costs and discounts) of $10,239 million and $8,241 million, respectively. The fair value of our borrowings is determined based on observable and quoted prices and spreads of identical and comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 8, “Borrowings” for further information.

Non-recurring

Fair Value Measurements

Equity investments without readily determinable fair value as of March 31, 2023 and December 31, 2022, were $119 million and $117 million, respectively.

NOTE 13. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

DERIVATIVES AND HEDGING.

Our primary objective in executing and holding derivatives is to reduce the earnings and cash flow volatility associated with fluctuations in foreign currency exchange rates and commodity prices. These hedge contracts reduce, but do not entirely eliminate, the impact of foreign currency rate and commodity price movements. The Company does not enter into or hold derivative instruments for speculative trading purposes.

We use foreign currency contracts to reduce the volatility of cash flows related to forecasted revenues, expenses, assets, and liabilities, including intercompany balances denominated in foreign currencies. These contracts are generally zero to 27 months in duration but with remaining maturities of up to 23 months as of December 31, 2022. The objective of the foreign currency contracts is to ultimately reduce the extent to which the U.S. dollar-equivalent cash flows are affected by changes in the applicable U.S. dollar/foreign currency exchange rates. We evaluate the effectiveness of our foreign currency contracts designated as cash flow hedges on a quarterly basis.

We use cross-currency swap contracts to reduce the volatility associated with the translation of the assets and liabilities for subsidiaries with a different functional currency than USD. The objective of the cross-currency swap contracts is to ultimately reduce the extent to which the U.S. dollar-equivalent net investments are affected

by changes in the applicable U.S. dollar and/or foreign currency exchange rates. We also use cross-currency swaps synthetically convert certain

USD-denominated

bonds to Euro-denominated bonds and effectively adjust (i.e., reduce) the interest rate from the stated fixed coupon rate on the

USD-denominated

bonds to the fixed coupon rate on the cross-currency swap.

The embedded derivatives the Company recognizes primarily consist of foreign currency-related features in our purchase or sales contracts where the currency is not the functional currency of either party to the contract.

Cash Flow Hedges

For derivative instruments designated as cash flow hedges, changes in the fair value of designated hedging instruments are initially recorded as a component of AOCI and subsequently reclassified to earnings in the period in which the hedged transaction occurs and to the same financial statement line item impacted by the hedged forecasted transaction.

The total amount in AOCI related to cash flow hedges of foreign currency-denominated forecasted transactions was a net $9 million gain as of December 31, 2022. We expect to reclassify $20 million of

pre-tax

net deferred gains associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the earnings effects of the related forecasted transactions.

Pre-tax

gains (losses) reclassified from AOCI into earnings were $67 million, $8 million, and $27 million for the years ended December 31, 2022, 2021, and 2020, respectively. As of December 31, 2022, the maximum length of time over which we are hedging our forecasted transactions was approximately two years.

Net Investment Hedges

As of December 31, 2022, the Company had $2,132 million notional of receive-fixed USD,

pay-fixed

EUR-functional

subsidiaries.

The Company uses the spot method to assess hedge effectiveness for its net investment hedges. As such, for derivative instruments designated as net investment hedges, changes in fair value of the designated hedging instruments attributable to fluctuations in foreign currency spot exchange rates only are initially recorded as a component of the Cumulative Translation Adjustment (“CTA”) portion of Other Comprehensive Income (Loss), Net (“OCI”) until the hedged subsidiary is either sold or substantially liquidated.

The initial value of the excluded components including periodic interest accruals is recognized within Interest and other financial charges – net in the Combined Statements of Income over the life of the hedging instrument. Any difference between the change in fair value of the hedging instrument attributable to the excluded components and the amounts recognized in earnings is recorded as a component of CTA.

Finally, the cash flows for the periodic interest settlements on the cross-currency swaps are recorded in the operating activities section of the Combined Statements of Cash Flows. Notional settlements and settlements from termination of the cross-currency swaps are recorded through the investing activities section of the Combined Statements of Cash Flows, following those of the hedged item (i.e., the hedged net investment).

Non-Designated

Hedges

The Company also executes derivative instruments, such as foreign currency forward contracts and commodity swaps, that are not designated to qualifying hedging relationships under U.S. GAAP. These derivatives are intended to serve as economic hedges of foreign currency and commodity price risk, and depending on the derivative type, hedges of monetary assets and liabilities, including intercompany balances subject to remeasurement.

The changes in fair value of

non-designated

hedges and embedded derivatives are recorded in Other (income) expense – net and Cost of products in the Combined Statements of Income based on the nature of the derivative contract. The cash flows associated with

non-designated

hedges are recorded through the operating and investing activities sections of the Combined Statements of Cash Flows.

The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated:

Gross Fair Value of Outstanding Derivative Instruments


	As of December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,240	$	32	$	53

Derivatives accounted for as cash flow hedges		1,240		32		53

Cross-currency swaps		2,132		—		111

Derivatives accounted for as net investment hedges		2,132		—		111

Foreign currency exchange contracts		4,456		9		20
Embedded derivatives		604		24		18
Equity contracts		8		—		6
Commodity derivatives		48		1		1

Derivatives not designated as hedges		5,116		34		45

Total derivatives	$	8,488	$	66	$	209


	As of December 31, 2021
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	2,463	$	49	$	11

Derivatives accounted for as cash flow hedges		2,463		49		11

Cross-currency swaps		—		—		—

Derivatives accounted for as net investment hedges		—		—		—

Foreign currency exchange contracts		7,510		29		37
Embedded derivatives		789		6		8
Equity contracts		—		—		—
Commodity derivatives		24		3		—

Derivatives not designated as hedges		8,323		38		45

Total derivatives	$	10,786	$	87	$	56

Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis on our Combined Statements of Financial Position and in the table above.

As of December 31, 2022, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $39 million.

The table below presents the

pre-tax

gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges:

Pre-tax

Gains (Losses) Recognized in OCI Related to Cash flow and Net Investment Hedges


	For the years ended December 31
	2022			2021		2020
Cash flow hedges	$	37		$	40	$	(36	)
Net investment hedges		(111	)		—		—

The table below represents the activity in our derivative financial instruments reflected in the Combined Statements of Income:

Derivative Financial Instruments


	2022								2021					2020
	Cost of products			Other (income) expense – net			Interest and other financial charges – net		Cost of products		Other (income) expense – net			Cost of products			Other (income) expense – net
Effects of cash flow hedges (a)	$	(54	)	$	—		$	—	$	8	$	—		$	11		$	—
Effects of net investment hedges (b)		—			—			—		—		—			—			—
Effects of fair value hedges		—			—			—		12		(24	)		(15	)		19
Effect of derivatives not designated as hedges (c)		96			(22	)		—		—		(10	)		—			9

(a)	Cash flow hedges include foreign currency exchange contracts.

(b)	Represents amounts excluded from effectiveness testing for 2022. Net investment hedges include cross-currency swaps.

(c)	Derivatives not designated as hedges include foreign currency exchange contracts, embedded derivatives, equity contracts, and commodity derivatives.

Counterparty Credit Risk

The Company would be exposed to credit-related losses in the event of

non-performance

by counterparties on executed derivative instruments. The credit exposure of derivative contracts is represented by the fair value of contracts as of the reporting date. The fair value of the Company’s derivatives can change significantly from period to period based on, among other factors, market movements, and changes in our positions.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, by limiting the amount of credit exposure to individual counterparties, and by actively monitoring counterparty credit ratings and the amount of individual credit exposure.

We also employ master netting arrangements that limit the risk of counterparty

non-payment

on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

FAIR VALUE MEASUREMENTS.

The following table represents financial assets and liabilities that are recorded and measured at fair value on a recurring basis:


As of December 31	2022								2021
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Derivatives	$	—	$	66	$	—	$	66	$	—	$	87	$	—	$	87
Liabilities:
Derivatives		—		203		6		209		—		56		—		56
Contingent Consideration		—		—		42		42		—		—		112		112

Contingent Consideration

The contingent consideration liabilities as of December 31, 2022 and 2021 were recorded in connection with previous business acquisitions. During the year ended December 31, 2022, we recorded a benefit of $65 million from fair value adjustments related to the remeasurement of contingent consideration liabilities. This benefit is recognized within Selling, general, and administrative in the Combined Statements of Income. Changes in the Level 3 fair value measurement of contingent consideration were not material during the years ended December 31, 2021 or 2020.

Fair Value of Other Financial Instruments

The estimated fair value of long-term debt (including the current portion) as of December 31, 2022, was $8,512 million compared to a carrying value (which includes a reduction for amortized debt issuance costs and discounts) of $8,241 million. The fair value of our borrowings is determined based on observable and quoted prices and spreads of identical and comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 9, “Borrowings” for further information.

Earnings Per Share

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Earnings per share

NOTE 16. EARNINGS PER SHARE

On January 3, 2023, there were approximately 454 million shares of GE HealthCare common stock outstanding, including the 19.9% interest in our outstanding shares of common stock retained by GE following the Distribution. The computation of basic and diluted earnings per common share for all periods through December 31, 2022 was calculated using this same number of common shares outstanding since no GE HealthCare equity awards were outstanding as of the Distribution Date and is net of Net (income) loss attributable to noncontrolling interest which is fully associated with continuing operations.

Earnings Per Share


	For the three months ended March 31
(In millions, except per share amounts)	2023			2022
Numerator:
Net income	$	383		$	402
Net income attributable to noncontrolling interests		(11	)		(13	)

Net income attributable to GE HealthCare		372			389
Deemed preferred stock dividend of redeemable noncontrolling interest		(183	)		—

Net income attributable to GE HealthCare common stockholders	$	189		$	389

Denominator:
Basic weighted-average shares outstanding		454			454
Dilutive effect of common stock equivalents		3			—

Diluted weighted-average shares outstanding		457			454

Basic Earnings Per Share	$	0.42		$	0.86
Diluted Earnings Per Share	$	0.41		$	0.86

Antidilutive securities (a)		4			—

(a)	Diluted EPS excludes certain shares issuable under stock based compensation plans because the effect would have been antidilutive.

Income Taxes

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 10. INCOME TAXES

Our income tax rate was 29.9% and 24.6% for the three months ended March 31, 2023 and 2022, respectively. The tax rate for 2023 is higher than the U.S. statutory rate primarily due to the cost of global activities, including the U.S. taxation on international operations, withholding taxes, and state taxes. The tax rate for 2022 is higher than the U.S. statutory rate primarily due to the cost of global activities, including the U.S. taxation on international operations and state taxes.

The Company is currently being audited in a number of jurisdictions for tax years 2004-2021, including China, Egypt, France, Germany, Norway, the United Kingdom, and the U.S.

In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions from within “Interest and other financial charges — net” to within “Benefit (provision) for income taxes.” See Note 1, “Organization and Basis of Presentation” for further information.

Post

Spin-Off,

the Company’s previously undistributed earnings of certain of our foreign subsidiaries are no longer indefinitely reinvested in

non-U.S.

businesses due to current U.S. funding needs. Therefore, an incremental deferred tax liability of $30 million has been recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings.

Also, in connection with the

Spin-Off,

our net deferred income tax assets increased by $3,099 million primarily due to transfers from GE, including $964

million related to pension and postretirement benefits, with the remainder primarily attributable to tax attributes that were not part of the Company’s stand-alone operations, and changes to valuation on a GE HealthCare basis.

NOTE 11. INCOME TAXES

The provision for income taxes calculations has been prepared on a separate return basis as if the Company were a separate group of companies under common ownership. However, the results have been combined as if the Company were filing on a combined basis for U.S. federal, U.S. state, and

Non-U.S.

income tax purposes, where permissible by law. The Company is subject to income taxes in the U.S. (both federal and state) and in numerous foreign jurisdictions. Changes in the tax laws or regulations in these jurisdictions, or in positions by the relevant authorities regarding their application, administration, or interpretation, may affect our tax liability, return on investments, and business operations.

The Tax Cuts and Jobs Act imposes tax on U.S. shareholders for global intangible

low-taxed

income (“GILTI”) earned by certain

non-U.S.

subsidiaries. The Company has elected to account for GILTI as a period cost.

Income Before Income Taxes


	For the years ended December 31
	2022		2021		2020
U.S. income	$	1,090	$	1,587	$	1,620
Non-U.S. income		1,422		1,288		1,090

Total	$	2,512	$	2,875	$	2,710

Provision for Income Taxes


	For the years ended December 31
	2022			2021			2020
Current
U.S. Federal	$	396		$	141		$	250
Non – U.S.		324			422			463
U.S. State		97			55			65

Deferred
U.S. Federal		(213	)		82			—
Non – U.S.		7			(101	)		(129	)
U.S. State		(48	)		1			3

Total	$	563		$	600		$	652

Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate


	For the years ended December 31
	2022			2021			2020
Income before taxes	$	2,512		$	2,875		$	2,710

Tax expected at 21%		528			604			569
Foreign operations		47			(43	)		42
U.S. tax on foreign operations		(36	)		(23	)		(45	)
Uncertain tax positions		6			11			25
R&D benefits		(33	)		(32	)		(30	)
State taxes, net of federal benefit		39			45			47
Valuation allowance		8			33			37
Other		4			5			7

Provision for income taxes	$	563		$	600		$	652

Actual income tax rate		22.4	%		20.9	%		24.1	%

UNRECOGNIZED TAX BENEFITS.

The Company is subject to periodic tax audits by tax authorities in the U.S. (both federal and state) and the numerous countries in which we operate. In 2021, the Company settled with tax authorities in certain foreign jurisdictions. While the Company currently is being audited in a number of jurisdictions for tax years 2004-2021, including China, Norway, France, Germany, Egypt, the United Kingdom, and the United States, we believe that there are no jurisdictions in which the ultimate outcome of unresolved issues or claims is likely to be material to the results of operations, financial position, or cash flows. We believe that we have made adequate provisions for all unrecognized tax benefits.

UNRECOGNIZED TAX BENEFITS RECONCILIATION.

The balance of unrecognized tax benefits, the amount of related interest and penalties, and what we believe to be the range of reasonably possible changes in the next 12 months are as follows:


	2022			2021			2020
Balance at January 1	$	365		$	684		$	622
Additions for tax positions of the current year		9			9			18
Additions for tax positions of prior years		137			14			78
Reductions for tax positions of prior years		(41	)		(78	)		(17	)
Settlements with tax authorities		(1	)		(262	)		(14	)
Expiration of the statute of limitations		(4	)		(2	)		(3	)

Balance as of December 31	$	465		$	365		$	684

During 2022, $

132

million of unrecognized tax benefits were contributed to the Company by GE which are included in the Combined Statements of Financial Position as of December 31, 2022, and are included in the Additions for tax positions of prior years line in the table above.

Unrecognized Tax Benefits


	For the years ended December 31
	2022		2021		2020
Unrecognized tax benefits	$	465	$	365	$	684
Accrued interest on unrecognized tax benefits		56		53		72
Reasonably possible reduction to the balance of unrecognized tax benefits in succeeding 12 months		45		36		64
Portion that, if recognized, would reduce tax expense and effective tax rate		153		111		99

We classify interest on tax deficiencies as interest expense; we classify income tax penalties as a provision for income taxes. For the years ended December 31, 2022, 2021, and 2020, $12 million, $9 million, and $6 million of Interest and other financial charges – net, respectively, was recognized in the Combined Statements of Income. No accrual for penalties was made in the periods.

DEFERRED INCOME TAXES.

We regularly evaluate the recoverability of our deferred tax assets and establish a valuation allowance, if necessary, to reduce the deferred tax assets to an amount that is more likely than not to be realized (a likelihood of more than 50%). Significant judgment is required in determining whether a valuation allowance is necessary and the amount of such valuation allowance. In assessing the recoverability of our deferred tax assets at December 31, 2022, we considered all available evidence, including the nature of financial statement losses, reversing taxable temporary differences, estimated future operating profits, and tax planning strategies.

Deferred Income Taxes


	As of
	December 31, 2022			December 31, 2021
Total assets	$	1,550		$	1,287
Total liabilities		(370	)		(385	)

Net deferred income tax asset (liability)	$	1,180		$	902

Components of the Net Deferred Income Tax Asset (Liability)


	As of
	December 31, 2022			December 31, 2021
Deferred tax assets:
Employee benefits	$	222		$	255
Contract liabilities		193			186
Inventories		84			83
Operating loss carryforwards		176			138
Other accrued expenses		70			36
Receivables		42			54
Lease liabilities		57			62
Tax credit carryforwards		128			133
Contract assets		99			120
Property, plant, and equipment		338			413
Capitalized R&D		554			307

Total deferred income tax asset		1,963			1,787
Valuation allowances		(272	)		(279	)

Total deferred income tax asset after valuation allowance		1,691			1,508


	As of
	December 31, 2022			December 31, 2021
Deferred tax liabilities:
Goodwill & other intangible assets	$	(458	)	$	(517	)
ROU assets		(47	)		(56	)
Other		(6	)		(33	)

Total deferred income tax liability		(511	)		(606	)

Net deferred income tax asset (liability)	$	1,180		$	902

Effective January 1, 2022, taxpayers are required to capitalize certain R&D expenses and amortize them over five or fifteen years pursuant to the Code. This provision increased our taxable income for the year ended December 31, 2022, and resulted in additional cash payments for U.S. federal and state income taxes. This provision also generated a $293 million deferred tax asset for the year ended December 31, 2022. In the event the capitalization of research costs is adjusted through retroactive legislation effective for 2022, the Company expects to record a reduction to the deferred tax asset resulting in a charge to tax expense under the Tax Matters Agreement with GE.

In connection with the Separation, certain deferred income taxes were contributed to the Company by GE. During 2022, net deferred income taxes of $80 million were contributed to the Company by GE and are recognized within Deferred income taxes in the Combined Statements of Financial Position as of December 31, 2022.

Valuation allowances primarily relate to

non-U.S.

deferred taxes where there were historical losses and U.S. federal and state credit carryforwards. Activity in the valuation allowance for the years ended December 31, 2022, 2021, and 2020 consists of the following:


Balance at January 1, 2020	$	228
Provision for income taxes		43
Foreign currency exchange and other		(21	)

Balance at December 31, 2020	$	250
Provision for income taxes		39
Foreign currency exchange and other		(10	)

Balance at December 31, 2021	$	279
Provision for income taxes		(5	)
Foreign currency exchange and other		(2	)

Balance at December 31, 2022	$	272

Reductions of valuation allowances recorded in individual taxing jurisdictions were not material for the years ended December 31, 2022, 2021, and 2020.

NET OPERATING LOSSES.

As of December 31, 2022, the Company had net operating loss carryforwards of $1,517 million (primarily related to Sweden, Germany, and Brazil, which can be carried forward indefinitely). The gross net operating loss carryforwards resulted in a deferred tax asset of $358 million at December 31, 2022. This amount excludes accruals of $182 million for unrecognized tax benefits the Company has recorded related to the underlying tax positions which generated the net operating losses.

UNDISTRIBUTED EARNINGS.

Substantially all of the undistributed earnings of our foreign subsidiaries are indefinitely reinvested in active

non-U.S.

business operations as there are no current needs to repatriate these earnings to fund ongoing operations by entities other than the subsidiaries generating such undistributed earnings. As of December 31, 2022, the cumulative amount of indefinitely reinvested foreign earnings was approximately $7,999 million. Computation of any deferred tax liability associated with any other remaining basis differences is not currently practicable.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Schedule of Long-Term Borrowings Composition

Receivables - Schedule Of Current Receivables (Detail) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Receivables [Abstract]
Current customer receivables	$ 3,150	$ 3,112	$ 3,028
Non-income based tax receivables	192	174	163
Other sundry receivables	122	100	143
Sundry receivables	314	274	306
Allowance for credit losses	(91)	(91)	(107)
Total receivables – net	$ 3,373	$ 3,295	$ 3,227

Borrowings (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Debt Disclosure [Abstract]

Long-Term Borrowings Composition


	As of
	March 31, 2023		December 31, 2022
5.550% senior notes due November 15, 2024	$	1,000	$	1,000
5.600% senior notes due November 15, 2025		1,500		1,500
5.650% senior notes due November 15, 2027		1,750		1,750
5.857% senior notes due March 15, 2030		1,250		1,250
5.905% senior notes due November 22, 2032		1,750		1,750
6.377% senior notes due November 22, 2052		1,000		1,000
Term Loan Facility		2,000		—
Other		33		38

Total principal debt issued		10,283		8,288

Less: Unamortized debt issuance costs and discounts		44		47
Less: Current portion of long-term borrowings		5		7

Long-term borrowings, net of current portion	$	10,234	$	8,234

Long-Term Borrowings Composition


	As of
	December 31, 2022		December 31, 2021
5.550% senior notes due November 15, 2024	$	1,000	$	—
5.600% senior notes due November 15, 2025		1,500		—
5.650% senior notes due November 15, 2027		1,750		—
5.857% senior notes due March 15, 2030		1,250		—
5.905% senior notes due November 22, 2032		1,750		—
6.377% senior notes due November 22, 2052		1,000		—
Other		38		37

Total principal debt issued		8,288		37

Less: Unamortized debt issuance costs and discounts		47		—
Less: Current portion of long-term borrowings		7		6

Long-term borrowings, net of current portion	$	8,234	$	31

Schedule of Maturities of Long-Term Debt

Scheduled maturities of long-term debt, excluding amortization of discounts and debt issuance costs, are as follows:


2023	$	7
2024		1,025
2025		1,504
2026		2
2027		1,750
Thereafter		4,000

Total	$	8,288

Supplemental Financial Information - Summary of Property, Plant, and Equipment – Net (Parenthetical) (Details) - USD ($)
$ in Millions

Mar. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

ROU operating lease assets

$ 306

$ 313

^[1]

$ 358

^[1]

Equipment leased to customers [Member]

ROU operating lease assets

$ 39

$ 40

[1]	See Note 7, “Leases” for further information.

Postretirement Benefit Plans - Summary of Assumptions (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Weighted-average benefit obligations assumptions
Discount rate	4.26%	1.91%	1.44%
Compensation increases	2.99%	2.81%	2.65%
Weighted-average benefit cost assumptions
Discount rate	1.91%	1.44%	1.80%
Expected rate of return on plan assets	6.32%	5.39%	5.40%

Segment and Geographical Information - Revenue From External Customers By Geographic Areas (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 4,707	$ 4,343	$ 18,341	$ 17,585	$ 17,164
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues			7,819	7,060	7,146
China [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues			2,325	2,510	2,133
Others [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues			$ 8,197	$ 8,015	$ 7,885

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

ESTIMATES AND ASSUMPTIONS.

The preparation of the combined financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the combined financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows.

Estimates are used for, but are not limited to, determining the following: revenue from contracts with customers, recoverability of long-lived assets and inventory, valuation of goodwill and intangible assets, useful lives used in depreciation and amortization, asset retirement obligations, income taxes and related valuation allowances, accruals for contingencies including legal and product warranties, actuarial assumptions used to determine costs of pension and other postretirement benefits, valuation and recoverability of receivables, valuation of derivatives, and valuation of assets acquired, liabilities assumed, and contingent consideration as a result of acquisitions.

While there has not been a material impact to our accounting estimates as of December 31, 2022 and December 31, 2021 and the results for the years ended December 31, 2022, 2021, and 2020, a number of estimates could be affected by the ongoing Coronavirus Disease 2019

(“COVID-19”)

pandemic. The severity, magnitude, and duration, as well as the economic consequences of the

COVID-19

pandemic, are uncertain and difficult to predict. As a result, our accounting estimates and assumptions may change over time in response to

COVID-19.

Such changes could result in future impairments of goodwill, intangible assets, long-lived assets, and investment securities, incremental credit losses on receivables, a decrease in the realizability of our tax assets, or an increase in our related obligations as of the time of a relevant measurement event.

REVENUE RECOGNITION.

Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and

stand-by

preventative maintenance and corrective services, as well as related parts and labor, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services.

The Company recognizes a contract with a customer when there is a legally enforceable agreement between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on the consideration specified in the contract with each customer net of any sales incentives, discounts, returns, chargebacks, group purchasing organization fees, rebates, or credits, as well as taxes collected from customers that are remitted to government authorities. Our estimates for these deductions, which are accounted for as variable consideration, are based on historical experience and consider current and forecasted market trends. We record these estimated amounts as a reduction to revenue when we recognize the related product or service sales. Payment terms are generally within 12 months. Payment terms within 12 months are not treated as significant financing components.

Contracts for the sale of products and services often include multiple distinct performance obligations, usually involving an upfront deliverable of equipment and future performance obligations such as installation, training, or the future delivery of products or services. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative stand-alone selling price. Stand-alone selling price is obtained from sources such as the separate selling price for that or a similar item if reasonably available. If such evidence is not reasonably available, we use our best estimate of selling price, which is established consistent with the pricing strategy of the Company and considers product configuration, geography, customer type, and other market-specific factors.

Revenue is recognized in the period in which the customer obtains control of the underlying products or services, allowing them the ability to direct the use of, and obtain substantially all of, the remaining benefits of such product or service. This may occur at a point in time or over time. Shipping and handling costs to deliver products to customers are expensed as incurred and recognized within Cost of products or Cost of services in our Combined Statements of Income.

For standard, assurance-type warranties that are provided with products, we estimate the cost that may be incurred during the warranty period and record a liability at the time the revenue is recognized. The provision recorded reflects the estimated costs of replacement and

free-of-charge

services that will be incurred related to the products sold. Service-type warranties or extended warranties sold with products are considered separate performance obligations. As such, a portion of the overall transaction price is allocated to these performance obligations and recognized in revenue over time, as the performance obligations are satisfied.

The Company capitalizes certain direct incremental costs incurred to obtain a contract, primarily commissions. Costs to obtain a contract are classified as current or

non-current

assets in the Combined Statements of Financial Position and are recognized based on the timing of when the Company expects to earn related revenues. Management assesses these costs for impairment based on periodic assessments of recoverability.

Performance Obligations Satisfied at a Point in Time

We primarily recognize revenue from sales of products at the point in time that the customer obtains control, which is generally no earlier than when the customer has physical possession. Where arrangements include customer acceptance provisions based on seller- or customer-specified criteria, we recognize revenue when we have concluded that the customer has control of the products, which is typically at the point of acceptance. Our

billing terms for these

point-in-time

product contracts generally coincide with delivery to the customer and customer acceptance; however, periodically, we receive customer advances and deposits from customers. These are recognized as contract liabilities in the Combined Statements of Financial Position. Any differences between the timing of our revenue recognition and customer billings (based on contractual terms) result in changes to our contract asset or contract liability positions.

Performance Obligations Satisfied Over Time

We recognize revenue from the sale of certain service contracts, including preventative maintenance, corrective services, and extended warranties over time on a ratable basis consistent with the nature, timing, and extent of our services, which primarily relate to routine maintenance and

as-needed

product repairs. Our billing terms for these contracts vary and can occur in advance of or following the period of service; however, we generally invoice periodically as services are provided. The differences between the timing of our revenue recognized and customer billings (based on contractual terms) result in changes to our contract asset or contract liability positions.

See Note 3, “Revenue Recognition” for further information.

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH.

The cash presented in the Combined Statements of Financial Position represents cash not subject to the GE centralized cash management process. Cash held in commingled accounts with GE, or its affiliates, is presented within Net parent investment in the Combined Statements of Financial Position. Cash deposits, short-term investments, and high-liquidity mutual funds with original maturities of three months or less are included in Cash, cash equivalents, and restricted cash. Restricted cash primarily relates to funds restricted in connection with escrow accounts and other contractual and legal restrictions.

The following table provides a reconciliation of Cash, cash equivalents, and restricted cash reported within the Combined Statements of Financial Position to the amounts shown in the Combined Statements of Cash Flows.

Cash, Cash Equivalents, and Restricted Cash


	As of
	December 31, 2022		December 31, 2021
Cash and cash equivalents	$	1,440	$	554
Short-term restricted cash		5		2

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Financial Position		1,445		556

Long-term restricted cash (a)		6		5

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Cash Flows	$	1,451	$	561

(a)	Long-term restricted cash is recognized within All other assets in the Combined Statements of Financial Position.

INVESTMENT SECURITIES.

Publicly traded equity securities for which we do not have the ability to exercise significant influence are recorded at fair value with changes in fair value recognized in Other (income) expense – net in the Combined Statements of Income. Privately held equity securities for which we do not have the ability to exercise significant influence are accounted for using the measurement alternative approach and are recorded at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, with changes in the measurement recognized through Other (income) expense – net in the Combined Statements of Income.

EQUITY METHOD INVESTMENTS.

Equity method investments are investments in entities in which we do not have a controlling financial interest, but over which we have significant influence. Equity method investments are assessed for other-than-temporary impairment when events occur or circumstances change that indicate it is more likely than not the fair value of the asset is below its carrying value. Equity method investments are recognized within All other assets in the Combined Statements of Financial Position. Our share of the results of equity method investments is recognized within Other (income) expense – net in the Combined Statements of Income.

See Note 16, “Supplemental Financial Information” for further information.

RECEIVABLES.

Amounts due from customers arising from the sales of products and services are recorded at the outstanding amount, less allowances for credit losses, chargebacks, and other credits. We regularly monitor the recoverability of our receivables. See Note 5, “Receivables” for further information.

FINANCING RECEIVABLES.

Our financing receivables portfolio consists of a variety of loans and leases, including both larger-balance,

non-homogeneous

loans and leases, and smaller-balance homogeneous loans and leases.

Loans

Loans represent term loans that are collateralized by equipment and other assets. Loans are classified as either held for sale or held for investment (“HFI”) based on management’s intent and ability to hold the loans for the foreseeable future. Loans which the Company does not have the ability and intent to hold for investment purposes and those which the Company intends to hold for sale in the foreseeable future are accounted for as loans held for sale. Loans held for sale are recorded at the lower of historical cost or current fair value with any fair value write-down (or change to the write-down) recorded as a valuation allowance through current period earnings in the period in which the change occurs. Loans classified as HFI are recorded at amortized cost.

Investment in Finance Leases

Finance leases include mostly sales-type leases of equipment and represent net unpaid rentals and estimated unguaranteed residual values of leased equipment, less related deferred income and less the allowance for credit losses. See Note 7, “Leases” for further information.

See “Allowance for credit losses” below for the Company’s policy regarding allowances on financing receivables.

Credit Quality Indicators

We manage our financing receivables portfolio using delinquency and nonaccrual data as key performance indicators. We assess the overall quality of the portfolio based on a potential risk of loss measure. The metric incorporates both the borrower’s credit quality along with any related collateral protection. Financing receivables are considered past due if default on a contractual principal or interest payment exists for a period of 30 days or more. We stop accruing interest on financing receivables at the earlier of when collection of an account becomes doubtful or the account becomes 90 days past due. Although we stop accruing interest in advance of payments, we recognize income within Other (income) expense – net in the Combined Statements of Income when we determine that the account is returned to accrual status, provided that the amount does not exceed that which would have been earned at the historical effective interest rate.

See Note 6, “Financing Receivables” for further information.

ALLOWANCE FOR CREDIT LOSSES.

When we record customer receivables, contract assets, and financing receivables, we maintain an allowance for credit losses for the current expected credit losses. Each period, the allowance for credit losses is adjusted through earnings to reflect expected credit losses over the remaining lives of the assets. The credit losses are recognized within Selling, general, and administrative in the Combined Statements of Income. For financing receivables, expected credit losses are calculated based on the gross carrying amount of the financial asset, multiplied by a factor reflecting the probability of default and the loss in the event of default. We routinely evaluate our entire portfolio for potential specific credit or collection issues that might indicate an impairment.

We estimate expected credit losses based on relevant information from past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. When measuring expected credit losses, we pool assets with similar credit risk characteristics. Changes in the relevant information may significantly affect the estimates of expected credit losses.

INVENTORIES.

All inventories are stated at lower of cost or net realizable values. Cost of inventories is determined on a

first-in,

first-out

(“FIFO”) basis.

Consumables and

single-use

service spare parts are used within our service business during a service call and are generally classified in current inventory as our stock of this inventory turns relatively quickly. However, if the

on-hand

inventory quantity exceeds annual historical and expected future consumption for a consumable service spare part and the part is still necessary to support systems under service contracts, the part is considered to be

non-current

and is recognized within All other assets in the Combined Statements of Financial Position.

We also maintain a supply of new and used spare parts for use in future customer field service of the installed base. The portion of this inventory that is not anticipated to be used in the next 12 months has been classified as

non-current

within All other assets, given these parts can be used in the service business over many years. As these service parts age, they are subject to a tiered obsolescence framework, which takes into consideration part age, consumption and

on-hand

material levels, and postproduction equipment life cycle stage.

As necessary, we record provisions and write-downs for excess, slow moving, and obsolete inventory. To determine these amounts, we regularly review inventory quantities on hand and compare them to historical utilization and estimates of future product demand, market conditions, and technological developments.

See Note 16, “Supplemental Financial Information” for further information.

PROPERTY, PLANT, AND EQUIPMENT.

The cost of property, plant, and equipment is depreciated on a straight-line basis over its estimated useful life. Equipment leased to others under operating leases is depreciated on a straight-line basis over the term of the lease. Repair and maintenance costs are expensed as incurred.

See Note 16, “Supplemental Financial Information” for further information.

LEASE ACCOUNTING.

Lessee Arrangements

At lease commencement, we record a lease liability and corresponding

right-of-use

(“ROU”) asset. ROU assets are recognized within Property, plant, and equipment – net and lease liabilities are recognized within All other current liabilities and All other liabilities in the Combined Statements of Financial Position. Options to extend a lease are included as part of the ROU lease asset and liability at commencement when it is reasonably certain the Company will exercise the option. We have elected to combine lease and

non-lease

components in determining our lease liability for all leased assets except our vehicle leases.

Non-lease

components are generally related to services that the lessor performs for the Company associated with the leased asset. As the Company’s leases typically do not provide an implicit rate, the present value of our lease liability is determined using GE’s incremental collateralized borrowing rate at lease commencement. For leases with an initial term of 12 months or less, an ROU asset and lease liability are not recognized, and lease expense is recognized on a straight-line basis over the lease term. Certain of our leases include provisions for variable lease payments which are based on, but not limited to, maintenance, insurance, taxes, index escalations, and usage-based amounts. The Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. We review ROU assets for impairment annually or when events occur or circumstances change that indicate that the asset may be impaired.

Lessor Arrangements

Equipment leased to others under operating leases is recognized within Property, plant, and equipment – net in the Combined Statements of Financial Position. Leases classified as sales-type leases or direct financing leases are recognized within All other current assets and All other assets, respectively, in the Combined Statements of Financial Position. The terms of the related contracts, including the proportion of fixed versus variable payments and any options to shorten or extend the lease term or purchase the underlying asset, vary by customer. Finance lease receivables are tested for impairment as described in the “Financing Receivables” section above.

See Note 6, “Financing Receivables” and Note 7, “Leases” for further information.

GOODWILL AND OTHER INTANGIBLE ASSETS.

Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in a business combination. In accordance with U.S. GAAP, goodwill is not amortized. We test goodwill for impairment at the reporting unit level annually in the fourth quarter of each year using October 1

as the measurement date.

The Company also tests goodwill for impairment when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. The Company uses quantitative assessments and qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company chooses to perform a qualitative assessment and concludes that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a further quantitative fair value test is performed. We recognize an impairment charge if the carrying amount of a reporting unit exceeds its fair value. The market approach is used for estimating the fair values for our reporting

units. Under the market approach, we estimate the fair value based on market multiples of earnings derived from comparable publicly traded companies with operating and investment characteristics similar to the reporting unit. It is reasonably possible that the judgments and estimates used could change in future periods.

In-process

research and development (“IPR&D”) acquired as part of a business acquisition is capitalized at fair value when acquired and is considered an indefinite-lived intangible asset. We test indefinite-lived intangible assets for impairment annually in the third quarter of each year or when events occur or circumstances change that indicate it is more likely than not the fair value of the asset is below its carrying value. When the IPR&D project is complete, the asset is considered a finite-lived intangible asset and would be subject to an impairment test at that date. Thereafter, the IPR&D asset is amortized over its estimated useful life and is subject to impairment assessment in the same manner as all amortizing intangible assets.

For other intangible assets that are not deemed indefinite-lived, the cost of the intangible asset is amortized on a straight-line basis over the asset’s estimated useful life. Amortizable intangible assets are reviewed for impairment when events or changes in circumstances indicate that the related carrying amounts may not be recoverable. In such circumstances, they are tested for impairment based on undiscounted cash flows and, if impaired, written down to estimated fair value based on either discounted cash flows or appraised values.

Internal-Use

Software

Internal-use

software is software that is developed, purchased, or modified to meet internal needs and for which no substantive plan exists to sell, lease, or otherwise market the software externally. All costs associated with project tasks classified in the preliminary project development or post-implementation/operation stage are expensed as incurred. Capitalization of application development stage costs begin after both of the following occur: (a) the preliminary project development stage is completed and (b) management authorizes and commits to funding the software project and it is probable that the project will be completed and the software will be used for the purpose for which it was intended. Capitalization ceases when the project is substantially complete. Capitalized amounts are recognized within Other intangible assets – net in the Combined Statements of Financial Position and are amortized on a straight-line basis over the asset’s estimated useful life.

External Use Software

External use software relates to software that is (a) intended to be sold, licensed, or marketed to our customers or is (b) embedded and integral to our tangible products for which research and development (“R&D”) has been completed. Costs that are related to the conceptual formulation and design of software are expensed as incurred. Costs that are incurred after technological feasibility has been established until general release of the product are capitalized as an intangible asset and recognized within Other intangible assets – net in the Combined Statements of Financial Position. Capitalized costs for software to be sold, leased, or otherwise marketed are amortized on an individual product basis using straight-line amortization over the estimated useful life of the product. The Company performs regular reviews to assess whether unamortized capitalized external use software program costs remain recoverable through future revenue.

See Note 8, “Acquisitions, Goodwill, and Other Intangible Assets” for further information.

DERIVATIVES AND HEDGING.

We use derivatives to reduce the earnings, equity, and cash flow volatility associated with risks related to foreign currency and commodity prices. Our policies are to use derivatives solely for managing risks and not for speculative purposes.

We employ the following hedge types: (i) cash flow hedges of foreign currency risk associated with third-party and/or intercompany foreign-denominated revenues and expenses, (ii) net investment hedges of foreign currency

risk associated with investments in

non-U.S

dollar (“USD”) functional subsidiaries, and (iii) economic hedges, that are not designated as qualifying hedging relationships, of foreign currency and commodity price risk associated with monetary assets and liabilities, including intercompany balances.

In order for a hedging relationship to qualify for hedge accounting treatment, U.S. GAAP requires that, at inception and at each reporting period thereafter, the hedging relationship meets U.S. GAAP hedge accounting requirements. U.S. GAAP mandates, among other requirements, that each hedging relationship is documented appropriately at hedge inception and that hedge effectiveness is assessed at hedge inception and as of each reporting period thereafter. For certain cash flow hedges of foreign currency risk, hedge effectiveness is assessed quantitatively, as of hedge inception and on an ongoing basis thereafter, using regression analysis. For other hedges of foreign currency risk, hedge effectiveness is assessed qualitatively, as of hedge inception and on an ongoing basis thereafter. For quantitative assessments of effectiveness, fair values of both the derivative instrument and the hedged item are calculated using valuation models incorporating market-based assumptions.

See Note 13, “Financial Instruments and Fair Value Measurements” for further information.

INCOME TAXES.

The Company’s income tax provision was prepared using the separate return method. The calculation of income taxes on a separate return basis requires a considerable amount of judgment and use of both estimates and allocations. As a result, actual transactions included in the consolidated financial statements of GE may not be included in these combined financial statements. Similarly, the tax treatment of certain items reflected in the combined financial statements may not be reflected in the consolidated financial statements and tax returns of GE. Therefore, items such as net operating losses, credit carryforwards, and valuation allowances may exist in the stand-alone combined financial statements that may or may not exist in GE’s consolidated financial statements. Beginning in 2023, as a stand-alone entity, GE HealthCare will file tax returns on its own behalf and its deferred taxes and actual income tax rate may differ from those in the historical periods.

All income taxes due to or due from GE that have not been settled or recovered by the end of the period are recognized within Net parent investment in the Combined Statements of Financial Position. Any differences between actual amounts paid or received by the Company and taxes accrued under the separate return method are deemed to be settled and are recognized within Net parent investment in the Combined Statements of Financial Position.

Current obligations for tax in jurisdictions where the Company does not file a consolidated tax return with GE, including certain foreign and certain U.S. state tax jurisdictions, are recorded as accrued liabilities and recognized within All other liabilities in the Combined Statements of Financial Position. The effects of tax adjustments and settlements with taxing authorities are presented in the combined financial statements in the period to which they relate.

Uncertain tax positions that meet the more likely than not recognition threshold are measured to determine the amount of tax benefit to recognize in the combined financial statements. An uncertain tax position is measured at the largest amount of benefit that the Company believes has a greater than 50% likelihood of realization upon settlement. Tax benefits not meeting the measurement or realization criteria represent unrecognized tax benefits. The Company recognizes interest related to income tax matters in Interest and other financial charges – net in the Combined Statements of Income. Penalties related to income tax matters are recognized within Benefit (provision) for income taxes in the Combined Statements of Income. Our policy is to adjust these reserves when facts and circumstances change, such as the actual settlement or effective settlement of positions with the relevant taxing authorities.

Deferred income tax balances reflect the effects of temporary differences between the carrying amounts of assets and liabilities and their respective tax bases, as well as from net operating loss and tax credit carryforwards. The

deferred income tax balances are stated at enacted tax rates expected to be in effect when those taxes are paid or recovered. Deferred income tax assets represent amounts available to reduce income taxes payable on taxable income in future years. We evaluate the recoverability of these future tax deductions and credits by evaluating all available positive and negative evidence, specifically assessing the adequacy of future expected taxable income from all sources, including reversal of existing taxable temporary differences, forecasted operating earnings, and available tax planning strategies. To the extent we consider it more likely than not that a deferred tax asset will not be recovered, a valuation allowance is established. Deferred taxes are provided for our investment in affiliates and associated companies based upon our evaluation of the undistributed earnings of such entities.

See Note 11, “Income Taxes” for further information.

POSTRETIREMENT BENEFIT PLANS.

Certain employees, former employees, and retirees of the Company participate in postretirement benefit plans sponsored by either the Company or GE.

Pension Benefits (Sponsored by the Company)

Management accounts for pension plans sponsored by the Company as defined benefit plans and categorizes plan assets for disclosure purposes in accordance with the fair value hierarchy

Pension benefits are calculated using significant inputs to the actuarial models that measure pension benefit obligations and related effects on operations. Two assumptions, discount rate and expected return on assets, are important elements of plan expense and related asset and liability measurement. The Company evaluates these critical assumptions at least annually on a plan and country-specific basis. The Company periodically evaluates other assumptions involving demographic factors such as retirement age, mortality, and turnover, and updates them to reflect our experience and expectations for the future. Actual results in any given year often will differ from actuarial assumptions because of economic and other factors.

Projected benefit obligations are measured as the present value of expected payments. We discount those cash payments using the weighted average of market-observed yields for high-quality fixed-income securities with maturities that correspond to the expected timing of benefit payment. Generally, lower discount rates increase present values and increase subsequent-year pension expense; higher discount rates decrease present values and decrease subsequent-year pension expense. The components of net periodic benefit costs, other than the service cost component, are recognized within

Non-operating

benefit costs in the Combined Statements of Income for plans sponsored by the Company.

We amortize gains and losses, as well as the effects of changes in actuarial assumptions and plan provisions, that exceed 10% of the greater of plan assets or benefit obligations. The period over which gains and losses are amortized is generally over the average remaining service of employees.

Pension and Other Postretirement Benefit Plans (Sponsored by GE)

Pension and other postretirement benefit plans sponsored by GE are accounted for as multiemployer plans. Therefore, the related assets and liabilities are not reflected in the Combined Statements of Financial Position. The Combined Statements of Income reflect a proportionate allocation of net periodic benefit costs for the multiemployer plans associated with the Company.

See Note 10, “Postretirement Benefit Plans” for further information.

LOSS CONTINGENCIES.

Loss contingencies are uncertain and unresolved matters that arise in the ordinary course of business and result from events that have the potential to result in a future loss. Such contingencies include, but are not limited to, product warranties, claims, litigation, environmental obligations, regulatory investigations and proceedings, product quality, and losses resulting from other events and developments. When a loss is considered probable and reasonably estimable, we record a liability in the amount of our best estimate for the loss. When there appears to be a range of possible losses with equal likelihood, liabilities are based on the low end of such range. Disclosure is provided for material loss contingencies when a loss is probable but a reasonable estimate cannot be made and when it is reasonably possible that a loss will be incurred or the amount of a loss will exceed the recorded provision. We regularly review contingencies to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or range of loss can be made. Legal costs incurred in connection with loss contingencies are expensed as incurred.

See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information.

SUPPLY CHAIN FINANCE PROGRAMS.

The Company participates in voluntary supply chain finance programs with third parties, which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables as borrowings.

TRADE PAYABLES ACCELERATED PAYMENT PROGRAM.

The Company’s U.S. and Canada operations, and certain of its suppliers, participated in the Trade Payables Services (“TPS”) accounts payable programs with GE’s financial services operations (“GE Capital”) through its termination on September 30, 2020. The Company settled its obligations by reimbursing TPS on the invoice’s contractual due date. As the payables in the TPS program relate to operating activities incurred in the ordinary course of business and retain the principal characteristics of a trade payable, the results of this program are included in Cash from operating activities in our Combined Statements of Cash Flows.

FAIR VALUE MEASUREMENTS.

The following sections describe the valuation methodologies we use to measure financial and

non-financial

instruments accounted for at fair value. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. These inputs establish a fair value hierarchy:

•

Level 1 — Quoted prices for identical instruments in active markets.

•

Level 2 — Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.

•

Level 3 — Significant inputs to the valuation model are unobservable.

See Note 13, “Financial Instruments and Fair Value Measurements” for further information.

RECURRING FAIR VALUE MEASUREMENTS.

For financial assets and liabilities measured at fair value on a recurring basis, primarily investment securities, derivatives, and contingent consideration, fair value is the price we would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. In the absence of active markets for the identical assets or liabilities, such measurements involve developing assumptions based on market observable data and, in the absence of such data, internal information that is consistent with what market participants would use in a hypothetical transaction that occurs at the measurement date.

Investment Securities

Publicly traded equity securities are valued using Level 1 quoted price inputs.

Derivatives

The majority of our derivatives are valued using internal models. The models maximize observable inputs including interest rates and both forward and spot prices for currencies and commodities. As of December 31, 2022 and 2021, foreign currency contracts, commodity exchange contracts, and embedded derivatives were valued using Level 2 inputs.

Contingent Consideration

When an acquisition involves a contingent consideration arrangement, we record on the date of acquisition a liability equal to the fair value of the estimated additional consideration we may be obligated to pay in the future. The fair value is based upon estimates of future financial projections under various potential scenarios using a probability-weighted expected payment model discounted to present value. The estimates used to determine the fair value are subject to significant judgement and as such are considered Level 3 inputs. We subsequently remeasure this liability each reporting period and record changes in the fair value within Selling, general, and administrative in the Combined Statements of Income.

There were no transfers between Levels 1, 2, and 3 during the years ended December 31, 2022 and 2021. See Note 13, “Financial Instruments and Fair Value Measurements” for further information.

NON-RECURRING

FAIR VALUE MEASUREMENTS.

Certain assets are measured at fair value on a

non-recurring

basis. These assets may include financing receivables and long-lived assets reduced to fair value upon classification as held for sale and impaired equity method investments and long-lived assets, which, when written down to fair value upon an impairment, are not subsequently adjusted to fair value unless further impairment occurs. The following sections describe the valuation methodologies the Company uses to measure those assets not measured on a recurring fair value basis.

Equity Method Investments

Equity method investments are initially recorded at cost and are adjusted in each period for the Company’s share of the investee’s income or loss and dividends paid. In instances of impairment, equity method investments are written down to fair value using market observable data such as quoted prices when available. When market observable data is unavailable, investments are valued using either a discounted cash flow model, comparative market multiples, third-party pricing sources, or a combination of these approaches, as appropriate. These investments are generally valued using Level 3 inputs.

Equity Investments Without Readily Determinable Fair Value

Equity investments without readily determinable fair value are accounted for under the measurement alternative and adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer. In the instance of impairment, if any, equity investments are adjusted to fair value using market observable data if available. If market observable data is not available, fair values are estimated using discounted cash flow models, comparative market multiples, or a combination of these approaches using Level 3 inputs.

Financing Receivables

We generally use market data, including pricing on recently closed market transactions, to value financing receivables that are held for sale. Such financing receivables are valued using Level 2 inputs. When the data is unobservable, we use valuation methodologies based on current market interest rate data adjusted for inherent credit risk. Such financing receivables are valued using Level 3 inputs.

Long-Lived Assets

Fair values of long-lived assets are primarily developed internally and are corroborated by available external appraisal information, as applicable. These assets are generally valued using Level 3 inputs. See Note 15, “Restructuring and Other Activities” for impairments recognized related to long-lived assets.

FOREIGN CURRENCY.

We have determined that the functional currency for many of our international operations is the local currency, and for other international operations the functional currency is the U.S. dollar. The basis of this determination is the currency in which each of the international operations primarily generates and expends cash. When the functional currency is not the U.S. dollar, asset and liability accounts are translated at

period-end

exchange rates. The Company translates functional currency income and expense amounts to their U.S. dollar equivalents using average exchange rates for the period. These translation gains and losses are recognized within Accumulated other comprehensive income (loss) – net (“AOCI”) in the Combined Statements of Financial Position.

Gains and losses from foreign currency transactions, such as those resulting from the settlement of monetary items in the

non-functional

currency and those resulting from remeasurements of monetary items, are included in Cost of products, Cost of services, Selling, general, and administrative, and Research and development in the Combined Statements of Income, depending on the underlying nature of the item. Net gains (losses) from foreign currency transactions were $(88) million, $130 million, and $(47) million for the years ended December 31, 2022, 2021, and 2020, respectively.

BUSINESS COMBINATIONS.

Our combined financial statements include the operations of acquired businesses from the date of acquisition. The Company accounts for acquired businesses using the acquisition method of accounting in accordance with U.S. GAAP, which requires that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date. When we acquire the remaining equity ownership of a company in which we hold an equity interest, we remeasure our equity interest to fair value. Any excess of the purchase price over the assigned values of the net assets acquired is recorded as Goodwill. Transaction costs are expensed as incurred. For those arrangements that involve potential future contingent consideration, on the date of acquisition we record a liability equal to the fair value of the estimated additional consideration we may be obligated to pay in the future.

See Note 13, “Financial Instruments and Fair Value Measurements” for further information.

DISCONTINUED OPERATIONS.

Certain of our operations have been presented as discontinued. We present businesses whose disposal represents a strategic shift that has, or will have, a major effect on our operations and financial results as discontinued operations when the components meet the criteria for held for sale, are sold, or

spun-off.

Presentation as discontinued operations is consistent for all periods presented.

See Note 18, “Discontinued Operations” for further information.

RESTRUCTURING COSTS.

We record liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. Employee termination costs are accrued when the restructuring actions are probable and estimable. Costs for

one-time

termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.

See Note 15, “Restructuring and Other Activities” for further information.

RESEARCH AND DEVELOPMENT.

The Company conducts R&D activities to create new products, develop new applications for existing products, and enhance existing products. This includes direct R&D expenses as well as expenses incurred for R&D services from GE or other third parties. Clinical study and certain research costs are recognized over the service periods specified in the contracts and adjusted as necessary based upon an ongoing review of the level of effort and costs actually incurred. R&D costs are expensed as incurred.

ACCOUNTING CHANGES.

Recent Accounting Pronouncements Reflected in These Combined Financial Statements

In November 2021, the FASB issued ASU

No. 2021-10,

Government Assistance (Topic 832): Disclosures by Business Entities about Government

Assistance

. The ASU requires entities to disclose information about certain types of government assistance they receive, including cash grants and tax

credits. The new guidance requires expanded disclosure regarding the qualitative and quantitative characteristics of the nature, amount, timing, and significant terms and conditions of transactions with a government arising from a grant or other forms of assistance accounted for under a contribution model. The Company adopted this guidance on January 1, 2022 using a prospective method, and the adoption did not have a material impact on the combined financial statements.

In July 2021, the FASB issued ASU

No. 2021-05,

Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments

. The ASU revises lessor lease classification guidance and requires accounting for certain leases with variable lease payments that do not depend on a reference index or rate as operating leases. Such classification is required if the lease would have been classified as a sales-type or direct financing lease in accordance with guidance in FASB ASC Topic 842 and the lessor would have otherwise recognized a

day-one

loss. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company adopted this guidance on January 1, 2022 using a prospective method, and the adoption did not have a material impact on our combined financial statements.

On January 1, 2021, we adopted ASU

No. 2019-12,

Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

. The ASU removes certain exceptions from the guidance in ASC 740 related to intra-period tax allocations, interim calculations, and the recognition of deferred tax liabilities for outside basis differences and clarifies and simplifies several other aspects of accounting for income taxes. Different transition methods apply to the various income tax simplifications. For the changes requiring a retrospective or modified retrospective transition, the adoption of the new standard did not have a material impact to our combined financial statements.

On October 1, 2020, we adopted ASU

No. 2020-04,

Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial

Reporting

. The ASU provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions

affected by reference rate reform if certain criteria are met. We applied the accounting relief as relevant contract and hedge accounting relationship modifications were made during the reference rate reform transition period. The adoption did not have a material impact to our combined financial statements.

Other Recent Accounting Pronouncements

In September 2022, the FASB issued ASU

No. 2022-04

, Liabilities – Supplier Finance Programs (Subtopic

405-50)

. The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for rollforward information, which is effective for fiscal years beginning after December 15, 2023. We are currently evaluating the impact that this guidance will have on our combined financial statements.

In October 2021, the FASB issued ASU

No. 2021-08,

Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from

Contracts with Customers

. The ASU requires companies to apply the definition of a performance obligation under ASC 606 to recognize and measure

contract assets and contract liabilities relating to contracts with customers acquired in a business combination. Prior to the adoption of this ASU, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. The ASU results in the acquirer recording acquired contract assets and liabilities on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The adoption of this ASU is not expected to have a material impact on our combined financial statements; however, the impact in future periods will be dependent upon the contract assets acquired and contract liabilities assumed in any future business combinations.

Summary of Significant Accounting Policies (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Cash and Cash Equivalents [Abstract]

Summary of cash, cash equivalents, and restricted cash

Cash, Cash Equivalents and Restricted Cash


	As of
	March 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,324	$	1,440
Short-term restricted cash		3		5

Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position		2,327		1,445

Long-term restricted cash (a)		7		6
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows	$	2,334	$	1,451

(a)	Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Cash, Cash Equivalents, and Restricted Cash


	As of
	December 31, 2022		December 31, 2021
Cash and cash equivalents	$	1,440	$	554
Short-term restricted cash		5		2

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Financial Position		1,445		556

Long-term restricted cash (a)		6		5

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Cash Flows	$	1,451	$	561

(a)	Long-term restricted cash is recognized within All other assets in the Combined Statements of Financial Position.

Leases - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease right of use assets additions through spin off	$ 25
Operating lease liabilities additions through spin off	34
Finance lease income	$ 12	$ 16	$ 13

Financial Instruments And Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Financial Instruments and Fair Value Measurements Disclosure [Line Items]
AOCI, cash flow hedge, cumulative gain loss after tax	$ (30)	$ 56	$ 9	$ 32	$ 16	$ 7
Cash flow hedge gain loss to be reclassified within 12 Months	$ 27		$ 20
Maximum length of time hedged in cash flow hedge	2 years		2 years
Derivative notional amount	$ 8,971		$ 8,488	10,786
Derivative asset and libailities subject to master netting arrangement liability and asset offset	56		39
Fair Value, Recurring [Member]
Financial Instruments and Fair Value Measurements Disclosure [Line Items]
Long-term debt, fair value	10,819		8,512
Long-term debt	10,239		8,241
Fair Value, Nonrecurring [Member]
Financial Instruments and Fair Value Measurements Disclosure [Line Items]
Equity investments without readily determinable fair value	119		117
Contingent Consideration [Member]
Financial Instruments and Fair Value Measurements Disclosure [Line Items]
Liabilities, fair value adjustment	0	0	65	0	0
Cash Flow Hedging [Member]
Financial Instruments and Fair Value Measurements Disclosure [Line Items]
Pre-tax gains (losses) reclassified from AOCI into earnings	33	$ 11	67	8	$ 27
Cash Flow Hedging [Member] \| Designated as Hedging Instrument [Member]
Financial Instruments and Fair Value Measurements Disclosure [Line Items]
Derivative notional amount	1,226		1,240	2,463
Net Investment Hedging [Member] \| Designated as Hedging Instrument [Member]
Financial Instruments and Fair Value Measurements Disclosure [Line Items]
Derivative notional amount	2,176		2,132	0
Net Investment Hedging [Member] \| Currency Swap [Member] \| Designated as Hedging Instrument [Member]
Financial Instruments and Fair Value Measurements Disclosure [Line Items]
Derivative notional amount	$ 2,176		$ 2,132	$ 0

Leases - Summary Of Maturity of Lease Liabilities (Detail) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Lessee, Operating Lease, Liability, to be Paid [Abstract]
2023		$ 116
2024		89
2025		66
2026		50
2027		27
Thereafter		30
Total		378
Less: imputed interest		(31)
Total lease liability as of December 31, 2022	$ 341	$ 347	$ 366

Condensed Consolidated and Combined Statements of Financial Position (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance of doubtful accounts	$ 91	$ 91	$ 107
Common stock, par or stated value per share	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized	1,000,000,000	100,000	100,000
Common stock, shares issued	454,617,131	100	0
Common stock, shares outstanding	454,617,131	100	0

Accumulated Other Comprehensive (Income) Loss - Net

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]

Accumulated Other Comprehensive (Income) Loss – Net

NOTE 11. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) — NET

Changes in Accumulated other comprehensive income (loss) (“AOCI”) by component, net of income taxes, for the three months ended March 31, 2023 and 2022 were as follows:


	For the three months ended March 31, 2023
	Currency translation adjustments (a)			Benefit plans			Cash flow hedges			Total AOCI
December 31, 2022	$	(1,845	)	$	(42	)	$	9		$	(1,878	)

Other comprehensive income (loss) before reclasses — net of taxes of $(11), $2, and $4		85			(13	)		(13	)		59
Unrecognized gain transferred from GE pension — net of taxes of $0, $(509), and $0 (b)		—			1,972			—			1,972
Reclasses from AOCI — net of taxes of $0, $16, and $7		—			(52	)		(26	)		(78	)

March 31, 2023	$	(1,760	)	$	1,865		$	(30	)	$	75


	For the three months ended March 31, 2022
	Currency translation adjustments (a)			Benefit plans			Cash flow hedges			Total AOCI
December 31, 2021	$	(969	)	$	(100	)	$	32		$	(1,037	)

Other comprehensive income (loss) before reclasses — net of taxes of $(2), $(9), and $(6)		(153	)		(5	)		35			(123	)
Reclasses from AOCI — net of taxes of $0, $0, and $0		—			—			(11	)		(11	)

March 31, 2022	$	(1,122	)	$	(105	)	$	56		$	(1,171	)

(a)	The amount of foreign currency translation recognized in Other comprehensive income (loss) during the three months ended March 31, 2023 and 2022 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “Financial Instruments and Fair Value Measurements.”

(b)	Refer to Note 9, “Postretirement Benefit Plans” for further information on the unrecognized gain transferred from GE pension in connection with the Spin-Off.

NOTE 12. ACCUMULATED OTHER COMPREHENSIVE (INCOME) LOSS – NET

Accumulated Other Comprehensive (Income) Loss


	Currency translation adjustments (a)			Benefit plans			Cash flow hedges			Total AOCI
January 1, 2020	$	1,705		$	310		$	7		$	2,022

AOCI before reclasses – net of taxes of $(16), $21, and $(10)		(374	)		6			36			(332	)
Reclasses from AOCI – net of taxes of $—, $40, and $6 (b)		(688	)		(136	)		(27	)		(851	)

December 31, 2020	$	643		$	180		$	16		$	839

AOCI before reclasses – net of taxes of $9, $57, and $12		326			(74	)		(40	)		212
Reclasses from AOCI – net of taxes of $—, $(37), and $3		—			(6	)		(8	)		(14	)

December 31, 2021	$	969		$	100		$	(32	)	$	1,037

AOCI before reclasses – net of taxes of $5, $39, and $10		876			(58	)		(27	)		791
Reclasses from AOCI – net of taxes of $—, $—, and $(17)		—			—			50			50

December 31, 2022	$	1,845		$	42		$	(9	)	$	1,878

(a)	The amount of foreign currency translation recognized in other comprehensive income during the years ended December 31, 2022, 2021, and 2020 included net gains (losses) relating to net investment hedges, as further discussed in Note 13, “Financial Instruments and Fair Value Measurements.”

(b)	The total reclassification from AOCI included $836 million related to the sale of our BioPharma business in 2020, including currency translation of $688 million, net of taxes.

Accumulated Other Comprehensive (Income) Loss - Net (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]

Accumulated Other Comprehensive (Income) Loss – Net

Changes in Accumulated other comprehensive income (loss) (“AOCI”) by component, net of income taxes, for the three months ended March 31, 2023 and 2022 were as follows:


	For the three months ended March 31, 2023
	Currency translation adjustments (a)			Benefit plans			Cash flow hedges			Total AOCI
December 31, 2022	$	(1,845	)	$	(42	)	$	9		$	(1,878	)

Other comprehensive income (loss) before reclasses — net of taxes of $(11), $2, and $4		85			(13	)		(13	)		59
Unrecognized gain transferred from GE pension — net of taxes of $0, $(509), and $0 (b)		—			1,972			—			1,972
Reclasses from AOCI — net of taxes of $0, $16, and $7		—			(52	)		(26	)		(78	)

March 31, 2023	$	(1,760	)	$	1,865		$	(30	)	$	75


	For the three months ended March 31, 2022
	Currency translation adjustments (a)			Benefit plans			Cash flow hedges			Total AOCI
December 31, 2021	$	(969	)	$	(100	)	$	32		$	(1,037	)

Other comprehensive income (loss) before reclasses — net of taxes of $(2), $(9), and $(6)		(153	)		(5	)		35			(123	)
Reclasses from AOCI — net of taxes of $0, $0, and $0		—			—			(11	)		(11	)

March 31, 2022	$	(1,122	)	$	(105	)	$	56		$	(1,171	)

(a)	The amount of foreign currency translation recognized in Other comprehensive income (loss) during the three months ended March 31, 2023 and 2022 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “Financial Instruments and Fair Value Measurements.”

(b)	Refer to Note 9, “Postretirement Benefit Plans” for further information on the unrecognized gain transferred from GE pension in connection with the Spin-Off.

Accumulated Other Comprehensive (Income) Loss


	Currency translation adjustments (a)			Benefit plans			Cash flow hedges			Total AOCI
January 1, 2020	$	1,705		$	310		$	7		$	2,022

AOCI before reclasses – net of taxes of $(16), $21, and $(10)		(374	)		6			36			(332	)
Reclasses from AOCI – net of taxes of $—, $40, and $6 (b)		(688	)		(136	)		(27	)		(851	)

December 31, 2020	$	643		$	180		$	16		$	839

AOCI before reclasses – net of taxes of $9, $57, and $12		326			(74	)		(40	)		212
Reclasses from AOCI – net of taxes of $—, $(37), and $3		—			(6	)		(8	)		(14	)

December 31, 2021	$	969		$	100		$	(32	)	$	1,037

AOCI before reclasses – net of taxes of $5, $39, and $10		876			(58	)		(27	)		791
Reclasses from AOCI – net of taxes of $—, $—, and $(17)		—			—			50			50

December 31, 2022	$	1,845		$	42		$	(9	)	$	1,878

(a)	The amount of foreign currency translation recognized in other comprehensive income during the years ended December 31, 2022, 2021, and 2020 included net gains (losses) relating to net investment hedges, as further discussed in Note 13, “Financial Instruments and Fair Value Measurements.”

(b)	The total reclassification from AOCI included $836 million related to the sale of our BioPharma business in 2020, including currency translation of $688 million, net of taxes.

Receivables (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Schedule Of Current Receivables

Current Receivables


	As of
	March 31, 2023			December 31, 2022
Current customer receivables (a)	$	3,150		$	3,112

Non-income based tax receivables		192			174
Other sundry receivables		122			100

Sundry receivables		314			274
Allowance for credit losses		(91	)		(91	)

Total current receivables — net	$	3,373		$	3,295

(a)

Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $200 million and $157 million as of March 31, 2023 and December 31, 2022, respectively. The increase in chargebacks is primarily due to higher wholesaler product levels.

Current Receivables


	As of
	December 31, 2022			December 31, 2021
Current customer receivables (a)	$	3,112		$	3,028

Non-income based tax receivables		174			163
Other sundry receivables		100			143

Sundry receivables		274			306
Allowance for credit losses		(91	)		(107	)

Total receivables – net	$	3,295		$	3,227

(a)

Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $157 million and $129 million as of December 31, 2022 and 2021, respectively. The increase in chargebacks is primarily due to higher wholesaler product levels.

Summary Of Accounts Receivable, Allowance for Credit Loss

Activity in the allowance for credit losses related to current receivables for the years ended December 31, 2022, 2021, and 2020 consisted of the following:


Balance at January 1, 2020	$	85
Additions charged to costs and expenses		18
Write-offs		(14	)
Foreign currency exchange and other		4

Balance at December 31, 2020	$	93

Additions charged to costs and expenses		12
Write-offs		(10	)
Foreign currency exchange and other		12

Balance at December 31, 2021	$	107

Additions charged to costs and expenses		2
Write-offs		(13	)
Foreign currency exchange and other		(5	)

Balance at December 31, 2022	$	91

Schedule Of Non Current Receivables

Long-Term Receivables


	As of
	March 31, 2023			December 31, 2022
Long-term customer receivables	$	71		$	80
Sundry receivables		71			57
Non-income based tax receivables		28			28
Supplier advances		11			11
Allowance for credit losses		(30	)		(31	)

Total long-term receivables — net (a)	$	151		$	145

(a)	Long-term receivables are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Long-Term Receivables


	As of
	December 31, 2022			December 31, 2021
Long-term customer receivables	$	80		$	83
Sundry receivables		57			49
Non-income based tax receivables		28			37
Supplier advances		11			—
Allowance for credit losses (a)		(31	)		(31	)

Total long-term receivables – net (b)	$	145		$	138

(a)	Write-offs of long-term receivables were not material for the years ended December 31, 2022 and 2021.

(b)	Long-term receivables are recognized within All other assets in the Combined Statements of Financial Position.

Schedule Of Current Customer Receivables Sold

Activity related to current customer receivables sold by the Company is as follows:


	For the years ended December 31
	2022			2021
Balance at January 1	$	15		$	1,628
GE HealthCare sales to WCS and third parties (a)		9			5,456
Collections and other activities		(18	)		(7,076	)
Reclassification from long-term customer receivables		1			7

Balance as of December 31	$	7		$	15

(a)	Sales to WCS are considered related party and were $5,442 million for the year ended December 31, 2021. Sales to WCS were not significant for the year ended December 31, 2022.

Acquisitions, Goodwill, And Other Intangible Assets

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Disclosure Of Acquisitions Goodwill And Other Intangible Assets [Abstract]

Disclosure Of Acquisitions, Goodwill, And Other Intangible Assets [Text Block]

NOTE 7. ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

On February 17, 2023, the Company acquired 100% of the stock of Caption Health, Inc. (“Caption Health”) for $127 million of upfront payment, $10 million future holdback payment and potential

earn-out

payments valued at $13 million based primarily on various milestones and sales targets. The preliminary purchase price allocation resulted in goodwill of $105 million, intangible assets of $60 million, and deferred tax liabilities of $14 million. The goodwill associated with the acquired business is

non-deductible

for tax purposes and is reported in the Ultrasound segment. Caption Health is an artificial intelligence (“AI”) company whose technology expands access to

AI-guided

ultrasound screening for novice users.

See Note 12, “Financial Instruments and Fair Value Measurements” for further information about the fair value measurement of contingent consideration.

Goodwill


	Balance as of December 31, 2022		Acquisitions		Foreign exchange and other		Balance as of March 31, 2023
Imaging	$	4,409	$	—	$	4	$	4,413
Ultrasound		3,835		105		1		3,941
PCS		2,036		—		1		2,037
PDx		2,533		—		—		2,533

Total Goodwill	$	12,813	$	105	$	6	$	12,924

We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. We did not identify any reporting units that required an interim impairment test since the last annual impairment testing date.

Substantially all other intangible assets are subject to amortization. Intangible assets decreased during the three months ended March 31, 2023, primarily as a result of amortization, partially offset by $

million of additions related to the acquisition of Caption Health. Amortization expense was $96 million and $103 million for the three months ended March 31, 2023 and 2022, respectively.

NOTE 8. ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

On December 21, 2021, the Company acquired 100% of the stock of BK Medical, a leader in surgical ultrasound imaging and guidance technology, for $1,466 million. The purchase price allocation resulted in goodwill of $1,020 million, amortizable intangible assets of $393 million, net tangible assets of $114 million, and net deferred tax liabilities of $61 million. The goodwill associated with the acquired business is

non-deductible

for tax purposes and is reported in the Ultrasound segment.

On May 5, 2021, the Company acquired 100% of the stock of Zionexa, a France-based company that is a leading innovator of

in-vivo

oncology and neurology biomarkers for $32 million and potential

earn-out

payments valued at $91 million based primarily on sales targets and regulatory approvals. The purchase price allocation resulted in goodwill of $43 million, primarily amortizable intangible assets of $114 million, deferred tax liabilities of $25 million, and other net liabilities assumed of $9 million. The goodwill associated with the acquired business is primarily deductible for tax purposes and is reported in the PDx segment.

On December 30, 2020, the Company acquired the remaining 69% of the stock of Prismatic Sensors AB, a Sweden-based company developing novel sensor technology for CT machines, for $74 million and potential

earn-out

payments valued at $20 million. The Company had a previous equity ownership in Prismatic Sensors AB with a fair value of $35 million. The purchase price allocation resulted in goodwill of $89 million, indefinite-lived intangible assets of $48 million, and other net liabilities assumed of $8 million. The goodwill associated with the acquired business is primarily deductible for tax purposes and is reported in the Imaging segment.

See Note 13, “Financial Instruments and Fair Value Measurements” for further information about the fair value measurement of contingent consideration.

Changes in Goodwill Balances


	Imaging			Ultrasound			PCS			PDx			Total
Balance at January 1, 2021	$	4,449		$	2,868		$	2,058		$	2,493		$	11,868

Acquisitions		1			1,020			—			43			1,064
Foreign currency exchange and other (a)		(17	)		(12	)		(9	)		(2	)		(40	)

Balance at December 31, 2021		4,433			3,876			2,049			2,534			12,892

Acquisitions		—			—			—			—			—
Foreign currency exchange and other (a)		(24	)		(41	)		(13	)		(1	)		(79	)

Balance at December 31, 2022	$	4,409		$	3,835		$	2,036		$	2,533		$	12,813

(a)	Other includes purchase accounting adjustments related to the acquisition of BK Medical which closed on December 21, 2021. There were no significant changes for the 12 months ended December 31, 2022 to the preliminary fair values that were recognized as of December 31, 2021.

In performing the annual goodwill impairment tests during 2022, 2021, and 2020, we determined that the fair values of each of our reporting units exceeded their carrying values. Therefore, no impairment was recorded.

Intangible Assets


	As of December 31, 2022							As of December 31, 2021
	Gross Carrying Amount		Accumulated Amortization			Net		Gross Carrying Amount		Accumulated Amortization			Net
Customer-related	$	60	$	(10	)	$	50	$	64	$	(9	)	$	55
Patents and technology		2,544		(1,815	)		729		2,556		(1,713	)		843
Capitalized software		2,309		(1,638	)		671		2,500		(1,610	)		890
Trademarks and other		35		(27	)		8		43		(32	)		11
Indefinite-lived assets (a)		62		—			62		48		—			48

Total	$	5,010	$	(3,490	)	$	1,520	$	5,211	$	(3,364	)	$	1,847

(a)	Indefinite-lived intangible assets primarily relate to acquired IPR&D prior to project completion and are not amortized.

There were no intangible assets acquired during the year ended December 31, 2022. Amortization expense was $405 million, $400 million, and $408 million for the years ended December 31, 2022, 2021, and 2020, respectively. No material impairments of intangible assets were recognized in the years ended December 31, 2022, 2021, or 2020.

Estimated annual

pre-tax

amortization expense for intangible assets over the next five calendar years is as follows:

Estimated Intangible

Pre-tax

Amortization


	2023		2024		2025		2026		2027
Estimated annual pre-tax amortization	$	357	$	295	$	248	$	193	$	106

Receivables - Schedule Of Current Receivables (Parenthetical) (Detail) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Receivables [Abstract]
Chargebacks of accounts receivable	$ 200	$ 157	$ 129

Revenue Recognition

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Revenue Recognition

NOTE 2. REVENUE RECOGNITION

Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and

stand-by

Contract and Other Deferred Assets


	As of
	March 31, 2023		December 31, 2022
Contract assets	$	593	$	584
Other deferred assets		390		405

Contract and other deferred assets		983		989
Non-current contract assets (a)		38		37
Non-current other deferred assets (a)		81		82

Total contract and other deferred assets	$	1,102	$	1,108

(a)	Non-current contract and other deferred assets are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Contract assets primarily reflect revenue recognized on contracts in excess of billings based on contractual terms. Contract assets are classified as current or

non-current

based on the amount of time expected to lapse until the Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs.

CONTRACT LIABILITIES.

Contract liabilities primarily include customer advances and deposits received when orders are placed and billed in advance of completion of performance obligations. Contract liabilities are classified as current or

non-current

based on the periods over which remaining performance obligations are expected to be satisfied and fulfilled with our customers.

As of March 31, 2023 and December 31, 2022, contract liabilities were approximately $2,681 million and $2,526 million, respectively, of which the

non-current

portion of $650 million and $630 million, respectively, was recognized in All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position. Contract liabilities increased by $155

million in 2023 primarily due to an increase in customer advances and deposits as a result of product orders growth relative to fulfillment and the normal annual service contract billing cycle. Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately

$759 million and $715 million for the three months ended March 31, 2023 and 2022, respectively.

REMAINING PERFORMANCE OBLIGATIONS.

Remaining performance obligations represent the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the ability to cancel or terminate without incurring a substantive penalty. As of March 31, 2023, the aggregate amount of the contracted revenues allocated to our unsatisfied (or partially unsatisfied) performance obligations was $14,490 million. We expect to recognize revenue as we satisfy our remaining performance obligations as follows: a) product-related remaining performance obligations of $4,966 million of which 99% is expected to be recognized within two years, and the remaining thereafter; and b) services-related remaining performance obligations of $9,524 million of which 67% and 97% is expected to be recognized within two years and five years, respectively, and the remaining thereafter.

NOTE 3. REVENUE RECOGNITION

Contract and Other Deferred Assets


	As of
	December 31, 2022		December 31, 2021
Contract assets	$	584	$	433
Other deferred assets		405		369

Contract and other deferred assets		989		802
Non-current contract assets (a)		37		19
Non-current other deferred assets (a)		82		77

Total contract and other deferred assets	$	1,108	$	898

(a)	Non-current contract and other deferred assets are recognized within All other assets in the Combined Statements of Financial Position.

Contract assets primarily reflect revenue recognized on contracts in excess of billings based on contractual terms. Contract assets are classified as current or

non-current

based on the amount of time expected to lapse until the

Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs.

Capitalized costs to obtain a contract were $204 million and $176 million as of December 31, 2022 and 2021, respectively. Generally, these costs are recognized within two years of being capitalized. When recognized, the costs to obtain a contract are recorded within Selling, general, and administrative in the Combined Statements of Income.

CONTRACT LIABILITIES.

Contract liabilities primarily include customer advances and deposits received when orders are placed and billings in advance of completion of performance obligations. Contract liabilities are classified as current or

non-current

based on the periods over which remaining performance obligations are expected to be satisfied and fulfilled with our customers.

As of December 31, 2022 and 2021, contract liabilities were approximately $2,526 million and $2,496 million, respectively, of which the

non-current

portion of $630 million and $632 million, respectively, was recognized in All other liabilities in the Combined Statements of Financial Position. Contract liabilities increased by $30 million in 2022 primarily due to an increase in customer advances and deposits as a result of product orders growth relative to fulfillment. Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately $1,562 million and $1,552 million for the years ended December 31, 2022 and 2021, respectively.

REMAINING PERFORMANCE OBLIGATIONS.

Remaining Performance Obligations represent the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the ability to cancel or terminate without incurring a substantive penalty. As of December 31, 2022, the aggregate amount of the contracted revenues allocated to our unsatisfied (or partially unsatisfied) performance obligations was $14,343 million. We expect to recognize revenue as we satisfy our remaining performance obligations as follows: a) product-related remaining performance obligations of $4,992 million of which 98% is expected to be recognized within two years, and the remaining thereafter; and b) services-related remaining performance obligations of $9,351 million of which 67% and 96% is expected to be recognized within two and five years, respectively, and the remaining thereafter.

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Summary of Income Before Income Taxes

Condensed Consolidated and Combined Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net income	$ 383	$ 402	$ 1,967	$ 2,293	$ 13,897
Adjustments to reconcile Net income from continuing operations to Cash from (used for) operating activities
Depreciation and amortization of property, plant, and equipment	61	56	228	225	222
Amortization of intangible assets	96	103	405	400	408
Net periodic postretirement benefit plan (income) expense	(101)	3
Postretirement plan contributions	(91)	(6)
Gain on fair value remeasurement of contingent consideration			(65)	0	0
Provision for income taxes	163	131	563	600	652
Share-based compensation	24	19
Cash paid during the year for income taxes	(102)	(203)	(851)	(615)	(809)
Cash paid during the year for interest	(42)	0
Changes in operating assets and liabilities, excluding the effects of acquisitions and dispositions:
Receivables	(22)	(139)	(231)	(1,336)	(221)
Due from related parties	5	(5)	13	157	21
Inventories	(122)	(244)	(402)	(435)	100
Contract and other deferred assets	12	(34)	(222)	23	(57)
Accounts payable	87	319	481	263	(113)
Due to related parties	6	16	(33)	(21)	(94)
Contract liabilities	119	77	138	(21)	312
All other operating activities	(8)	(27)	161	92	139
Cash from (used for) operating activities	468	468
Cash flows – investing activities
Additions to property, plant, and equipment	(143)	(100)	(310)	(242)	(237)
Dispositions of property, plant, and equipment	0	3	4	15	16
Additions to internal-use software			0	(6)	(22)
Purchases of businesses, net of cash acquired	(127)	0	0	(1,481)	(78)
All other investing activities	4	(3)	(92)	(47)	(2)
Cash from (used for) investing activities	(266)	(100)
Cash flows – financing activities
Net increase (decrease) in borrowings (maturities of 90 days or less)	(9)	2	9	(7)	(10)
Newly issued debt, net of debt issuance costs (maturities longer than 90 days)	2,000	0	8,198	5	4
Repayments and other reductions (maturities longer than 90 days)	(6)	(1)	(3)	(10)	(10)
Net transfers (to) from GE	(1,317)	(391)	(8,934)	(238)	(2,098)
All other financing activities	5	(30)	(92)	(13)	(52)
Cash from (used for) financing activities	673	(420)
Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash	8	(3)	(3)	(34)	14
Increase (decrease) in cash, cash equivalents, and restricted cash	883	(55)	890	(451)	143
Cash, cash equivalents, and restricted cash at beginning of year	1,451	561	561	1,012	869
Less cash, cash equivalents, and restricted cash of discontinued operations at December 31			0	0	0
Cash, cash equivalents, and restricted cash as of ending of year	$ 2,334	$ 506	1,451	561	1,012
Supplemental disclosure of cash flows information
Cash paid during the year for interest			0	(21)	(46)
Non-cash investing and financing activities
Purchase of property, plant, and equipment included in accounts payable			43	29	(26)
Continuing Operations [Member]
Net income			1,949	2,275	2,058
Changes in operating assets and liabilities, excluding the effects of acquisitions and dispositions:
Cash from (used for) operating activities			2,134	1,607	2,618
Cash flows – investing activities
Cash from (used for) investing activities			(398)	(1,761)	(323)
Cash flows – financing activities
Cash from (used for) financing activities			(822)	(263)	(2,166)
Discontinued Operations [Member]
Net income			18	18	11,839
Changes in operating assets and liabilities, excluding the effects of acquisitions and dispositions:
Cash from (used for) operating activities			(21)	0	(931)
Cash flows – investing activities
Cash from (used for) investing activities			0	0	20,309
Cash flows – financing activities
Cash from (used for) financing activities			$ 0	$ 0	$ (19,378)

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]


	For the years ended December 31
	2022		2021		2020
U.S. income	$	1,090	$	1,587	$	1,620
Non-U.S. income		1,422		1,288		1,090

Total	$	2,512	$	2,875	$	2,710

Summary of Provision for Income Taxes


	For the years ended December 31
	2022			2021			2020
Current
U.S. Federal	$	396		$	141		$	250
Non – U.S.		324			422			463
U.S. State		97			55			65

Deferred
U.S. Federal		(213	)		82			—
Non – U.S.		7			(101	)		(129	)
U.S. State		(48	)		1			3

Total	$	563		$	600		$	652

Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate


	For the years ended December 31
	2022			2021			2020
Income before taxes	$	2,512		$	2,875		$	2,710

Tax expected at 21%		528			604			569
Foreign operations		47			(43	)		42
U.S. tax on foreign operations		(36	)		(23	)		(45	)
Uncertain tax positions		6			11			25
R&D benefits		(33	)		(32	)		(30	)
State taxes, net of federal benefit		39			45			47
Valuation allowance		8			33			37
Other		4			5			7

Provision for income taxes	$	563		$	600		$	652

Actual income tax rate		22.4	%		20.9	%		24.1	%

Summary of Reconciliation of Unrecognized Tax Benefits

The balance of unrecognized tax benefits, the amount of related interest and penalties, and what we believe to be the range of reasonably possible changes in the next 12 months are as follows:


	2022			2021			2020
Balance at January 1	$	365		$	684		$	622
Additions for tax positions of the current year		9			9			18
Additions for tax positions of prior years		137			14			78
Reductions for tax positions of prior years		(41	)		(78	)		(17	)
Settlements with tax authorities		(1	)		(262	)		(14	)
Expiration of the statute of limitations		(4	)		(2	)		(3	)

Balance as of December 31	$	465		$	365		$	684

Summary of Unrecognized Tax Benefits


	For the years ended December 31
	2022		2021		2020
Unrecognized tax benefits	$	465	$	365	$	684
Accrued interest on unrecognized tax benefits		56		53		72
Reasonably possible reduction to the balance of unrecognized tax benefits in succeeding 12 months		45		36		64
Portion that, if recognized, would reduce tax expense and effective tax rate		153		111		99

Summary of Deferred Income Taxes


	As of
	December 31, 2022			December 31, 2021
Total assets	$	1,550		$	1,287
Total liabilities		(370	)		(385	)

Net deferred income tax asset (liability)	$	1,180		$	902

Summary of Components of the Net Deferred Income Tax Asset Liability


	As of
	December 31, 2022			December 31, 2021
Deferred tax assets:
Employee benefits	$	222		$	255
Contract liabilities		193			186
Inventories		84			83
Operating loss carryforwards		176			138
Other accrued expenses		70			36
Receivables		42			54
Lease liabilities		57			62
Tax credit carryforwards		128			133
Contract assets		99			120
Property, plant, and equipment		338			413
Capitalized R&D		554			307

Total deferred income tax asset		1,963			1,787
Valuation allowances		(272	)		(279	)

Total deferred income tax asset after valuation allowance		1,691			1,508


	As of
	December 31, 2022			December 31, 2021
Deferred tax liabilities:
Goodwill & other intangible assets	$	(458	)	$	(517	)
ROU assets		(47	)		(56	)
Other		(6	)		(33	)

Total deferred income tax liability		(511	)		(606	)

Net deferred income tax asset (liability)	$	1,180		$	902

Summary of Valuation Allowance

Valuation allowances primarily relate to

non-U.S.


Balance at January 1, 2020	$	228
Provision for income taxes		43
Foreign currency exchange and other		(21	)

Balance at December 31, 2020	$	250
Provision for income taxes		39
Foreign currency exchange and other		(10	)

Balance at December 31, 2021	$	279
Provision for income taxes		(5	)
Foreign currency exchange and other		(2	)

Balance at December 31, 2022	$	272

Leases - Schedule Of Assets And Liabilities Lessee (Detail) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Assets and Liabilities, Lessee [Abstract]
Operating lease ROU assets		$ 313	$ 358
Current operating lease liabilities		104	104
Non-current operating lease liabilities		243	262
Total operating lease liabilities	$ 341	$ 347	$ 366

Financing Receivables (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Schedule of financing receivables

Financing Receivables


	As of
	March 31, 2023			December 31, 2022
Loans, net of deferred income	$	31		$	29
Investment in financing leases, net of deferred income		73			72
Allowance for credit losses		(4	)		(4	)

Current financing receivables — net (a)		100			97

Loans, net of deferred income		44			44
Investment in financing leases, net of deferred income		157			158
Allowance for credit losses		(5	)		(6	)

Non-current financing receivables — net (a)	$	196		$	196

(a)	Current financing receivables and non-current financing receivables are recognized within All other current assets and All other assets, respectively, in the Condensed Consolidated and Combined Statements of Financial Position.

Financing Receivables


	As of
	December 31, 2022			December 31, 2021
Loans, net of deferred income	$	29		$	25
Investment in financing leases, net of deferred income		72			77
Allowance for credit losses (a)		(4	)		(3	)

Current financing receivables – net (b)	$	97		$	99

Loans, net of deferred income		44			41
Investment in financing leases, net of deferred income		158			149
Allowance for credit losses (a)		(6	)		(4	)

Non-current financing receivables – net (b)	$	196		$	186

(a)	Allowance for credit losses activity related to current and non-current financing receivables including write-offs, net of recoveries, was not material for the years ended December 31, 2022 and 2021.

(b)	Current financing receivables and non-current financing receivables are recognized within All other current assets and All other assets, respectively, in the Combined Statements of Financial Position.

Postretirement Benefit Plans - Summary of Weighted Average Asset Allocation Of Pension Plans (Detail) - Pension Plan [Member]	Dec. 31, 2022
Defined Benefit Plan, Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	17.00%
Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage	16.00%
Defined Benefit Plan, Debt Security [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	44.00%
Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage	48.00%
Defined Benefit Plan, Real Estate [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	6.00%
Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage	6.00%
Defined Benefit Plan Private Equities And Other Investment [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	33.00%
Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage	30.00%

Restructuring And Other Activities - Restructuring and Other Activities (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring and Related Activities [Abstract]
Employee termination costs	$ 10	$ 9	$ 74	$ 127	$ 108
Facility and other exit costs	1	3	46	20	11
Asset write-downs	1	0	26	8	15
Total restructuring and other activities	$ 12	$ 12	$ 146	$ 155	$ 134

Condensed Consolidated and Combined Statements of Changes in Equity - USD ($) $ in Millions	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Net Parent Investment [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total Equity [Member]
Balances as of January 1 at Dec. 31, 2019	$ 21,397				$ 23,400	$ (2,022)	$ 19
Cumulative effect of adoption of new accounting principles	(19)				(19)	0	0
Net income	13,846				13,846	0	8	$ 13,854
Currency translation adjustments – net of taxes	1,062				0	1,062	0
Benefit plans – net of taxes	130				0	130	0
Investment securities and cash flow hedges – net of taxes	(9)				0	(9)	0
Transfers (to) Parent	(21,661)				(21,661)	0	0
Changes in equity attributable to noncontrolling interests	(3)				0	0	(3)
Balances as of December 31 at Dec. 31, 2020	14,751				15,566	(839)	24
Net income	2,247				2,247	0	7	2,254
Currency translation adjustments – net of taxes	(326)				0	(326)	0
Benefit plans – net of taxes	80				0	80	0
Investment securities and cash flow hedges – net of taxes	48				0	48	0
Transfers (to) Parent	(121)				(121)	0	0
Changes in equity attributable to noncontrolling interests	(10)				0	0	(10)
Balances as of December 31 at Dec. 31, 2021	16,676				17,692	(1,037)	21
Net income	389				389
Currency translation adjustments – net of taxes	(153)				0	(153)	0
Benefit plans – net of taxes	(5)				0	(5)	0
Investment securities and cash flow hedges – net of taxes	24
Transfers (to) Parent	(353)				(353)	0	0
Changes in equity attributable to noncontrolling interests	0				0	0	0
Balances as of December 31 at Mar. 31, 2022	16,578				17,728	(1,171)	21
Balances as of January 1 at Dec. 31, 2021	16,676				17,692	(1,037)	21
Net income	1,916				1,916	0	4	$ 1,920
Currency translation adjustments – net of taxes	(878)				0	(876)	(2)
Benefit plans – net of taxes	58				0	58	0
Investment securities and cash flow hedges – net of taxes	(23)				0	(23)	0
Transfers (to) Parent	(8,373)				(8,373)	0	0
Changes in equity attributable to noncontrolling interests	(18)				0	0	(18)
Balances as of December 31 at Dec. 31, 2022	9,362				11,235	(1,878)	5
Balances as of December 31 (Shares) at Dec. 31, 2022		0
Cash flow hedges – net of taxes	24					24
Net transfers from Parent, including Spin-Off-related adjustments	(2,834)				(4,833)	2,000	(1)
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment (Shares)		454
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment		$ 5	$ 6,397		(6,402)
Issuance of common stock in connection with employee stock plans (Shares)		1
Issuance of common stock in connection with employee stock plans	4		4
Net income	372			$ 372
Currency translation adjustments – net of taxes	57				0	57	0
Benefit plans – net of taxes	(65)				0	(65)	0
Investment securities and cash flow hedges – net of taxes	(39)
Share-based compensation expense	24		24
Changes in equity attributable to noncontrolling interests	2				0	0	2
Changes in equity due to redemption value adjustments on redeemable noncontrolling interests	(187)			(187)
Balances as of December 31 at Mar. 31, 2023	6,696	$ 5	$ 6,425	$ 185	$ 0	75	$ 6
Balances as of December 31 (Shares) at Mar. 31, 2023		455
Cash flow hedges – net of taxes	$ (39)					$ (39)

Share-Based Compensation - Schedule of Weighted Average Fair Value of Options, RSUS, and PSUS Granted To Employees (Detail)	3 Months Ended
	Mar. 31, 2023 $ / shares	Mar. 31, 2023 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk free rate	3.60%
Dividend yield	0.00%
Expected volatility	26.50%
Expected term	6 years 3 months 18 days
Strike price	$ 71	$ 71
Share-Based Payment Arrangement, Option [Member] \| 2023 Long Term Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options	25
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 72
Restricted Stock Units (RSUs) [Member] \| 2023 Long Term Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	72
Performance Shares [Member] \| 2023 Long Term Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 84

Supplemental Financial Information - Summary of Property, Plant, and Equipment – Net (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2022

Mar. 31, 2023

Dec. 31, 2021

$ 4,989

$ 5,060

$ 4,693

(2,988)

(3,039)

(2,816)

ROU operating lease assets

2,001

1,877

313

^[1]

306

358

^[1]

Property, plant, and equipment – net

$ 2,314

$ 2,327

2,235

Land and improvements

^[2]

8 years

^[2]

$ 70

^[2]

(1)

Buildings, structures and related equipment

^[2]

1,889

1,756

(1,109)

(1,006)

Buildings, structures and related equipment | Minimum [Member]

$ 780

750

Buildings, structures and related equipment | Maximum [Member]

8 years

40 years

Machinery and equipment

^[3]

$ 2,541

2,466

^[3]

(1,791)

(1,746)

Machinery and equipment | Minimum [Member]

^[3]

$ 750

720

Machinery and equipment | Maximum [Member]

^[3]

4 years

Leasehold costs and manufacturing plants under construction

^[3]

20 years

$ 489

394

(87)

(63)

Leasehold costs and manufacturing plants under construction | Minimum [Member]

$ 402

$ 331

Leasehold costs and manufacturing plants under construction | Maximum [Member]

1 year

10 years

[1]	See Note 7, “Leases” for further information.
[2]	Depreciable lives exclude land.
[3]	Equipment leased to customers is classified as Machinery and equipment and is reported at cost less accumulated depreciation, and was $39 million and $40 million as of December 31, 2022 and 2021, respectively.

Related Parties - Summary of Corporate Allocations (Detail) - Parent Company [Member] - Prior to Spin Off Event [Member] $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Costs for centralized services [Member]
Related Party Transaction [Line Items]
Related Party Costs	$ 13
Costs associated with employee medical insurance [Member]
Related Party Transaction [Line Items]
Related Party Costs	30
Costs for corporate and shared services [Member]
Related Party Transaction [Line Items]
Related Party Costs	$ 116

Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Supplemental Financial Information [Abstract]

Receivables - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest expenses	$ 136	$ 4	$ 77	$ 40	$ 66
Working Capital Solutions [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts, receivable sale			0	5,442
Interest expenses			$ 46	$ 21

Postretirement Benefit Plans - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jan. 01, 2023
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	$ 33	$ 31		$ 9	$ 25	$ 27
Defined Contribution Plan, Cost				123	119	83
Defined Benefit Plan, Benefit Obligation				703	940	1,048
Contribution received by defined benefit plan from employer				18	20
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)				(193)	(59)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)				(5)	(4)	(4)
Defined Benefit Plan, Plan Assets, Amount				425	553	537
Contribution expected to be received by defined benefit plan from employer in remainder of 2023	255
Liability, Defined Benefit Pension Plan	50	20
Prior to Spin Off Event [Member]
Defined Benefit Plan Disclosure [Line Items]
Post-retirement defined benefit programs with assets or obligations Not reportable							$ 20
After Spin Off Event [Member]
Defined Benefit Plan Disclosure [Line Items]
Post-retirement defined benefit programs with assets or obligations Not reportable							50
Contributions by employer to post retirement defined benefit programs not reportable							$ 11
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Amount				61	76
Subsequent Event [Member]
Defined Benefit Plan Disclosure [Line Items]
Contribution received by defined benefit plan from employer			$ 19
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)			3
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)			$ 2
Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation				20
Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation				20
Us Ge Principal Pension And Principal Retiree Benefit Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)		24		73	96	194
Non US Based Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)		4		$ 11	$ 22	$ 19
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	(80)	3
Contribution received by defined benefit plan from employer	48
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	(1)	(1)
Other Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	(21)	0
Contribution received by defined benefit plan from employer	43
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	$ (22)	$ 0

Supplemental Financial Information (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Summary of Inventories

Inventories


	As of
	March 31, 2023		December 31, 2022
Raw materials	$	1,097	$	1,053
Work in process		107		91
Finished goods		1,052		1,011

Inventories (a)	$	2,256	$	2,155

(a)	Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Inventories


	As of
	December 31, 2022		December 31, 2021
Raw materials	$	1,053	$	900
Work in process		91		104
Finished goods		1,011		942

Inventories (a)	$	2,155	$	1,946

(a)	Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Combined Statements of Financial Position. See the supplemental table for “All Other Current and Non-Current Assets” for further information.

Summary of property, plant, and equipment – net


	As of
	March 31, 2023			December 31, 2022
Original cost	$	5,060		$	4,989
Less accumulated depreciation and amortization		(3,039	)		(2,988	)
Right-of-use operating lease assets		306			313

Property, plant, and equipment — net	$	2,327		$	2,314

Property, Plant, and Equipment – Net


As of December 31	Depreciable lives (in years)	Original Cost				Accumulated Depreciation						Net Carrying Value
As of December 31	Depreciable lives (in years)	2022		2021		2022			2021			2022		2021
Land and improvements (a)	8	$	70	$	77	$	(1	)	$	(1	)	$	69	$	76
Buildings, structures and related equipment	8-40		1,889		1,756		(1,109	)		(1,006	)		780		750
Machinery and equipment (b)	4-20		2,541		2,466		(1,791	)		(1,746	)		750		720
Leasehold costs and manufacturing plants under construction	1-10		489		394		(87	)		(63	)		402		331

Property, plant, and equipment – net, exclusive of ROU operating lease assets		$	4,989	$	4,693	$	(2,988	)	$	(2,816	)	$	2,001	$	1,877

ROU operating lease assets (c)													313		358

Property, plant, and equipment – net												$	2,314	$	2,235

(a)	Depreciable lives exclude land.

(b)	Equipment leased to customers is classified as Machinery and equipment and is reported at cost less accumulated depreciation, and was $39 million and $40 million as of December 31, 2022 and 2021, respectively.

(c)	See Note 7, “Leases” for further information.

Summary of other current and non-current assets

All Other Current and

Non-Current

Assets


	As of
	December 31, 2022		December 31, 2021
Prepaid expenses and deferred costs	$	163	$	163
Financing receivables – net		97		99
Derivative instruments		63		87
Other (a)		94		88

All other current assets	$	417	$	437

Equity method and other investments		322		341
Financing receivables – net		196		186
Long-term receivables – net		145		138
Long-term inventories		104		123
Long-term contract and other deferred assets		119		96
Other (b)		138		163

All other non-current assets	$	1,024	$	1,047

(a)	Current Other primarily consists of miscellaneous deferred charges.

(b)	Non-current Other primarily consists of long-term prepaid expenses, pension and other postretirement benefit plans with a surplus funded status, and advances to suppliers.

Summary of equity method investments

Equity Method Investments


				Equity method investment balance				Equity method income (loss)
As of December 31	Ownership Percentage			2022		2021		2022			2021		2020
Nihon Medi-Physics Limited		50	%	$	162	$	200	$	16		$	22	$	8
Other					20		23		(3	)		5		(1	)

Total				$	182	$	223	$	13		$	27	$	7

Summary of other current and non-current liabilities

All Other Current and

Non-Current

Liabilities


	As of
	December 31, 2022		December 31, 2021
Employee compensation and benefit liabilities (a)	$	853	$	884
Sales allowances, equipment projects, and other commercial liabilities		296		302
Uncertain and other income taxes and related liabilities		237		245
Product warranties		193		161
Accrued freight and utilities		150		118
Operating lease liabilities		104		104
Derivative instruments		86		56
Environmental and asset retirement obligations		34		35
Other (b)		237		257

All other current liabilities	$	2,190	$	2,162


	As of
	December 31, 2022		December 31, 2021
Non-current contract liabilities	$	630	$	632
Operating lease liabilities		243		262
Environmental and asset retirement obligations		251		238
Uncertain and other income taxes and related liabilities		182		133
Finance lease obligations		39		34
Sales allowances, equipment projects, and other commercial liabilities		36		30
Other (c)		222		155

All other non-current liabilities	$	1,603	$	1,484

(a)	Employee compensation and benefit liabilities primarily consists of accrued payroll, commissions, employee compensation and benefits, and pension and other postretirement benefit obligations.

(b)	Current Other primarily consists of miscellaneous accrued costs and interest payable.

(c)	Non-current Other primarily consists of liabilities related to derivative instruments.

Summary of redeemable noncontrolling interests

Redeemable Noncontrolling Interests


	For the three months ended March 31,
	2023			2022
Balance at beginning of period	$	230		$	220
Net income attributable to redeemable noncontrolling interests		10			9
Redemption value adjustments (a)		183			—
Exercise of redeemable noncontrolling interests (b)		(222	)		—

Balance at end of period	$	201		$	229

(a)

As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the

Spin-Off.

(b)	In February 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The expected redemption payment of $222 million is expected to be made in the second quarter of 2023 and has been recognized within All other current liabilities.

The activity attributable to redeemable noncontrolling interests for the years ended December 31, 2022, 2021, and 2020 is presented below.

Redeemable Noncontrolling Interests


	2022			2021			2020
Balance as of January 1	$	220		$	223		$	217
Net income attributable to redeemable noncontrolling interests		47			39			48
Distributions to and exercise of redeemable noncontrolling interests		(37	)		(42	)		(42	)

Balance as of December 31	$	230		$	220		$	223

Summary of other income (expense) – net

Other Income (Expense) — Net


	For the three months ended March 31,
	2023			2022
Net interest and investment income (expense)	$	13		$	(2	)
Equity method investment income		4			3
Change in fair value of assumed obligation		(13	)		—
Other items, net (a)		4			25

Total other income (expense) — net	$	8		$	26

(a)	Other items, net primarily consists of licensing and royalty income and gains and losses related to derivatives for the three months ended March 31, 2022.

Other Income (Expense) – Net


	For the years ended December 31
	2022			2021		2020
Net interest and investment (expense) income	$	(9	)	$	34	$	49
Equity method investment income		13			27		7
Other items, net (a)		58			62		5

Total other income (expense) – net	$	62		$	123	$	61

(a)	Other items, net primarily consists of licensing and royalty income and gains and losses related to derivatives.

Summary of cash, cash equivalents, and restricted cash

Cash, Cash Equivalents and Restricted Cash


	As of
	March 31, 2023		December 31, 2022
Cash and cash equivalents	$	2,324	$	1,440
Short-term restricted cash		3		5

Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position		2,327		1,445

Long-term restricted cash (a)		7		6
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows	$	2,334	$	1,451

(a)	Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Cash, Cash Equivalents, and Restricted Cash


	As of
	December 31, 2022		December 31, 2021
Cash and cash equivalents	$	1,440	$	554
Short-term restricted cash		5		2

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Financial Position		1,445		556

Long-term restricted cash (a)		6		5

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Cash Flows	$	1,451	$	561

(a)	Long-term restricted cash is recognized within All other assets in the Combined Statements of Financial Position.

Share-Based Compensation - Additional Information (Detail) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Oustanding	1,271
Weighted average exercise price \| $ / shares	$ 85
Intrinsic value \| $	$ 104
Weighted average contractual term	2 years
2023 Long Term Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized for issuance under share-based payment arrangement	41,000,000
Expiration Period	10 years
2023 Long Term Incentive Plan [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting Period	3 years
2023 Long Term Incentive Plan [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting Period	3 years 6 months

Subsequent Events

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Subsequent Events [Abstract]

Subsequent Events

NOTE 19. SUBSEQUENT EVENTS

On April 25th, 2023 the Company’s Board of Directors declared a cash dividend of $0.03 per share of common stock, payable on June 15, 2023, to stockholders of record on May 23, 2023.

NOTE 19. SUBSEQUENT EVENTS

On January 3, 2023, the Separation was completed through the Distribution of approximately 80.1% of outstanding shares of the Company to GE shareholders who held shares of GE common stock as of the close of business on December 16, 2022, the record date for the Distribution. As a result of the Distribution, GE stockholders received one share of the Company’s common stock for every three shares of GE common stock. On January 4, 2023, the Company began trading as an independent, publicly traded company under the stock symbol “GEHC” on the Nasdaq Stock Market LLC.

In connection with the Separation, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE, including, but not limited to the following:

•

Separation and Distribution Agreement

– sets forth the principal actions to be taken in connection with the Separation, including the transfer of

assets and assumption of liabilities, and establishes certain rights and obligations between the Company and GE following the Distribution, including procedures with respect to claims subject to indemnification and related matters.

•

Transition Services Agreement

– governs all matters relating to the provision of services between the Company and GE on a transitional basis. The

services the Company receives include support for digital technology, human resources, supply chain, finance, and real estate services, among others. The services generally commenced on the date of the Separation and will terminate up to 36 months following the Distribution Date depending upon the related transitional service.

•

Tax Matters Agreement (“TMA”)

– governs the respective rights, responsibilities, and obligations between the Company and GE with respect to all

tax matters (excluding employee-related taxes covered under the Employee Matters Agreement), in addition to certain restrictions which generally prohibit us from taking or failing to take any action in the

two-year

period following the Distribution that would prevent the Distribution from qualifying as

tax-free

for U.S. federal income tax purposes, including limitations on our ability to pursue certain strategic transactions. The TMA specifies the portion of tax liability for which the Company will bear contractual responsibility, and the Company and GE will each agree to indemnify each other against any amounts for which such indemnified party is not responsible.

•

Employee Matters Agreement

– addresses certain employment, compensation, and benefits matters, including the allocation of employees between

the Company and GE and the allocation and treatment of certain assets and liabilities relating to our employees and former employees.

•

Adoption of Incentive Plans

– adopted (a) the GE HealthCare 2023 Long-Term Incentive Plan (the “GE HealthCare LTIP”) and (b) the GE

HealthCare Mirror 2022 Long-Term Incentive Plan, the GE HealthCare Mirror 2007 Long-Term Incentive Plan and the GE HealthCare Mirror 1990 Long-Term Incentive Plan (collectively, the “GE HealthCare Mirror LTIPs”), in each case, effective as of the Distribution Date. The GE HealthCare Mirror LTIPs were adopted to assume the converted stock options and RSUs (including performance stock units) held by employees of GE HealthCare or one of its subsidiaries and corporate and former employees of GE or one of its subsidiaries, including those held by our executive officers, in each case as a result of the

Spin-Off.

Grants of equity awards made after the

Spin-Off

to our executive officers and other employees will be made under the GE HealthCare LTIP. The GE HealthCare LTIP and the GE HealthCare Mirror LTIPs became effective as of the Distribution Date.

As a result of the Separation, the Company will record certain

spin-off

related transactions during the first quarter of 2023, including, but not limited to the following:

•

Deferred compensation arrangements – GE transferred obligations related to deferred compensation arrangements for

non-GE

HealthCare employees of $525 million to GE HealthCare. We did not record any liabilities associated with these obligations in our Combined Statements of Financial Position as of December 31, 2022 and 2021. In January 2023, the Company entered into

non-designated

hedges that

are intended to serve as economic hedges for the deferred compensation arrangements that are exposed to stock market volatility. The gross notional amount of the hedges was $224 million.

•

Income taxes – GE transferred additional deferred income taxes to the Company. The amounts assumed by the Company are primarily tax attributes of approximately $1,700 million to $2,200 million that were not part of the Company’s stand-alone operations and approximately $958 million of deferred income taxes related to pension plans transferred to the Company; see Note 10, “Postretirement Benefit Plans” for further information. There was also approximately $516 million of deferred income tax liabilities on unrecognized gains to be recorded in AOCI related to pension plans transferred to the Company. These amounts are not included in the Combined Statements of Financial Position as of December 31, 2022 and 2021. There may be changes to these amounts to reflect realizability and measurement conclusions on a GE HealthCare basis.

Following the Separation, the Company has remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE is obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of

non-fulfillment

of contractual obligations by the relevant obligors, the Company could be obligated to make payments under the applicable instruments for which GE is obligated to reimburse and indemnify the Company. As of January 3, 2023, the Company’s maximum aggregate exposure, subject to GE reimbursement, is approximately $164 million. In addition, GE has agreed to fund on behalf of the Company certain technology costs of approximately $75 million expected to occur within one year from the Separation.

On February 1, 2023, our Board of Directors approved a

one-time

equity grant of approximately $100 million, including approximately 1.5 million stock options and 0.8 million restricted stock units of GE HealthCare Technologies Inc. to approximately 8,200 employees. The stock options and restricted stock units were valued based on the share price as of the close of trading on February 1, 2023, and will vest 50% on February 1, 2025, and 50% on February 1, 2026.

Receivables - Summary Of Accounts Receivable, Allowance for Credit Loss (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Allowance for Credit Loss [Abstract]
Beginning Balance	$ 107	$ 93	$ 85
Additions charged to costs and expenses	2	12	18
Write-offs	(13)	(10)	(14)
Foreign currency exchange and other	(5)	12	4
Ending Balance	$ 91	$ 107	$ 93

Postretirement Benefit Plans - Summary of Composition of Plan Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Plan assets measured at fair value	$ 278	$ 351
Plan assets measured at net asset value	147	202
Total plan assets	425	553
Defined Benefit Plan, Equity Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets measured at fair value	33	61
Plan assets measured at net asset value	34	83
Defined Benefit Plan, Debt Security [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets measured at fair value	174	200
Plan assets measured at net asset value	31	47
Defined Benefit Plan, Real Estate [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets measured at fair value	12	20
Plan assets measured at net asset value	13	11
Defined Benefit Plan Private Equities And Other Investment [Member]
Defined Benefit Plan Disclosure [Line Items]
Plan assets measured at fair value	59	70
Plan assets measured at net asset value	$ 69	$ 61

Income Taxes - Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Expected Tax Rate	21.00%	21.00%	21.00%

Leases - Summary Of Contractual Maturities (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received, Fiscal Year Maturity [Abstract]
2023	$ 83
2024	63
2025	44
2026	29
2027	16
Thereafter	13
Total	$ 248	$ 243

Financial Instruments And Fair Value Measurements (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Financial Instruments and Fair Value Measurements Disclosure [Abstract]

Schedule of Gross Fair Value of Outstanding Derivative Instruments

The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated:

Fair Value of Derivatives


	March 31, 2023						December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,226	$	25	$	62	$	1,240	$	32	$	53

Derivatives accounted for as cash flow hedges		1,226		25		62		1,240		32		53

Cross-currency swaps		2,176		21		167		2,132		—		111

Derivatives accounted for as net investment hedges		2,176		21		167		2,132		—		111

Foreign currency exchange contracts		4,690		38		22		4,456		9		20
Embedded derivatives		594		19		14		604		24		18
Equity contracts		231		15		3		8		—		6
Commodity derivatives		54		1		3		48		1		1

Derivatives not designated as hedges		5,569		73		42		5,116		34		45

Total derivatives	$	8,971	$	119	$	271	$	8,488	$	66	$	209

Gross Fair Value of Outstanding Derivative Instruments


	As of December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,240	$	32	$	53

Derivatives accounted for as cash flow hedges		1,240		32		53

Cross-currency swaps		2,132		—		111

Derivatives accounted for as net investment hedges		2,132		—		111

Foreign currency exchange contracts		4,456		9		20
Embedded derivatives		604		24		18
Equity contracts		8		—		6
Commodity derivatives		48		1		1

Derivatives not designated as hedges		5,116		34		45

Total derivatives	$	8,488	$	66	$	209


	As of December 31, 2021
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	2,463	$	49	$	11

Derivatives accounted for as cash flow hedges		2,463		49		11

Cross-currency swaps		—		—		—

Derivatives accounted for as net investment hedges		—		—		—

Foreign currency exchange contracts		7,510		29		37
Embedded derivatives		789		6		8
Equity contracts		—		—		—
Commodity derivatives		24		3		—

Derivatives not designated as hedges		8,323		38		45

Total derivatives	$	10,786	$	87	$	56

Schedule of Pre-tax Gains (Losses) Recognized in OCI Related to Cash flow and Net Investment Hedges

The table below presents the

pre-tax

gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges:

Pre-tax

Gains (Losses) Recognized in OCI Related to Cash flow and Net Investment Hedges


	For the three months ended March 31
	2023			2022
Cash flow hedges	$	(17	)	$	41
Net investment hedges		35			—

Pre-tax

Gains (Losses) Recognized in OCI Related to Cash flow and Net Investment Hedges


	For the years ended December 31
	2022			2021		2020
Cash flow hedges	$	37		$	40	$	(36	)
Net investment hedges		(111	)		—		—

Schedule of Derivative Financial Instruments

The table below presents the gains (losses) of our derivative financial instruments in the Condensed Consolidated and Combined Statements of Income:

Derivative Financial Instruments


	For the three months ended March 31, 2023									For the three months ended March 31, 2022
	Cost of products		Cost of services		Selling, general and administrative		Other (a)			Cost of products			Cost of services		Selling, general and administrative		Other (a)
Foreign currency exchange contracts	$	27	$	6	$	—	$	—		$	9		$	2	$	—	$	—

Effects of cash flow hedges		27		6		—		—			9			2		—		—

Cross-currency swaps		—		—		—		—			—			—		—		—

Effects of net investment hedges		—		—		—		—			—			—		—		—

Foreign currency exchange		7		2		—		1			(1	)		—		—		—
Embedded derivatives		—		—		—		(1	)		—			—		—		3
Equity contracts		—		—		15		3			—			—		—		—
Commodity derivatives		—		—		—		(2	)		—			—		—		10

Effect of derivatives not designated as hedges	$	7	$	2	$	15	$	1		$	(1	)	$	—	$	—	$	13

(a)	Amounts inclusive of Other income (expense) — net on the Condensed Consolidated and Combined Statements of Income.

Derivative Financial Instruments


	2022								2021					2020
	Cost of products			Other (income) expense – net			Interest and other financial charges – net		Cost of products		Other (income) expense – net			Cost of products			Other (income) expense – net
Effects of cash flow hedges (a)	$	(54	)	$	—		$	—	$	8	$	—		$	11		$	—
Effects of net investment hedges (b)		—			—			—		—		—			—			—
Effects of fair value hedges		—			—			—		12		(24	)		(15	)		19
Effect of derivatives not designated as hedges (c)		96			(22	)		—		—		(10	)		—			9

(a)	Cash flow hedges include foreign currency exchange contracts.

(b)	Represents amounts excluded from effectiveness testing for 2022. Net investment hedges include cross-currency swaps.

(c)	Derivatives not designated as hedges include foreign currency exchange contracts, embedded derivatives, equity contracts, and commodity derivatives.

Summary Of Financial Assets And Liabilities

The following table represents financial assets and liabilities that are recorded and measured at fair value on a recurring basis:

Fair Value of Financial Assets and Liabilities


	March 31, 2023								December 31, 2022
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Investment securities	$	31	$	—	$	—	$	31	$	21	$	—	$	—	$	21
Derivatives		—		119		—		119		—		66		—		66
Liabilities:
Deferred compensation (a)		264		3		—		267		62		2		—		64
Derivatives		—		268		3		271		—		203		6		209
Contingent consideration		—		—		57		57		—		—		42		42

(a)	Certain deferred compensation plans whose value is derived from market-based securities values were transferred from GE as part of the Spin-Off.

The following table represents financial assets and liabilities that are recorded and measured at fair value on a recurring basis:


As of December 31	2022								2021
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Derivatives	$	—	$	66	$	—	$	66	$	—	$	87	$	—	$	87
Liabilities:
Derivatives		—		203		6		209		—		56		—		56
Contingent Consideration		—		—		42		42		—		—		112		112

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Borrowings - Schedule of Maturities of Long-Term Debt (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Maturities of Long-Term Debt [Abstract]
2023		$ 7
2024		1,025
2025		1,504
2026		2
2027		1,750
Thereafter		4,000
Total	$ 10,283	$ 8,288	$ 37

Postretirement Benefit Plans - Summary of Net Benefit Liability (Detail) - USD ($) $ in Millions	Jan. 01, 2023	Dec. 31, 2022	Dec. 31, 2021
Projected benefit obligations	$ 22,953	$ 406	$ 555
Fair value of assets	18,908	$ 63	$ 71
Net liability	4,045
Pension Plan [Member]
Projected benefit obligations	21,743
Fair value of assets	18,908
Net liability	2,835
Other Postretirement Benefits Plan [Member]
Projected benefit obligations	1,210
Fair value of assets	0
Net liability	$ 1,210

Discontinued Operations

12 Months Ended

Dec. 31, 2022

Discontinued Operations [Abstract]

DISCONTINUED OPERATIONS

NOTE 18. DISCONTINUED OPERATIONS

In February 2019, we announced an agreement to sell our BioPharma business to Danaher Corporation. On March 31, 2020, we completed the sale for $20,718 million, after certain working capital adjustments. The consideration consisted of $20,301 million in cash and $417 million of pension liabilities that were assumed by Danaher Corporation. The Combined Statements of Income present the results of the BioPharma business as discontinued operations in the historical periods prior to sale, as further disclosed below.

Results of Discontinued Operations


	For the years ended December 31
	2022		2021		2020
Sales of products	$	—	$	—	$	785
Sales of services		—		—		45

Total revenues		—		—		830

Cost of products		—		—		230
Cost of services		—		—		28
Selling, general, and administrative		—		—		142
Research and development		—		—		44

Operating income of discontinued operations		—		—		386
Non-operating income (loss) (a)		—		—		(7	)
Gain on disposal		6		16		12,782

Income of discontinued operations, before income taxes		6		16		13,161
Benefit (provision) for income taxes		12		2		(1,317	)

Income from discontinued operations, net of taxes	$	18	$	18	$	11,844

Less net (loss) attributable to noncontrolling interests		—		—		(5	)

Income of discontinued operations, net of taxes and amounts attributable to noncontrolling interests	$	18	$	18	$	11,839

(a)	Non-operating income (loss) includes Interest and other financial charges – net, Non-operating benefit (income) costs, and Other (income) expense – net related to the discontinued operations of the BioPharma business.

Income Taxes - Summary of Components of the Net Deferred Income Tax Asset Liability (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Employee benefits	$ 222	$ 255
Contract liabilities	193	186
Inventories	84	83
Operating loss carryforwards	176	138
Other accrued expenses	70	36
Receivables	42	54
Lease liabilities	57	62
Tax credit carryforwards	128	133
Contract assets	99	120
Property, plant, and equipment	338	413
Capitalized R&D	554	307
Total deferred income tax asset	1,963	1,787
Valuation allowances	(272)	(279)	$ (250)	$ (228)
Total deferred income tax asset after valuation allowance	1,691	1,508
Deferred tax liabilities:
Goodwill & other intangible assets	(458)	(517)
ROU assets	(47)	(56)
Other	(6)	(33)
Total deferred income tax liability	(511)	(606)
Net deferred income tax asset (liability)	$ 1,180	$ 902

Share-Based Compensation - Schedule of Share-Based Compensation Activity (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions

3 Months Ended

Mar. 31, 2023

Outstanding (Shares)

^[1]

3,738

Granted (Shares)

2,037

Exercised/Vested (Shares)

(326)

(3)

(5)

5,441

3,182

Expected to vest (Shares)

1,681

Outstanding (Weighted average exercise price)

^[1]

$ 90

Granted (Weighted average exercise price)

Exercised/Vested (Weighted average exercise price)

Forfeited (Weighted average exercise price)

Expired (Weighted average exercise price)

143

Outstanding (Weighted average exercise price)

Exercisable (Weighted average exercise price)

Expected to vest (Weighted average exercise price)

$ 71

Outstanding (Weighted average contractual term)

6 years 7 months 6 days

Exercisable (Weighted average contractual term)

4 years 3 months 18 days

Expected to vest (Weighted average contractual term)

9 years 8 months 12 days

Outstanding (Intrinsic value)

$ 57

Exercisable (Intrinsic value)

Expected to vest (Intrinsic value)

$ 18

Restricted Stock Units (RSUs) [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Outstanding (Shares)(RSUs)

^[1]

3,551

Granted (Shares)(RSUs)

1,612

Exercised/Vested (Shares)(RSUs)

(558)

Forfeited (Shares)(RSUs)

(52)

Outstanding (Shares)(RSUs)

4,553

Expected to vest (Shares)(RSUs)

3,817

Outstanding (Weighted average exercise price)(RSUs)

^[1]

$ 58

Granted (Weighted average exercise price)(RSUs)

Exercised/Vested (Weighted average exercise price)(RSUs)

Forfeited (Weighted average exercise price)(RSUs)

Outstanding (Weighted average exercise price)(RSUs)

Expected to vest (Weighted average exercise price)(RSUs)

$ 54

Outstanding (Weighted average contractual term)(RSUs)

2 years

Expected to vest (Weighted average contractual term)(RSUs)

2 years

Outstanding (Intrinsic value)(RSUs)

$ 374

Exercisable (Intrinsic value)(RSUs)

$ 313

[1]

Our common stock began “regular way” trading on The Nasdaq Global Market on January 4, 2023. The shares outstanding as of January 4, 2023 pertain to GE equity-based awards issued by GE in prior periods to employees of the Company that were converted to GE HealthCare equity-based awards as part of the Spin-Off.

Receivables

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Receivables

NOTE 4. RECEIVABLES

Current Receivables


	As of
	March 31, 2023			December 31, 2022
Current customer receivables (a)	$	3,150		$	3,112

Non-income based tax receivables		192			174
Other sundry receivables		122			100

Sundry receivables		314			274
Allowance for credit losses		(91	)		(91	)

Total current receivables — net	$	3,373		$	3,295

(a)

Long-Term Receivables


	As of
	March 31, 2023			December 31, 2022
Long-term customer receivables	$	71		$	80
Sundry receivables		71			57
Non-income based tax receivables		28			28
Supplier advances		11			11
Allowance for credit losses		(30	)		(31	)

Total long-term receivables — net (a)	$	151		$	145

(a)	Long-term receivables are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

NOTE 5. RECEIVABLES

Current Receivables


	As of
	December 31, 2022			December 31, 2021
Current customer receivables (a)	$	3,112		$	3,028

Non-income based tax receivables		174			163
Other sundry receivables		100			143

Sundry receivables		274			306
Allowance for credit losses		(91	)		(107	)

Total receivables – net	$	3,295		$	3,227

(a)

Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $157 million and $129 million as of December 31, 2022 and 2021, respectively. The increase in chargebacks is primarily due to higher wholesaler product levels.

Activity in the allowance for credit losses related to current receivables for the years ended December 31, 2022, 2021, and 2020 consisted of the following:


Balance at January 1, 2020	$	85
Additions charged to costs and expenses		18
Write-offs		(14	)
Foreign currency exchange and other		4

Balance at December 31, 2020	$	93

Additions charged to costs and expenses		12
Write-offs		(10	)
Foreign currency exchange and other		12

Balance at December 31, 2021	$	107

Additions charged to costs and expenses		2
Write-offs		(13	)
Foreign currency exchange and other		(5	)

Balance at December 31, 2022	$	91

Long-Term Receivables


	As of
	December 31, 2022			December 31, 2021
Long-term customer receivables	$	80		$	83
Sundry receivables		57			49
Non-income based tax receivables		28			37
Supplier advances		11			—
Allowance for credit losses (a)		(31	)		(31	)

Total long-term receivables – net (b)	$	145		$	138

(a)	Write-offs of long-term receivables were not material for the years ended December 31, 2022 and 2021.

(b)	Long-term receivables are recognized within All other assets in the Combined Statements of Financial Position.

SALES OF CUSTOMER RECEIVABLES.

Previously, the Company sold customer receivables to GE’s Working Capital Solutions (“WCS”) business. These programs were discontinued in 2021. Separately, the Company from time to time sells current or long-term receivables to third parties in response to customer-sponsored requests or programs, to facilitate sales, or for risk mitigation purposes.

Activity related to current customer receivables sold by the Company is as follows:


	For the years ended December 31
	2022			2021
Balance at January 1	$	15		$	1,628
GE HealthCare sales to WCS and third parties (a)		9			5,456
Collections and other activities		(18	)		(7,076	)
Reclassification from long-term customer receivables		1			7

Balance as of December 31	$	7		$	15

(a)	Sales to WCS are considered related party and were $5,442 million for the year ended December 31, 2021. Sales to WCS were not significant for the year ended December 31, 2022.

Under the programs, the Company incurred interest expense and finance charges of $21 million and $46 million for the years ended December 31, 2021 and 2020, respectively, which are included in Interest and other financial charges – net in the Combined Statements of Income. Such program charges were not material for the year ended December 31, 2022. The proceeds for the programs are included in Cash from (used for) operating activities in the Combined Statements of Cash Flows.

Income Taxes - Summary of Provision for Income Taxes (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current
U.S. Federal			$ 396	$ 141	$ 250
Non – U.S.			324	422	463
U.S. State			97	55	65
Deferred
U.S. Federal			(213)	82	0
Non – U.S.			7	(101)	(129)
U.S. State			(48)	1	3
Total	$ 163	$ 131	$ 563	$ 600	$ 652

Cash and Cash Equivalents [Abstract]

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Supplemental Financial Information - Summary Of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)
$ in Millions

Mar. 31, 2023

Dec. 31, 2022

Mar. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Cash and cash equivalents

$ 2,324

$ 1,440

$ 554

Short-term restricted cash

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Financial Position

2,327

1,445

556

Long-term restricted cash

^[1]

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Cash Flows

$ 2,334

$ 1,451

$ 506

$ 561

$ 1,012

$ 869

[1]	Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Supplemental Financial Information - Summary of Equity Method Investments (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Equity method investment balance			$ 182	$ 223
Equity method income (loss)	$ 4	$ 3	$ 13	27	$ 7
Nihon Medi-Physics Limited [Member]
Schedule of Equity Method Investments [Line Items]
Ownership Percentage			50.00%
Equity method investment balance			$ 162	200
Equity method income (loss)			16	22	8
Other [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment balance			20	23
Equity method income (loss)			$ (3)	$ 5	$ (1)

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2022

Discontinued Operations [Abstract]

Schedule oF results of discontinued operations

Results of Discontinued Operations


	For the years ended December 31
	2022		2021		2020
Sales of products	$	—	$	—	$	785
Sales of services		—		—		45

Total revenues		—		—		830

Cost of products		—		—		230
Cost of services		—		—		28
Selling, general, and administrative		—		—		142
Research and development		—		—		44

Operating income of discontinued operations		—		—		386
Non-operating income (loss) (a)		—		—		(7	)
Gain on disposal		6		16		12,782

Income of discontinued operations, before income taxes		6		16		13,161
Benefit (provision) for income taxes		12		2		(1,317	)

Income from discontinued operations, net of taxes	$	18	$	18	$	11,844

Less net (loss) attributable to noncontrolling interests		—		—		(5	)

Income of discontinued operations, net of taxes and amounts attributable to noncontrolling interests	$	18	$	18	$	11,839

(a)	Non-operating income (loss) includes Interest and other financial charges – net, Non-operating benefit (income) costs, and Other (income) expense – net related to the discontinued operations of the BioPharma business.

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

Property, Plant and Equipment [Abstract]

Postretirement Benefit Plans - Summary of Amounts Recorded in AOCI (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Net loss (gain)	$ 60	$ 138
Prior service cost (credit)	(5)	(9)
Total recorded in AOCI	$ 55	$ 129

Property, Plant, And Equipment And Operating Leases - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Operating lease, liability	$ 341		$ 347	$ 366
Operating lease, expense	$ 56	$ 56

Borrowings - Schedule of Long-Term Borrowings Composition (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal debt issued	$ 10,283	$ 8,288	$ 37
Less: Unamortized debt issuance costs and discounts	44	47	0
Less: Current portion of long-term borrowings	5	7	6
Long-term borrowings, net of current portion	10,234	8,234	31
5.550% senior notes due November 15, 2024 [Member]
Debt Instrument [Line Items]
Principal debt issued	1,000	1,000	0
5.600% senior notes due November 15, 2025 [Member]
Debt Instrument [Line Items]
Principal debt issued	1,500	1,500	0
5.650% senior notes due November 15, 2027 [Member]
Debt Instrument [Line Items]
Principal debt issued	1,750	1,750	0
5.857% senior notes due March 15, 2030 [Member]
Debt Instrument [Line Items]
Principal debt issued	1,250	1,250	0
5.905% senior notes due November 22, 2032 [Member]
Debt Instrument [Line Items]
Principal debt issued	1,750	1,750	0
6.377% senior notes due November 22, 2052 [Member]
Debt Instrument [Line Items]
Principal debt issued	1,000	1,000	0
Term Loan Facility [Member]
Debt Instrument [Line Items]
Principal debt issued	2,000	0
Other [Member]
Debt Instrument [Line Items]
Principal debt issued	$ 33	$ 38	$ 37

Earnings Per Share - Summary of Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net income	$ 383	$ 402	$ 1,967	$ 2,293	$ 13,897
Net (income) loss attributable to noncontrolling interests	(11)	(13)	(51)	(46)	(51)
Net income attributable to GE HealthCare	372	389	$ 1,916	$ 2,247	$ 13,846
Deemed preferred stock dividend of redeemable noncontrolling interest	(183)	0
Net income attributable to GE HealthCare common stockholders	$ 189	$ 389
Denominator:
Basic weighted-average shares outstanding	454	454
Dilutive effect of common stock equivalents	3	0
Diluted weighted-average shares outstanding	457	454
Basic earnings per share	$ 0.42	$ 0.86
Diluted earnings per share	$ 0.41	$ 0.86
Antidilutive securities	4	0

Leases - Schedule Of Operating Lease Expense (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Lease, Cost [Abstract]
Long-term (fixed)	$ 115	$ 114	$ 135
Long-term (variable)	98	67	64
Short-term	4	4	2
Total operating lease expense	$ 217	$ 185	$ 201

Property, Plant, And Equipment And Operating Leases

3 Months Ended

Mar. 31, 2023

Property, plant, and equipment and operating leases

NOTE 6. PROPERTY, PLANT, AND EQUIPMENT AND OPERATING LEASES

Property, Plant, and Equipment — Net


	As of
	March 31, 2023			December 31, 2022
Original cost	$	5,060		$	4,989
Less accumulated depreciation and amortization		(3,039	)		(2,988	)
Right-of-use operating lease assets		306			313

Property, plant, and equipment — net	$	2,327		$	2,314

OPERATING LEASE LIABILITIES.

Operating lease liabilities recognized within all other current and

non-current

liabilities in the Condensed Consolidated and Combined Statements of Financial Position were $341 million and $347 million as of March 31, 2023 and December 31, 2022, respectively. Expense related to our operating lease portfolio was $56 million for both the three months ended March 31, 2023 and 2022.

Commitments Guarantees Product Warranties And Other Loss Contingencies Disclosure - Summary Of Purchase Commitments (Detail) $ in Millions	Dec. 31, 2022 USD ($)
Commitments Guarantees Product Warranties And Other Loss Contingencies Disclosure [Abstract]
2023	$ 245
2024	174
2025	95
2026	86
2027	40
Thereafter	40
Total	$ 680

Segment And Geographical Information

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Segment Reporting [Abstract]

Segment And Geographical Information

NOTE 3. SEGMENT INFORMATION

GE HealthCare’s operations are organized and managed through four reportable segments: Imaging, Ultrasound, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”). These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments. A description of our reportable segments has been provided in the “Business” section of our Annual Report on Form

10-K

for the year ended December 31, 2022.

The performance of these segments is principally measured based on Total revenues and an earnings metric defined as “Segment EBIT.” Segment EBIT is calculated as Income from continuing operations less the following: Benefit (provision) for income taxes, Interest and other financial charges — net,

Non-operating

benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gains and losses on business dispositions,

Spin-Off

and separation costs, amortization of acquisition-related intangible assets, and investment revaluation gains and losses.

Total Revenues by Segment


	For the three months ended March 31
	2023		2022
Imaging:
Radiology	$	2,088	$	1,918
Interventional Guidance		408		393

Total Imaging		2,496		2,311
Total Ultrasound		859		815
PCS:
Monitoring Solutions		552		521
Life Support Solutions		229		195

Total PCS		781		716
Total PDx		558		484
Other (a)		13		17

Total revenues	$	4,707	$	4,343

(a)	Financial information not presented within the reportable segments, shown within the Other category, represents the HealthCare Financial Services (“HFS”) business which does not meet the definition of an operating segment.

Segment EBIT


	For the three months ended March 31
	2023			2022
Segment EBIT
Imaging	$	191		$	206
Ultrasound		207			192
PCS		109			65
PDx		155			138
Other (a)		2			(2	)

	$	664		$	599
Restructuring costs		(12	)		(12	)
Acquisition and disposition-related benefits (charges)		(1	)		(15	)
Gain (loss) of business dispositions and divestments		—			3
Spin-Off and separation costs		(58	)		—
Amortization of acquisition-related intangible assets		(31	)		(33	)
Investment revaluation gain (loss)		5			(8	)
Interest and other financial charges — net		(136	)		(4	)
Non-operating benefit income (costs)		115			2

Income from continuing operations before income taxes	$	546		$	533

(a)	Financial information not presented within the reportable segments, shown within the Other category, represents the HFS business and certain other investments which do not meet the definition of an operating segment.

NOTE 4. SEGMENT AND GEOGRAPHICAL INFORMATION

GE HealthCare’s operations are organized and managed through four reportable segments: Imaging, Ultrasound, PCS, and PDx. The Company’s organizational structure is based upon the availability of separate financial information that is evaluated regularly by the Company’s Chief Operating Decision Maker (“CODM”) for the purpose of assessing performance and allocating resources. The Company’s CODM is its Chief Executive Officer. These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments.

Non-operating

benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gains and losses on business dispositions,

Spin-Off

and separation costs, amortization of acquisition-related intangible assets, and investment revaluation gains and losses. Consistent accounting policies have been applied by all segments for all

reporting periods. A description of our reportable segments has been provided in Note 1, “Organization and Basis of Presentation.”

Total Revenues by Segment


	For the years ended December 31
	2022		2021		2020
Imaging:
Radiology	$	8,395	$	8,019	$	7,626
Interventional Guidance		1,590		1,414		1,333

Total Imaging		9,985		9,433		8,959
Total Ultrasound		3,422		3,172		2,703
PCS:
Monitoring Solutions		2,092		2,119		2,243
Life Support Solutions		824		796		1,432

Total PCS		2,916		2,915		3,675
Total PDx		1,958		2,018		1,780
Other (a)		60		47		47

Total revenues	$	18,341	$	17,585	$	17,164

(a)	Financial information not presented within the reportable segments, shown within the Other category, represents the HealthCare Financial Services (“HFS”) business which does not meet the definition of an operating segment.

There was no single customer that accounted for more than 10% of the Company’s revenues for the years ended December 31, 2022, 2021, or 2020.

Additionally, no customers accounted for more than 10% of accounts receivable as of December 31, 2022 or 2021.

Segment EBIT


	For the years ended December 31
	2022			2021			2020
Segment EBIT
Imaging	$	1,100		$	1,240		$	1,182
Ultrasound		908			885			640
PCS		341			356			698
PDx		520			693			504
Other (a)		(8	)		(2	)		(43	)

		2,861			3,172			2,981
Restructuring costs		(146	)		(155	)		(134	)
Acquisition and disposition-related benefits (charges)		34			(14	)		—
Gain (loss) of business dispositions and divestments		1			2			(3	)
Spin-Off and separation costs		(14	)		—			(2	)
Amortization of acquisition-related intangible assets		(121	)		(90	)		(83	)
Investment revaluation gain (loss)		(31	)		3			22
Interest and other financial charges – net		(77	)		(40	)		(66	)
Non-operating benefit income (costs)		5			(3	)		(5	)

Income from continuing operations before income taxes	$	2,512		$	2,875		$	2,710

(a)	Financial information not presented within the reportable segments, shown within the Other category, represents the HFS business and certain other investments which do not meet the definition of an operating segment.

The Company does not report total assets by segment for internal or external reporting purposes as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

GEOGRAPHIC INFORMATION.

Revenues are classified according to the region to which products and services are sold.

Total Revenues by Geographic Region


	For the years ended December 31
	2022		2021		2020
United States	$	7,819	$	7,060	$	7,146
China		2,325		2,510		2,133
Other		8,197		8,015		7,885

Total revenues	$	18,341	$	17,585	$	17,164

Long-Lived Assets - Net by Geographic Region


	As of
	December 31, 2022		December 31, 2021
United States	$	860	$	839
China		393		357
Norway		249		228
Other		812		811

Total long-lived assets - net	$	2,314	$	2,235

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

Property, Plant and Equipment [Abstract]

Cover Page	3 Months Ended
Cover Page	Mar. 31, 2023
Document Information [Line Items]
Document Type	S-4
Amendment Flag	false
Entity Central Index Key	0001932393
Entity Registrant Name	GE HealthCare Technologies Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2515116
Entity Address, Address Line One	500 W. Monroe Street
Entity Address, Postal Zip Code	60661
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
City Area Code	833
Local Phone Number	735-1139
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	Frank R. Jimenez, Esq.
Entity Address, Address Line One	500 W. Monroe Street
Entity Address, Postal Zip Code	60661
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
City Area Code	833
Local Phone Number	735-1139

Postretirement Benefit Plans - Summary of Components of Expense (Income) (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Service cost – Operating			$ 19	$ 24	$ 23
Interest cost			17	15	17
Expected return on plan assets			(27)	(27)	(26)
Amortization of net loss (gain)			5	17	18
Amortization of prior service cost (credit)			(5)	(4)	(4)
Curtailment / settlement loss (gain)			0	0	(1)
Non-operating			(10)	1	4
Net periodic (income) expense	$ 33	$ 31	$ 9	$ 25	$ 27
Pension Plan [Member]
Service cost – Operating	14	5
Interest cost	292	4
Expected return on plan assets	(356)	(7)
Amortization of net loss (gain)	(29)	2
Amortization of prior service cost (credit)	(1)	(1)
Non-operating	(94)	(2)
Net periodic (income) expense	(80)	3
Other Postretirement Benefits Plan [Member]
Service cost – Operating	2	0
Interest cost	15	0
Expected return on plan assets	0	0
Amortization of net loss (gain)	(16)	0
Amortization of prior service cost (credit)	(22)	0
Non-operating	(23)	0
Net periodic (income) expense	$ (21)	$ 0

Leases - Schedule Of Supplemental Information Related To Operating Leases (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Supplemental Information Related To Operating Leases [Abstract]
Operating cash flows used for operating leases	$ 113	$ 128	$ 138
Right-of-use assets obtained in exchange for new lease liabilities	$ 98	$ 94	$ 168
Weighted-average remaining lease term (in years)	4 years 4 months 24 days	4 years 8 months 12 days	4 years 10 months 24 days
Weighted-average discount rate	3.80%	3.30%	3.80%

Commitments Guarantees Product Warranties And Other Loss Contingencies Disclosure - Summary Of Changes In Liability for Product Warranties (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Product Warranty Liability [Line Items]
Opening balance	$ 193	$ 161	$ 161	$ 157	$ 152
Current-year provisions	49	55	238	228	207
Expenditures	(51)	(45)	(199)	(221)	(205)
Other changes	2	(1)	(7)	(3)	3
Ending balance	$ 193	$ 170	$ 193	$ 161	$ 157

Acquisitions, Goodwill, And Other Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions					3 Months Ended		12 Months Ended
	Feb. 17, 2023	Dec. 21, 2021	May 05, 2021	Dec. 30, 2020	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill					$ 12,924		$ 12,813	$ 12,892	$ 11,868
Goodwill, impairment loss							0	0	0
Indefinite-lived intangible assets acquired							0
Amortization of Intangible Assets					96	$ 103	405	400	408
Impairment of intangible assets (excluding goodwill)							0	0	0
Goodwill, acquired during period					105		0	1,064
Ultrasound [Member]
Goodwill					3,941		3,835	3,876	2,868
Goodwill, acquired during period					105		0	1,020
Imaging [Member]
Goodwill					4,413		4,409	4,433	$ 4,449
Goodwill, acquired during period					$ 0		$ 0	$ 1
BK Medical [Member] \| Ultrasound [Member]
Percentage of voting equity interests acquired at the acquisition date in the business combination		100.00%
Consideration transferred		$ 1,466
Goodwill		1,020
Finite intangible assets recognized as of the acquisition date		393
Indefinite lived intangible assets recognized as of the acquisition date		114
Deferred tax liability attributable to taxable temporary differences assumed at the acquisition date		$ 61
Zionexa [Member] \| PDx Segment [Member]
Percentage of voting equity interests acquired at the acquisition date in the business combination			100.00%
Consideration transferred			$ 32
Goodwill			43
Finite intangible assets recognized as of the acquisition date			114
Deferred tax liability attributable to taxable temporary differences assumed at the acquisition date			25
Business Combination potential earn-out payments			91
Other liabilities assumed at the acquisition date			$ 9
Stock of Prismatic Sensors AB [Member] \| Imaging [Member]
Percentage of voting equity interests acquired at the acquisition date in the business combination				69.00%
Consideration transferred				$ 74
Goodwill				89
Indefinite lived intangible assets recognized as of the acquisition date				48
Business Combination potential earn-out payments				20
Other liabilities assumed at the acquisition date				8
Fair value at acquisition-date of the equity interest in the acquiree immediately before the acquisition date				$ 35
Caption Health, Inc [Member]
Business combination consideration transferred Upfront Payment	$ 127
Business combination consideration transferred Future Holdback Payment	10
Goodwill, acquired during period	60
Business combination consideration transferred Potential Earn Out Payments	$ 13
Caption Health, Inc [Member] \| Ultrasound [Member]
Percentage of voting equity interests acquired at the acquisition date in the business combination	100.00%
Goodwill	$ 105
Finite intangible assets recognized as of the acquisition date	60
Deferred tax liability attributable to taxable temporary differences assumed at the acquisition date	$ 14

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Line Items]
Unrecognized tax benefits increase resulting from prior period tax positions			$ 137	$ 14	$ 78
Unrecognized tax benefits interest and other financial charges			12	9	$ 6
Unrecognized tax benefits income tax penalties accrued			0
Deferred tax assets generated due to research and development expense			293
Net deferred income tax asset	$ 4,336		1,550	$ 1,287
Net operating loss carryforwards			1,517
Deferred tax assets from gross operating loss carryforwards			358
Unrecognized tax benefits income tax penalties and interest accrued			182
Cumulative amount of indefinitely reinvested foreign earnings			$ 7,999
Effective income tax rate	29.90%	24.60%	22.40%	20.90%	24.10%
Deferred tax liabilities withholding and other foreign taxes	$ 30
Deferred tax assets increase through spin off	3,099
Deferred tax assets increase through spin off pension and post retirement benefits	$ 964
General Electric Company [Member]
Income Tax Disclosure [Line Items]
Unrecognized tax benefits increase resulting from prior period tax positions			$ 132
Net deferred income tax asset			$ 80

Organization and Basis of Presentation - Additional information (Detail) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2023	Dec. 16, 2022	Nov. 30, 2022	Nov. 22, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Entity incorporation, date of incorporation	May 16, 2022
Common stock, shares issued	100	454,617,131					0
Share price	$ 1
Equity	$ 9,362	$ 6,696				$ 16,578	$ 16,676	$ 14,751	$ 21,397
Spin Off Related Adjustments [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Equity		2,834
Deferred compensation liabilities		548
Senior Unsecured Debt [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument face amount		$ 8,250			$ 8,250
General Electric Company [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of common stock outstanding			80.10%
Common stock, shares issued			454,000,000
Cash					4,221
General Electric Company [Member] \| Senior Unsecured Debt [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Debt instrument face amount				$ 8,250	$ 4,000

Share-Based Compensation - Schedule of Share-based Compensation Expense (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($)
Share-Based Payment Arrangement, Additional Disclosure [Abstract]
Compensation expense (pre-tax)	$ 24
Income tax benefits	(8)
Compensation expense (after-tax)	16
Unrecognized compensation expense	212
Cash received from stock options exercised	18
Intrinsic value of stock options exercised and RSU/PSUs vested	$ 48

Revenue Recognition - Summary of Contract and Other Deferred Assets (Detail) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Contract and Other Deferred Assets [Abstract]
Contract assets	$ 593	$ 584	$ 433
Other deferred assets	390	405	369
Contract and other deferred assets	983	989	802
Non-current contract assets	38	37	19
Non-current other deferred assets	81	82	77
Total contract and other deferred assets	$ 1,102	$ 1,108	$ 898

Leases - Schedule Of Net Investment In Financing Leases (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received, Gross Difference [Abstract]
Total minimum lease payments receivable	$ 248	$ 243
Less: deferred income	(30)	(27)
Discounted lease receivable	218	216
Estimated unguaranteed residual value of leased assets, net of deferred income	12	10
Investment in financing leases, net of deferred income	$ 230	$ 226

Condensed Consolidated and Combined Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income attributable to GE HealthCare	$ 372	$ 389	$ 1,916	$ 2,247	$ 13,846
Net (income) loss attributable to noncontrolling interests	(11)	(13)	(51)	(46)	(51)
Net income	383	402	1,967	2,293	13,897
Other comprehensive income (loss):
Currency translation adjustments – net of taxes	57	(153)	(878)	(326)	1,062
Benefit plans – net of taxes	(65)	(5)	58	80	130
Investment securities and cash flow hedges – net of taxes	(39)	24	(23)	48	(9)
Other comprehensive income (loss)	(47)	(134)	(843)	(198)	1,183
Comprehensive income	336	268	1,124	2,095	15,080
Comprehensive (income) attributable to noncontrolling interests	(11)	(13)	(51)	(46)	(51)
Comprehensive income attributable to GE HealthCare	$ 325	$ 255	$ 1,073	$ 2,049	$ 15,029

Property, Plant, And Equipment And Operating Leases - Schedule Of Property, Plant, and Equipment (Detail) - USD ($)
$ in Millions

Mar. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Less accumulated depreciation and amortization

$ 5,060

$ 4,989

$ 4,693

(3,039)

(2,988)

(2,816)

Right-of-use operating lease assets

306

313

^[1]

358

^[1]

Property, plant, and equipment — net

$ 2,327

$ 2,314

$ 2,235

[1]	See Note 7, “Leases” for further information.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Estimates and Assumptions

ESTIMATES AND ASSUMPTIONS.

(“COVID-19”)

pandemic. The severity, magnitude, and duration, as well as the economic consequences of the

COVID-19

pandemic, are uncertain and difficult to predict. As a result, our accounting estimates and assumptions may change over time in response to

COVID-19.

Revenue Recognition

REVENUE RECOGNITION.

Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and

stand-by

free-of-charge

The Company capitalizes certain direct incremental costs incurred to obtain a contract, primarily commissions. Costs to obtain a contract are classified as current or

non-current

Performance Obligations Satisfied at a Point in Time

billing terms for these

point-in-time

Performance Obligations Satisfied Over Time

as-needed

See Note 3, “Revenue Recognition” for further information.

Cash, Cash Equivalents, and Restricted Cash

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH.

Cash, Cash Equivalents, and Restricted Cash


	As of
	December 31, 2022		December 31, 2021
Cash and cash equivalents	$	1,440	$	554
Short-term restricted cash		5		2

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Financial Position		1,445		556

Long-term restricted cash (a)		6		5

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Cash Flows	$	1,451	$	561

(a)	Long-term restricted cash is recognized within All other assets in the Combined Statements of Financial Position.

Investment Securities

INVESTMENT SECURITIES.

Equity Method Investments

EQUITY METHOD INVESTMENTS.

See Note 16, “Supplemental Financial Information” for further information.

Receivables

RECEIVABLES.

Financing Receivables

FINANCING RECEIVABLES.

Our financing receivables portfolio consists of a variety of loans and leases, including both larger-balance,

non-homogeneous

loans and leases, and smaller-balance homogeneous loans and leases.

Loans

Investment in Finance Leases

See “Allowance for credit losses” below for the Company’s policy regarding allowances on financing receivables.

Credit Quality Indicators

See Note 6, “Financing Receivables” for further information.

Allowance for Credit Losses

ALLOWANCE FOR CREDIT LOSSES.

Inventories

INVENTORIES.

All inventories are stated at lower of cost or net realizable values. Cost of inventories is determined on a

first-in,

first-out

(“FIFO”) basis.

Consumables and

single-use

on-hand

non-current

and is recognized within All other assets in the Combined Statements of Financial Position.

non-current

on-hand

material levels, and postproduction equipment life cycle stage.

See Note 16, “Supplemental Financial Information” for further information.

Property, Plant, and Equipment

PROPERTY, PLANT, AND EQUIPMENT.

See Note 16, “Supplemental Financial Information” for further information.

Lease Accounting

LEASE ACCOUNTING.

Lessee Arrangements

At lease commencement, we record a lease liability and corresponding

right-of-use

non-lease

components in determining our lease liability for all leased assets except our vehicle leases.

Non-lease

Lessor Arrangements

See Note 6, “Financing Receivables” and Note 7, “Leases” for further information.

Goodwill and Other Intangible Assets

GOODWILL AND OTHER INTANGIBLE ASSETS.

as the measurement date.

In-process

Internal-Use

Software

Internal-use

External Use Software

See Note 8, “Acquisitions, Goodwill, and Other Intangible Assets” for further information.

Derivatives and Hedging

DERIVATIVES AND HEDGING.

risk associated with investments in

non-U.S

See Note 13, “Financial Instruments and Fair Value Measurements” for further information.

Income Taxes

INCOME TAXES.

See Note 11, “Income Taxes” for further information.

Postretirement Benefit Plans

POSTRETIREMENT BENEFIT PLANS.

Certain employees, former employees, and retirees of the Company participate in postretirement benefit plans sponsored by either the Company or GE.

Pension Benefits (Sponsored by the Company)

Management accounts for pension plans sponsored by the Company as defined benefit plans and categorizes plan assets for disclosure purposes in accordance with the fair value hierarchy

Non-operating

benefit costs in the Combined Statements of Income for plans sponsored by the Company.

Pension and Other Postretirement Benefit Plans (Sponsored by GE)

See Note 10, “Postretirement Benefit Plans” for further information.

Loss Contingencies

LOSS CONTINGENCIES.

See Note 14, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information.

Supply Chain Finance Programs

SUPPLY CHAIN FINANCE PROGRAMS.

Trade Payables Accelerated Payment Program

TRADE PAYABLES ACCELERATED PAYMENT PROGRAM.

Fair Value Measurements

FAIR VALUE MEASUREMENTS.

The following sections describe the valuation methodologies we use to measure financial and

non-financial

•

Level 1 — Quoted prices for identical instruments in active markets.

•

Level 3 — Significant inputs to the valuation model are unobservable.

See Note 13, “Financial Instruments and Fair Value Measurements” for further information.

Recurring Fair Value Measurements

RECURRING FAIR VALUE MEASUREMENTS.

Investment Securities

Publicly traded equity securities are valued using Level 1 quoted price inputs.

Derivatives

Contingent Consideration

There were no transfers between Levels 1, 2, and 3 during the years ended December 31, 2022 and 2021. See Note 13, “Financial Instruments and Fair Value Measurements” for further information.

Non-Recurring Fair Value Measurements

NON-RECURRING

FAIR VALUE MEASUREMENTS.

Certain assets are measured at fair value on a

non-recurring

Equity Method Investments

Equity Investments Without Readily Determinable Fair Value

Financing Receivables

Long-Lived Assets

Foreign Currency

FOREIGN CURRENCY.

period-end

Gains and losses from foreign currency transactions, such as those resulting from the settlement of monetary items in the

non-functional

Business Combinations

BUSINESS COMBINATIONS.

See Note 13, “Financial Instruments and Fair Value Measurements” for further information.

Discontinued Operations

DISCONTINUED OPERATIONS.

spun-off.

Presentation as discontinued operations is consistent for all periods presented.

See Note 18, “Discontinued Operations” for further information.

Reorganization Costs

RESTRUCTURING COSTS.

one-time

termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.

See Note 15, “Restructuring and Other Activities” for further information.

Research and Development

RESEARCH AND DEVELOPMENT.

Accounting Changes

ACCOUNTING CHANGES.

Recent Accounting Pronouncements Reflected in These Combined Financial Statements

In November 2021, the FASB issued ASU

No. 2021-10,

Government Assistance (Topic 832): Disclosures by Business Entities about Government

Assistance

. The ASU requires entities to disclose information about certain types of government assistance they receive, including cash grants and tax

In July 2021, the FASB issued ASU

No. 2021-05,

Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments

day-one

On January 1, 2021, we adopted ASU

No. 2019-12,

Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

On October 1, 2020, we adopted ASU

No. 2020-04,

Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial

Reporting

. The ASU provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions

Other Recent Accounting Pronouncements

In September 2022, the FASB issued ASU

No. 2022-04

, Liabilities – Supplier Finance Programs (Subtopic

405-50)

In October 2021, the FASB issued ASU

No. 2021-08,

Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from

Contracts with Customers

. The ASU requires companies to apply the definition of a performance obligation under ASC 606 to recognize and measure

Postretirement Benefit Plans - Summary of Amounts Recorded in Combined Statements of Financial Position (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Non-current assets – other	$ 65	$ 97
Current liabilities – other	(16)	(18)
Non-current liabilities – compensation and benefits	(327)	(466)
Net amount recorded	$ (278)	$ (387)

Acquisitions, Goodwill, And Other Intangible Assets - Schedule Of Goodwill (Detail) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

$ 12,813

$ 12,892

$ 11,868

105

1,064

(79)

^[1]

(40)

^[1]

12,924

12,813

12,892

Imaging [Member]

4,409

4,433

4,449

(24)

^[1]

(17)

^[1]

4,413

4,409

4,433

Ultrasound [Member]

3,835

3,876

2,868

105

1,020

(41)

^[1]

(12)

^[1]

3,941

3,835

3,876

PCS [Member]

2,036

2,049

2,058

(13)

^[1]

(9)

^[1]

2,037

2,036

2,049

PDx [Member]

2,533

2,534

2,493

(1)

^[1]

(2)

^[1]

$ 2,533

$ 2,534

[1]	Other includes purchase accounting adjustments related to the acquisition of BK Medical which closed on December 21, 2021. There were no significant changes for the 12 months ended December 31, 2022 to the preliminary fair values that were recognized as of December 31, 2021.

Share-Based Payment Arrangement [Abstract]

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Share-Based Compensation

12 Months Ended

Dec. 31, 2022

Share-Based Compensation

NOTE 15. SHARE-BASED COMPENSATION

We grant stock options, restricted stock units (“RSU”), and performance share units (“PSU”) to employees under the 2023 Long-Term Incentive Plan (“LTIP”).

The Talent, Culture, and Compensation Committee of the Board of Directors approves grants under the LTIP.

Under the LTIP, we are authorized to issue up to approximately 41 million shares. We record compensation expense for awards expected to vest over the vesting period. We estimate forfeitures based on experience and adjust expense to reflect actual forfeitures. When options are exercised, RSUs vest, and PSUs are earned, we issue shares from authorized unissued common stock.

Stock options provide employees the opportunity to purchase GE HealthCare shares in the future at the market price of our stock on the date the award is granted (the strike price). The options become exercisable over the vesting period, typically becoming fully vested in three to three and a half years, and expire 10 years from the grant date if not exercised. RSUs provide an employee with the right to receive one share of GE HealthCare

stock when the restrictions lapse over the vesting period. Upon vesting, each RSU is converted into one share of GE HealthCare common stock. PSUs provide an employee with the right to receive shares of GE HealthCare stock based upon achievement of certain performance and market metrics. Upon vesting, each PSU earned is converted into shares of GE HealthCare common stock. We value stock options using a Black-Scholes option pricing model, RSUs using the market price on the grant date, and PSUs using the market price on the grant date and a Monte Carlo simulation as needed based on performance metrics.

The following tables provide the weighted average fair value of options, RSUs, and PSUs granted to employees during the three months ended March 31, 2023 and the related stock option valuation assumptions used in the Black-Scholes model:

Weighted Average Grant Date Fair Value


	March 31, 2023
Stock options	$	25
RSUs		72
PSUs		84

Key Assumptions in the Black-Scholes Valuation for Stock Options


	March 31, 2023
Risk free rate		3.6	%
Dividend yield		—	%
Expected volatility		26.5	%
Expected term		6.3
Strike price	$	71

For new awards granted in 2023, the expected volatility was derived from a peer group’s blended historical and implied volatility as GE HealthCare does not have sufficient historical volatility based on the expected term of the underlying options. The expected term of the stock options was determined using the simplified method. The risk-free interest rate was determined using the implied yield currently available for

zero-coupon

U.S. government issues with a remaining term approximating the expected life of the options. The dividend yield input was zero as it was uncertain if a dividend would be paid at the time of the grant.

Share-Based Compensation Activity


	Stock options									RSUs
	Shares (in thousands)			Weighted average exercise price (in dollars)		Weighted average contractual term (in years)		Intrinsic value (in millions)		Shares (in thousands)			Weighted average grant date fair value (in dollars)		Weighted average contractual term (in years)		Intrinsic value (in millions)
Outstanding as of January 4, 2023 (a)		3,738		$	90						3,551		$	58
Granted		2,037			71						1,612			72
Exercised/Vested		(326	)		56						(558	)		70
Forfeited		(3	)		68						(52	)		63
Expired		(5	)		143						—			—

Outstanding as of March 31, 2023		5,441		$	85		6.6	$	57		4,553		$	63		2.0	$	374

Exercisable as of March 31, 2023		3,182		$	94		4.3	$	33		N/A			N/A		N/A		N/A

Expected to vest		1,681		$	71		9.7	$	18		3,817		$	54		2.0	$	313

(a)

Our common stock began “regular way” trading on The Nasdaq Global Market on January 4, 2023.

The shares outstanding as of January 4, 2023 pertain to GE equity-based awards issued by GE in prior periods to employees of the Company that were converted to GE HealthCare equity-based awards as part of the Spin-Off.

Total outstanding PSUs as of March 31, 2023 were 1,271 thousand shares with a weighted average fair value of $85

dollars

The intrinsic value and weighted average contractual term of PSUs outstanding were $104 million and 2.0 years, respectively.

The following tables present compensation expense and tax impact recognized as well as other share-based compensation data for the three months ended March 31, 2023.

Share-based Compensation Expense


	March 31, 2023
Compensation expense (pre-tax)	$	24
Income tax benefits		(8	)

Compensation expense (after-tax)	$	16

Other Share-based Compensation Data


	March 31, 2023
Unrecognized compensation expense (amortized over a weighted average period of 2.0 years)	$	212
Cash received from stock options exercised		18
Intrinsic value of stock options exercised and RSU/PSUs vested		48

Postretirement Benefit Plans - Summary of Plan Funded Status (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Balance at January 1	$ 940	$ 1,048
Service cost	19	24	$ 23
Interest cost	17	15	17
Participant contributions	1	1
Actuarial loss (gain) – net	(193)	(59)
Benefits paid	(38)	(44)
Exchange rate adjustments	(43)	(45)
Balance at December 31	703	940	1,048
Balance at January 1	553	537
Actual gain (loss) on plan assets	(101)	44
Employer contributions	18	20
Participant contributions	1	1
Benefits paid	(38)	(44)
Exchange rate adjustments	(8)	(5)
Balance at December 31	425	553	$ 537
Funded status – surplus (deficit)	$ (278)	$ (387)

Acquisitions, Goodwill, And Other Intangible Assets (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Disclosure Of Acquisitions Goodwill And Other Intangible Assets [Abstract]

Schedule Of Goodwill

Goodwill


	Balance as of December 31, 2022		Acquisitions		Foreign exchange and other		Balance as of March 31, 2023
Imaging	$	4,409	$	—	$	4	$	4,413
Ultrasound		3,835		105		1		3,941
PCS		2,036		—		1		2,037
PDx		2,533		—		—		2,533

Total Goodwill	$	12,813	$	105	$	6	$	12,924

Changes in Goodwill Balances


	Imaging			Ultrasound			PCS			PDx			Total
Balance at January 1, 2021	$	4,449		$	2,868		$	2,058		$	2,493		$	11,868

Acquisitions		1			1,020			—			43			1,064
Foreign currency exchange and other (a)		(17	)		(12	)		(9	)		(2	)		(40	)

Balance at December 31, 2021		4,433			3,876			2,049			2,534			12,892

Acquisitions		—			—			—			—			—
Foreign currency exchange and other (a)		(24	)		(41	)		(13	)		(1	)		(79	)

Balance at December 31, 2022	$	4,409		$	3,835		$	2,036		$	2,533		$	12,813

(a)	Other includes purchase accounting adjustments related to the acquisition of BK Medical which closed on December 21, 2021. There were no significant changes for the 12 months ended December 31, 2022 to the preliminary fair values that were recognized as of December 31, 2021.

Schedule Of Intangible Assets

Intangible Assets


	As of December 31, 2022							As of December 31, 2021
	Gross Carrying Amount		Accumulated Amortization			Net		Gross Carrying Amount		Accumulated Amortization			Net
Customer-related	$	60	$	(10	)	$	50	$	64	$	(9	)	$	55
Patents and technology		2,544		(1,815	)		729		2,556		(1,713	)		843
Capitalized software		2,309		(1,638	)		671		2,500		(1,610	)		890
Trademarks and other		35		(27	)		8		43		(32	)		11
Indefinite-lived assets (a)		62		—			62		48		—			48

Total	$	5,010	$	(3,490	)	$	1,520	$	5,211	$	(3,364	)	$	1,847

(a)	Indefinite-lived intangible assets primarily relate to acquired IPR&D prior to project completion and are not amortized.

Schedule Of Estimated Intangible Pre-tax Amortization

Estimated Intangible

Pre-tax

Amortization


	2023		2024		2025		2026		2027
Estimated annual pre-tax amortization	$	357	$	295	$	248	$	193	$	106

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Share-Based Payment Arrangement [Abstract]

Income Taxes - Summary of Deferred Income Taxes (Detail) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Total assets	$ 4,336	$ 1,550	$ 1,287
Total liabilities	$ (64)	(370)	(385)
Net deferred income tax asset (liability)		$ 1,180	$ 902

Share-Based Compensation - Schedule of Share-based Compensation Expense (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement, Additional Disclosure [Abstract]
Weighted-average period over which Compensation expense not yet recognized is expected to be recognized	2 years

Commitments Guarantees Product Warranties And Other Loss Contingencies Disclosure - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2023	Dec. 21, 2021
Purchase Obligation, Fiscal Year Maturity [Abstract]
Accrual for Environmental Loss Contingencies, Gross	$ 11			$ 9
Accretion Expense, Including Asset Retirement Obligations	$ 274	$ 264
Guarantor Obligations, Maximum Exposure, Undiscounted			$ 164

Discontinued Operations - Additional Information (Details) $ in Millions	Mar. 31, 2020 USD ($)
Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	$ 20,718
Discontinued operations held for sale or disposed of by sale settled through cash
Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	20,301
Discontinued operations held for sale or disposed of by sale settled through pension liabilites
Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	$ 417

Borrowings - Schedule of Long-Term Borrowings Composition (Parenthetical) (Detail)	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
5.550% senior notes due November 15, 2024 [Member]
Debt Instrument [Line Items]
Long term debt fixed interest rate	5.55%	5.55%	5.55%
Long term debt maturity date	Nov. 15, 2024	Nov. 15, 2024	Nov. 15, 2024
5.600% senior notes due November 15, 2025 [Member]
Debt Instrument [Line Items]
Long term debt fixed interest rate	5.60%	5.60%	5.60%
Long term debt maturity date	Nov. 15, 2025	Nov. 15, 2025	Nov. 15, 2025
5.650% senior notes due November 15, 2027 [Member]
Debt Instrument [Line Items]
Long term debt fixed interest rate	5.65%	5.65%	5.65%
Long term debt maturity date	Nov. 15, 2027	Nov. 15, 2027	Nov. 15, 2027
5.857% senior notes due March 15, 2030 [Member]
Debt Instrument [Line Items]
Long term debt fixed interest rate	5.857%	5.857%	5.857%
Long term debt maturity date	Mar. 15, 2030	Mar. 15, 2030	Mar. 15, 2030
5.905% senior notes due November 22, 2032 [Member]
Debt Instrument [Line Items]
Long term debt fixed interest rate	5.905%	5.905%	5.905%
Long term debt maturity date	Nov. 22, 2032	Nov. 22, 2032	Nov. 22, 2032
6.377% senior notes due November 22, 2052 [Member]
Debt Instrument [Line Items]
Long term debt fixed interest rate	6.377%	6.377%	6.377%
Long term debt maturity date	Nov. 22, 2052	Nov. 22, 2052	Nov. 22, 2052

Segment and Geographical Information - Schedule of Segment Reporting Information By Segment (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Segment Reporting Information [Line Items]
Total revenues	$ 4,707	$ 4,343	$ 18,341	$ 17,585	$ 17,164
Imaging [Member]
Segment Reporting Information [Line Items]
Total revenues	2,496	2,311
Imaging [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues			9,985	9,433	8,959
Imaging [Member] \| Radiology [Member]
Segment Reporting Information [Line Items]
Total revenues	2,088	1,918
Imaging [Member] \| Radiology [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues			8,395	8,019	7,626
Imaging [Member] \| Interventional Guidance [Member]
Segment Reporting Information [Line Items]
Total revenues	408	393
Imaging [Member] \| Interventional Guidance [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues			1,590	1,414	1,333
Ultrasound [Member]
Segment Reporting Information [Line Items]
Total revenues	859	815
Ultrasound [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues			3,422	3,172	2,703
PCS [Member]
Segment Reporting Information [Line Items]
Total revenues	781	716
PCS [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues			2,916	2,915	3,675
PCS [Member] \| Monitoring Solutions [Member]
Segment Reporting Information [Line Items]
Total revenues	552	521
PCS [Member] \| Monitoring Solutions [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues			2,092	2,119	2,243
PCS [Member] \| Life Support Solutions [Member]
Segment Reporting Information [Line Items]
Total revenues	229	195
PCS [Member] \| Life Support Solutions [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues			824	796	1,432
PDx [Member]
Segment Reporting Information [Line Items]
Total revenues	558	484
PDx [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues			1,958	2,018	1,780
Others [Member]
Segment Reporting Information [Line Items]
Total revenues	$ 13	$ 17
Others [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues			$ 60	$ 47	$ 47

Summary of Significant Accounting Policies - Additional information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Summary Of Significant Accounting Policies [Line Items]
Defined benefit plan effect of changes in actuarial assumptions and plan provisions percentage of plan assets	10.00%
Transfers between Levels 1, 2, and 3	$ 0	$ 0
Net gains (losses) from foreign currency transactions	$ (88)	$ 130	$ (47)

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2022

Schedule of Weighted Average Fair Value of Options, RSUS, and PSUS Granted To Employees

Weighted Average Grant Date Fair Value


	March 31, 2023
Stock options	$	25
RSUs		72
PSUs		84

Key Assumptions in the Black-Scholes Valuation for Stock Options


	March 31, 2023
Risk free rate		3.6	%
Dividend yield		—	%
Expected volatility		26.5	%
Expected term		6.3
Strike price	$	71

Schedule of Share-Based Compensation Activity

Share-Based Compensation Activity


	Stock options									RSUs
	Shares (in thousands)			Weighted average exercise price (in dollars)		Weighted average contractual term (in years)		Intrinsic value (in millions)		Shares (in thousands)			Weighted average grant date fair value (in dollars)		Weighted average contractual term (in years)		Intrinsic value (in millions)
Outstanding as of January 4, 2023 (a)		3,738		$	90						3,551		$	58
Granted		2,037			71						1,612			72
Exercised/Vested		(326	)		56						(558	)		70
Forfeited		(3	)		68						(52	)		63
Expired		(5	)		143						—			—

Outstanding as of March 31, 2023		5,441		$	85		6.6	$	57		4,553		$	63		2.0	$	374

Exercisable as of March 31, 2023		3,182		$	94		4.3	$	33		N/A			N/A		N/A		N/A

Expected to vest		1,681		$	71		9.7	$	18		3,817		$	54		2.0	$	313

(a)

Our common stock began “regular way” trading on The Nasdaq Global Market on January 4, 2023.

Schedule of Share-based Compensation Expense

The following tables present compensation expense and tax impact recognized as well as other share-based compensation data for the three months ended March 31, 2023.

Share-based Compensation Expense


	March 31, 2023
Compensation expense (pre-tax)	$	24
Income tax benefits		(8	)

Compensation expense (after-tax)	$	16

Other Share-based Compensation Data


	March 31, 2023
Unrecognized compensation expense (amortized over a weighted average period of 2.0 years)	$	212
Cash received from stock options exercised		18
Intrinsic value of stock options exercised and RSU/PSUs vested		48

Related Parties

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

RELATED PARTIES

NOTE 18. RELATED PARTIES

PRIOR TO

SPIN-OFF.

Prior to the

Spin-Off,

GE provided the Company with significant corporate infrastructure and shared services. Some of these services will continue to be provided by GE to the Company on a temporary basis under the Transition Services Agreement, as discussed below. The following disclosures summarize related party activity between GE HealthCare and GE. This activity, which occurred prior to the

Spin-Off,

is included in the condensed combined financial statements.

Pensions, Benefit, and Contribution Plans

As discussed in Note 9, “Postretirement Benefit Plans,” employees of the Company participated in pensions, benefit, and contribution plans that were sponsored by GE. The Company was charged $59 million for the three months ended March 31, 2022 related to employee participation in these plans. In connection with the

Spin-Off,

a portion of these plans were transferred to the Company.

Share-based Compensation

SG&A

in the Condensed Combined Statement of Income.

Corporate Overhead and Other Allocations from GE

GE provided certain services described below that were charged to the Company based

employee headcount, revenue, or other allocation methodologies.

Corporate Allocations from GE


	March 31, 2022
Costs for centralized services (a)	$	13
Costs associated with employee medical insurance (b)		30
Costs for corporate and shared services (c)		116

(a)	Costs for centralized services such as public relations, treasury and cash management, and other services were recognized within SG&A in the Condensed Combined Statement of Income.

(b)	Costs associated with employee medical insurance were recognized within Cost of products, Cost of services, SG&A , and Research and development (“R&D”) in the Condensed Combined Statement of Income based on the employee population.

(c)	Costs for corporate and shared services such as information technology, finance and other services were primarily recognized in SG&A and R&D in the Condensed Combined Statement of Income.

AFTER

SPIN-OFF.

In connection with the

Spin-Off,

the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE, including, but not limited to the following which had activity during the first quarter of 2023:

•

Separation and Distribution Agreement

— sets forth the principal actions to be taken in connection with the

Spin-Off,

including the transfer of assets and assumption of liabilities, and establishes certain rights and obligations between the Company and GE following the Distribution, including procedures with respect to claims subject to indemnification and related matters.

•

Transition Services Agreement

— governs all matters relating to the provision of services between the Company and GE on a transitional basis. The services the Company receives include support for digital technology, human resources, supply chain, finance, and real estate services, among others. The services generally commenced on the date of the

Spin-Off

and will terminate up to 36 months following the Distribution Date depending upon the related transitional service. For the three months ended March 31, 2023, we incurred $108 million, net, which represents fees charged from GE to the Company primarily for information technology, human resources, and

R&D

and is net of fees charged from the Company to GE for facilities and other shared services.

•

Tax Matters Agreement (“TMA”)

— governs the respective rights, responsibilities, and obligations between the Company and GE with respect to all tax matters (excluding employee-related taxes covered under the Employee Matters Agreement), in addition to certain restrictions which generally prohibit us from taking or failing to take any action in the

two-year

period following the Distribution that would prevent the Distribution from qualifying as

tax-free

Current amounts due from and to GE under the various agreements described above are recognized within Due from related parties or Due to related parties, as applicable, in the Condensed Consolidated and Combined Statements of Financial Position.

Non-current

amounts due from and to GE were $77 million and $108 million, respectively, as of March 31, 2023 and were recognized within All other assets or All other liabilities, as applicable, in the Condensed Consolidated Statements of Financial Position. These amounts primarily relate to tax and other indemnities.

GE HealthCare sells products and services in the ordinary course of business to certain entities associated with two members of our Board of Directors. During the three months ended March 31, 2023, we recognized revenue of $24 million from these entities in connection with providing products and services. Current amounts due from these entities as of March 31, 2023 were not significant.

NOTE 17. RELATED PARTIES

Prior to the Separation, GE provided the Company with significant corporate infrastructure and shared services. Some of these services will continue to be provided by GE to the Company on a temporary basis under the Transition Services Agreement. See Note 19, “Subsequent Events” for further information. Accordingly, as described in Note 1, “Organization and Basis of Presentation,” certain corporate and shared costs have been charged on the basis of direct usage by the Company as follows:

(a)

Employees of the Company participated in pensions and benefit plans that were sponsored by GE. The Company was charged $207 million, $237 million, and $296 million for the years ended December 31, 2022, 2021, and 2020, respectively. These costs were charged directly to the Company based on the specific employee eligibility for those benefits. See Note 10, “Postretirement Benefit Plans” for further information.

(b)

GE granted various employee benefits to its group employees, including those of the Company, under the GE Long-Term Incentive Plan. These benefits primarily included stock options and restricted stock units. Compensation expense associated with this plan was $67 million, $76 million, and $80 million for the years ended December 31, 2022, 2021, and 2020, respectively, which are included primarily in Selling, general, and administrative in the Combined Statements of Income. These costs were charged directly to the Company based on the specific employees receiving awards.

Additionally, certain GE Corporate Costs were charged to the Company based on allocation methodologies as follows:

(a)

Centralized services such as public relations, investor relations, treasury and cash management, executive management, security, government relations, community outreach, and corporate internal audit services were charged to the Company on a pro rata basis of GE’s estimates of each company’s usage at the beginning of the fiscal year. Costs of $42 million, $56 million, and $67 million for the years ended December 31, 2022, 2021, and 2020, respectively, were recognized within Selling, general, and administrative in the Combined Statements of Income.

(b)

Costs associated with employee medical insurance totaling $122 million, $132 million, and $137 million for the years ended December 31, 2022, 2021, and 2020, respectively, were charged to the Company based on employee headcount and are recognized within Cost of products, Cost of services, Selling, general, and administrative, or Research and development in the Combined Statements of Income based on the employee population.

(c)

Information technology, finance, insurance, research, supply chain, human resources, tax, and facilities activities were charged to the Company based on headcount, revenue, or other allocation methodologies. The Company incurred expenses for these services of $457 million, $455 million, and $503 million for the years ended December 31, 2022, 2021, and 2020, respectively, which are primarily included in Selling, general, and administrative and Research and development in the Combined Statements of Income.

Management believes that the expense and cost allocations have been determined on a basis that is a reasonable reflection of the utilization of services provided or the benefit received by the Company during 2022, 2021, and 2020. The amounts that would have been, or will be incurred, on a stand-alone basis could materially differ from the amounts allocated due to economies of scale, difference in management judgment, a requirement for more or fewer employees, or other factors. Management does not believe, however, that it is practicable to estimate what these expenses would have been had the Company operated as an independent entity, including any expenses associated with obtaining any of these services from unaffiliated entities. In addition, the future results of operations, financial position, and cash flows could differ materially from the historical results presented herein.

The Company participates in factoring programs, the majority of which were discontinued in 2021. The Company factored U.S. and

non-U.S.

receivables through WCS on a recourse and nonrecourse basis pursuant to various factoring and servicing agreements. See Note 5, “Receivables” for further information.

The Company historically participated in centralized GE Treasury programs. The arrangement was not reflective of the manner in which the Company would have financed its operations had it been a stand-alone business separate from GE during the periods presented. Long-term intercompany financing, including strategic financing and centralized cash management arrangements, were used to fund expansion or certain working capital needs. All adjustments relating to certain transactions among the Company and GE or GE entities, which include the transfer of the balance of cash to GE, transfer of the balance of cash held in centralized cash management arrangements to GE, settlement of certain intercompany debt between the Company and GE or GE entities, and pushdown of all costs of doing business that were paid on behalf of the Company by GE or GE entities, were excluded from the asset and liability balances in the Combined Statements of Financial Position. These amounts have instead been reported within Net parent investment as a component of equity in the Combined Statements of Financial Position. As of December 31, 2022 and 2021, respectively, net related party receivables of $97 million and $195 million were reclassified to Net parent investment in the Combined Statements of Financial Position.

The Company’s related party revenues were not significant for the years ended December 31, 2022, 2021, and 2020. The majority of related party revenues were generated from sales made to former GE industrial business units.

Financing Receivables

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Restructuring and Related Activities [Abstract]

Financing receivables

NOTE 5. FINANCING RECEIVABLES

Financing Receivables


	As of
	March 31, 2023			December 31, 2022
Loans, net of deferred income	$	31		$	29
Investment in financing leases, net of deferred income		73			72
Allowance for credit losses		(4	)		(4	)

Current financing receivables — net (a)		100			97

Loans, net of deferred income		44			44
Investment in financing leases, net of deferred income		157			158
Allowance for credit losses		(5	)		(6	)

Non-current financing receivables — net (a)	$	196		$	196

(a)	Current financing receivables and non-current financing receivables are recognized within All other current assets and All other assets, respectively, in the Condensed Consolidated and Combined Statements of Financial Position.

As of March 31, 2023, 6%, 4%, and 5% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2022, 7%, 6%, and 6% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral.

NOTE 6. FINANCING RECEIVABLES

Financing Receivables


	As of
	December 31, 2022			December 31, 2021
Loans, net of deferred income	$	29		$	25
Investment in financing leases, net of deferred income		72			77
Allowance for credit losses (a)		(4	)		(3	)

Current financing receivables – net (b)	$	97		$	99

Loans, net of deferred income		44			41
Investment in financing leases, net of deferred income		158			149
Allowance for credit losses (a)		(6	)		(4	)

Non-current financing receivables – net (b)	$	196		$	186

(a)	Allowance for credit losses activity related to current and non-current financing receivables including write-offs, net of recoveries, was not material for the years ended December 31, 2022 and 2021.

(b)	Current financing receivables and non-current financing receivables are recognized within All other current assets and All other assets, respectively, in the Combined Statements of Financial Position.

Total financing receivables classified as held for sale were $1 million and $17 million as of December 31, 2022 and 2021, respectively. Total financing receivables sold were $8 million, $104 million, and $52 million for the years ended December 31, 2022, 2021, and 2020, respectively.

As of December 31, 2022, 7%, 6%, and 6% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2021, 5%, 4%, and 5% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively.

Restructuring And Other Activities (Table)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Restructuring and Other Activities


	For the three months ended March 31
	2023		2022
Employee termination costs	$	10	$	9
Facility and other exit costs		1		3
Asset write-downs		1		—

Total restructuring and other activities	$	12	$	12

Restructuring and Other Activities


	For the years ended December 31
	2022		2021		2020
Employee termination costs	$	74	$	127	$	108
Facility and other exit costs		46		20		11
Asset write-downs		26		8		15

Total restructuring and other activities	$	146	$	155	$	134

Postretirement Benefit Plans - Summary of Plan Obligations in Excess of Plan Assets (Detail) - USD ($) $ in Millions	Jan. 01, 2023	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Accumulated benefit obligation	$ 22,906	$ 687	$ 912
Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation		390	528
Fair value of plan assets		63	71
Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	22,953	406	555
Fair value of plan assets	$ 18,908	$ 63	$ 71

Income Taxes - Summary of Valuation Allowance (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Valuation Allowance [Abstract]
Balance at the beginning	$ 279	$ 250	$ 228
Provision for income taxes	(5)	39	43
Foreign currency exchange and other	(2)	(10)	(21)
Balance at the end	$ 272	$ 279	$ 250

Leases

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Leases

NOTE 7. LEASES

OPERATING LEASES.

As a lessee, the Company leases certain logistics, office, and manufacturing facilities, as well as vehicles and other equipment. Certain of the Company’s leases may include options to extend. Our ROU operating lease assets are recognized within Property, plant, and equipment – net in the Combined Statements of Financial Position. Our operating lease liabilities are recognized within All other current liabilities and All other liabilities in the Combined Statements of Financial Position, as detailed below. During 2022, $25 million and $34 million of operating lease ROU assets and operating lease liabilities, respectively, transferred from GE to GE HealthCare related to the Separation.

Operating Lease Assets and Liabilities


	As of
	December 31, 2022		December 31, 2021
Operating lease ROU assets	$	313	$	358

Current operating lease liabilities		104		104
Non-current operating lease liabilities		243		262

Total operating lease liabilities	$	347	$	366

Operating Lease Expense


	For the years ended December 31
	2022		2021		2020
Long-term (fixed)	$	115	$	114	$	135
Long-term (variable)		98		67		64
Short-term		4		4		2

Total operating lease expense	$	217	$	185	$	201

Maturity of Lease Liabilities


	2023		2024		2025		2026		2027		Thereafter		Total
Undiscounted lease payments	$	116	$	89	$	66	$	50	$	27	$	30	$	378
Less: imputed interest														(31	)

Total lease liability as of December 31, 2022													$	347

Supplemental Information Related to Operating Leases


	For the years ended December 31
	2022			2021			2020
Operating cash flows used for operating leases	$	113		$	128		$	138
Right-of-use assets obtained in exchange for new lease liabilities		98			94			168
Weighted-average remaining lease term (in years)		4.4			4.7			4.9
Weighted-average discount rate		3.8	%		3.3	%		3.8	%

FINANCE LEASES.

The Company leases equipment manufactured or sold by the Company to customers through sales-type leases. Sales-type leases are included in financing receivables and are recognized within All other current assets and All other assets in the Combined Statements of Financial Position.

Finance lease income was $12 million, $16 million, and $13 million for the years ended December 31, 2022, 2021, and 2020, respectively, and is recognized within Other (income) expense – net in the Combined Statements of Income.

Net Investment in Financing Leases


	As of
	December 31, 2022			December 31, 2021
Total minimum lease payments receivable	$	248		$	243
Less: deferred income		(30	)		(27	)

Discounted lease receivable		218			216
Estimated unguaranteed residual value of leased assets, net of deferred income		12			10

Investment in financing leases, net of deferred income	$	230		$	226

Contractual Maturities


Due In	2023		2024		2025		2026		2027		Thereafter		Total
Net minimum lease payments receivable	$	83	$	63	$	44	$	29	$	16	$	13	$	248

We expect actual maturities to differ from contractual maturities, primarily as a result of prepayments.

Summary of Significant Accounting Policies - Summary of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)
$ in Millions

Mar. 31, 2023

Dec. 31, 2022

Mar. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Dec. 31, 2019

Cash and Cash Equivalents [Abstract]

Cash and cash equivalents

$ 2,324

$ 1,440

$ 554

Short-term restricted cash

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Financial Position

2,327

1,445

556

Long-term restricted cash

^[1]

Total cash, cash equivalents, and restricted cash as presented on the Combined Statements of Cash Flows

$ 2,334

$ 1,451

$ 506

$ 561

$ 1,012

$ 869

[1]	Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Leases (Tables)

12 Months Ended

Dec. 31, 2022

Leases [Abstract]

Schedule Of Assets And Liabilities Lessee

Operating Lease Assets and Liabilities


	As of
	December 31, 2022		December 31, 2021
Operating lease ROU assets	$	313	$	358

Current operating lease liabilities		104		104
Non-current operating lease liabilities		243		262

Total operating lease liabilities	$	347	$	366

Schedule Of Operating Lease Expense

Operating Lease Expense


	For the years ended December 31
	2022		2021		2020
Long-term (fixed)	$	115	$	114	$	135
Long-term (variable)		98		67		64
Short-term		4		4		2

Total operating lease expense	$	217	$	185	$	201

Summary Of Maturity of Lease Liabilities

Maturity of Lease Liabilities


	2023		2024		2025		2026		2027		Thereafter		Total
Undiscounted lease payments	$	116	$	89	$	66	$	50	$	27	$	30	$	378
Less: imputed interest														(31	)

Total lease liability as of December 31, 2022													$	347

Schedule Of Supplemental Information Related To Operating Leases

Supplemental Information Related to Operating Leases


	For the years ended December 31
	2022			2021			2020
Operating cash flows used for operating leases	$	113		$	128		$	138
Right-of-use assets obtained in exchange for new lease liabilities		98			94			168
Weighted-average remaining lease term (in years)		4.4			4.7			4.9
Weighted-average discount rate		3.8	%		3.3	%		3.8	%

Schedule Of Net Investment In Financing Leases

Net Investment in Financing Leases


	As of
	December 31, 2022			December 31, 2021
Total minimum lease payments receivable	$	248		$	243
Less: deferred income		(30	)		(27	)

Discounted lease receivable		218			216
Estimated unguaranteed residual value of leased assets, net of deferred income		12			10

Investment in financing leases, net of deferred income	$	230		$	226

Summary Of Contractual Maturities

Contractual Maturities


Due In	2023		2024		2025		2026		2027		Thereafter		Total
Net minimum lease payments receivable	$	83	$	63	$	44	$	29	$	16	$	13	$	248

Financial Instruments And Fair Value Measurements - Summary Of Financial Assets And Liabilities (Detail) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Asset	$ 119	$ 66	$ 87
Derivative Liability	271	209	56
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment securities	31	21
Derivative Asset	119	66	87
Deferred compensation	267	64
Derivative Liability	271	209	56
Contingent Consideration	57	42	112
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment securities	31	21
Derivative Asset	0	0	0
Deferred compensation	264	62
Derivative Liability	0	0	0
Contingent Consideration	0	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment securities	0	0
Derivative Asset	119	66	87
Deferred compensation	3	2
Derivative Liability	268	203	56
Contingent Consideration	0	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment securities	0	0
Derivative Asset	0	0	0
Deferred compensation	0	0
Derivative Liability	3	6	0
Contingent Consideration	$ 57	$ 42	$ 112

Financing Receivables - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financing Receivables [Line Items]
Financing receivable, Held for sale		$ 1	$ 17
Financing receivable, sale	$ 5	$ 8	$ 104	$ 52
Percentage of nonaccrual financing receivable balance outstanding that is past due		6.00%	5.00%
Financial Asset, 1 to 29 Days Past Due [Member]
Financing Receivables [Line Items]
Financing receivable, Held for sale	6
Percentage of financing receivable balance that is past due		7.00%	5.00%
Financial Asset, Equal to or Greater than 90 Days Past Due [Member]
Financing Receivables [Line Items]
Financing receivable, Held for sale	$ 4
Percentage of financing receivable balance that is past due		6.00%	4.00%

Income Taxes - Summary of Unrecognized Tax Benefits (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Uncertainties [Abstract]
Unrecognized tax benefits	$ 465	$ 365	$ 684	$ 622
Accrued interest on unrecognized tax benefits	56	53	72
Reasonably possible reduction to the balance of unrecognized tax benefits in succeeding 12 months	45	36	64
Portion that, if recognized, would reduce tax expense and effective tax rate	$ 153	$ 111	$ 99

Income Taxes - Summary of Income Before Income Taxes (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]
U.S. income			$ 1,090	$ 1,587	$ 1,620
Non-U.S. income			1,422	1,288	1,090
Total	$ 546	$ 533	$ 2,512	$ 2,875	$ 2,710

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Commitments Guarantees Product Warranties And Other Loss Contingencies Disclosure [Abstract]

Receivables - Schedule Of Non Current Receivables (Detail) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Receivables [Abstract]
Long-term customer receivables	$ 71	$ 80	$ 83
Sundry receivables	71	57	49
Non-income based tax receivables	28	28	37
Supplier advances	11	11	0
Allowance for credit losses	(30)	(31)	(31)
Total long-term receivables – net	$ 151	$ 145	$ 138

Commitments Guarantees Product Warranties And Other Loss Contingencies (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Schedule of product warranty

Product Warranties


	For the three months ended March 31
	2023			2022
Balance at beginning of period	$	193		$	161
Current-year provisions		49			55
Expenditures		(51	)		(45	)
Other changes		2			(1	)

Balance at end of period	$	193		$	170

Product Warranties


	2022			2021			2020
Balance at January 1	$	161		$	157		$	152
Current-year provisions		238			228			207
Expenditures		(199	)		(221	)		(205	)
Other changes		(7	)		(3	)		3

Balance as of December 31	$	193		$	161		$	157

Purchase obligation fiscal year maturity

As of December 31, 2022, we had the following purchase commitments that are legally binding and specify minimum purchase quantities or spending amounts. These purchase commitments do not exceed our projected requirements and the amounts below exclude open purchase orders with a remaining term of less than one year.

Other Contractual Obligations


	2023		2024		2025		2026		2027		Thereafter		Total
Other Contractual Obligations	$	245	$	174	$	95	$	86	$	40	$	40	$	680

Restructuring And Other Activities - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 12	$ 12		$ 146	$ 155	$ 134
Severance Costs	10	$ 9		74	127	$ 108
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	99			75
Other Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve				75	$ 58
GE HealthCare Technologies Inc [Member]
Restructuring Cost and Reserve [Line Items]
Severance Costs	$ 31			$ 31
Subsequent Event [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges			$ 71
Additional Restructuring Charges			$ 82

Acquisitions, Goodwill, And Other Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($)
$ in Millions

Dec. 31, 2022

Dec. 31, 2021

Indefinite Lived Intangible Assets Excluding Goodwill, Gross

^[1]

$ 62

$ 48

Indefinite Lived Intangible Assets Excluding Goodwill, Net

^[1]

Intangible Assets Gross Excluding Goodwill, Gross

5,010

5,211

Intangible Assets Gross Excluding Goodwill, Accumulated Amortization

(3,490)

(3,364)

Intangible Assets Net Including Goodwill, Net

1,520

1,847

Customer-related [Member]

Finite-Lived Intangible Assets, Accumulated Amortization

(10)

(9)

Patents and technology [Member]

Finite-Lived Intangible Assets, Accumulated Amortization

2,544

2,556

(1,815)

(1,713)

Capitalized software [Member]

729

843

Finite-Lived Intangible Assets, Accumulated Amortization

2,309

2,500

(1,638)

(1,610)

Trademarks and other [Member]

671

890

Finite-Lived Intangible Assets, Accumulated Amortization

(27)

(32)

Schedule of Total Revenues by Segment

$ 8

$ 11

[1]	Indefinite-lived intangible assets primarily relate to acquired IPR&D prior to project completion and are not amortized.

Condensed Consolidated and Combined Statements of Income - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues	$ 4,707	$ 4,343	$ 18,341	$ 17,585	$ 17,164
Gross profit	1,891	1,678	7,179	7,174	6,767
Selling, general, and administrative	1,062	931	3,631	3,563	3,237
Research and development	270	238	1,026	816	810
Total operating expenses	1,332	1,169	4,657	4,379	4,047
Operating income	559	509	2,522	2,795	2,720
Interest and other financial charges – net	136	4	77	40	66
Non-operating benefit (income) costs	(115)	(2)	(5)	3	5
Other (income) expense – net	(8)	(26)	(62)	(123)	(61)
Income from continuing operations before income taxes	546	533	2,512	2,875	2,710
Benefit (provision) for income taxes	(163)	(131)	(563)	(600)	(652)
Net income from continuing operations			1,949	2,275	2,058
Income from discontinued operations, net of taxes			18	18	11,839
Net income	383	402	1,967	2,293	13,897
Net (income) loss attributable to noncontrolling interests	(11)	(13)	(51)	(46)	(51)
Net income attributable to GE HealthCare	372	389	1,916	2,247	13,846
Deemed preferred stock dividend of redeemable noncontrolling interest	(183)	0
Net income attributable to GE HealthCare common stockholders	$ 189	$ 389
Earnings Per Share [Abstract]
Basic earnings per share	$ 0.42	$ 0.86
Diluted earnings per share	$ 0.41	$ 0.86
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Basic	454	454
Diluted	457	454
Product [Member]
Revenues	$ 3,131	$ 2,787	12,044	11,165	11,016
Cost of revenue	2,037	1,914	7,975	7,196	7,229
Service [Member]
Revenues	1,576	1,556	6,297	6,420	6,148
Cost of revenue	$ 779	$ 751	$ 3,187	$ 3,215	$ 3,168

Segment And Geographical Information (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Segment Reporting [Abstract]

Total Revenues by Segment


	For the three months ended March 31
	2023		2022
Imaging:
Radiology	$	2,088	$	1,918
Interventional Guidance		408		393

Total Imaging		2,496		2,311
Total Ultrasound		859		815
PCS:
Monitoring Solutions		552		521
Life Support Solutions		229		195

Total PCS		781		716
Total PDx		558		484
Other (a)		13		17

Total revenues	$	4,707	$	4,343

(a)	Financial information not presented within the reportable segments, shown within the Other category, represents the HealthCare Financial Services (“HFS”) business which does not meet the definition of an operating segment.

Total Revenues by Segment


	For the years ended December 31
	2022		2021		2020
Imaging:
Radiology	$	8,395	$	8,019	$	7,626
Interventional Guidance		1,590		1,414		1,333

Total Imaging		9,985		9,433		8,959
Total Ultrasound		3,422		3,172		2,703
PCS:
Monitoring Solutions		2,092		2,119		2,243
Life Support Solutions		824		796		1,432

Total PCS		2,916		2,915		3,675
Total PDx		1,958		2,018		1,780
Other (a)		60		47		47

Total revenues	$	18,341	$	17,585	$	17,164

Schedule of Segment EBIT

Segment EBIT


	For the three months ended March 31
	2023			2022
Segment EBIT
Imaging	$	191		$	206
Ultrasound		207			192
PCS		109			65
PDx		155			138
Other (a)		2			(2	)

	$	664		$	599
Restructuring costs		(12	)		(12	)
Acquisition and disposition-related benefits (charges)		(1	)		(15	)
Gain (loss) of business dispositions and divestments		—			3
Spin-Off and separation costs		(58	)		—
Amortization of acquisition-related intangible assets		(31	)		(33	)
Investment revaluation gain (loss)		5			(8	)
Interest and other financial charges — net		(136	)		(4	)
Non-operating benefit income (costs)		115			2

Income from continuing operations before income taxes	$	546		$	533

(a)	Financial information not presented within the reportable segments, shown within the Other category, represents the HFS business and certain other investments which do not meet the definition of an operating segment.

Segment EBIT


	For the years ended December 31
	2022			2021			2020
Segment EBIT
Imaging	$	1,100		$	1,240		$	1,182
Ultrasound		908			885			640
PCS		341			356			698
PDx		520			693			504
Other (a)		(8	)		(2	)		(43	)

		2,861			3,172			2,981
Restructuring costs		(146	)		(155	)		(134	)
Acquisition and disposition-related benefits (charges)		34			(14	)		—
Gain (loss) of business dispositions and divestments		1			2			(3	)
Spin-Off and separation costs		(14	)		—			(2	)
Amortization of acquisition-related intangible assets		(121	)		(90	)		(83	)
Investment revaluation gain (loss)		(31	)		3			22
Interest and other financial charges – net		(77	)		(40	)		(66	)
Non-operating benefit income (costs)		5			(3	)		(5	)

Income from continuing operations before income taxes	$	2,512		$	2,875		$	2,710

Summary of Total Revenues by Geographic Region

Total Revenues by Geographic Region


	For the years ended December 31
	2022		2021		2020
United States	$	7,819	$	7,060	$	7,146
China		2,325		2,510		2,133
Other		8,197		8,015		7,885

Total revenues	$	18,341	$	17,585	$	17,164

Schedule of Long-Lived Assets - Net by Geographic Region

Long-Lived Assets - Net by Geographic Region


	As of
	December 31, 2022		December 31, 2021
United States	$	860	$	839
China		393		357
Norway		249		228
Other		812		811

Total long-lived assets - net	$	2,314	$	2,235

Segment and Geographical Information - Additional Information (Detail) - Customer Concentration Risk [Member] - Health Care [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue Benchmark [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	10.00%	10.00%	10.00%
Accounts Receivable [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	10.00%	10.00%

Financial Instruments And Fair Value Measurements - Schedule of Gross Fair Value of Outstanding Derivative Instruments (Detail) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	$ 8,971	$ 8,488	$ 10,786
Derivative Asset	119	66	87
Derivative Liability	271	209	56
Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	5,569	5,116	8,323
Derivative Asset	73	34	38
Derivative Liability	42	45	45
Cash Flow Hedging [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	1,226	1,240	2,463
Derivative Asset	25	32	49
Derivative Liability	62	53	11
Net Investment Hedging [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	2,176	2,132	0
Derivative Asset	21	0	0
Derivative Liability	167	111	0
Foreign Exchange Contract [Member] \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	4,690	4,456	7,510
Derivative Asset	38	9	29
Derivative Liability	22	20	37
Foreign Exchange Contract [Member] \| Cash Flow Hedging [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	1,226	1,240	2,463
Derivative Asset	25	32	49
Derivative Liability	62	53	11
Currency Swap [Member] \| Net Investment Hedging [Member] \| Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	2,176	2,132	0
Derivative Asset	21	0	0
Derivative Liability	167	111	0
Embedded Derivative Financial Instruments [Member] \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	594	604	789
Derivative Asset	19	24	6
Derivative Liability	14	18	8
Equity Contract [Member] \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	231	8	0
Derivative Asset	15	0	0
Derivative Liability	3	6	0
Commodity Contract [Member] \| Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	54	48	24
Derivative Asset	1	1	3
Derivative Liability	$ 3	$ 1	$ 0

Accumulated Other Comprehensive (Income) Loss - Net (Parenthetical) (Detail) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Mar. 31, 2023

Mar. 31, 2022

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Currency translation adjustments

OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax

$ 11

$ 2

$ 5

$ 9

$ 16

Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Tax

Benefit plans

Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, Tax

Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, Tax

Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax

Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax

Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax

^[1]

$ 0

^[1]

$ 0

^[2]

$ 0

^[2]

(688)

^[2],[3]

Currency translation adjustments Member

Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax

Benefit plans Member

Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax

(509)

Cash flow hedges Member

Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax

$ 0

Bio Pharma Business [Member]

Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax

$ 836

[1]	The amount of foreign currency translation recognized in Other comprehensive income (loss) during the three months ended March 31, 2023 and 2022 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “Financial Instruments and Fair Value Measurements.”
[2]	The amount of foreign currency translation recognized in other comprehensive income during the years ended December 31, 2022, 2021, and 2020 included net gains (losses) relating to net investment hedges, as further discussed in Note 13, “Financial Instruments and Fair Value Measurements.”
[3]	The total reclassification from AOCI included $836 million related to the sale of our BioPharma business in 2020, including currency translation of $688 million, net of taxes.

Commitments, Guarantees, Product Warranties, And Other Loss Contingencies

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Commitments Guarantees Product Warranties And Other Loss Contingencies Disclosure [Abstract]

Commitments guarantees product warranties and other loss contingencies

NOTE 13. COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

GUARANTEES.

The Company has

off-balance

sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 8, “Borrowings” for further information. In addition, GE has provided parent company guarantees in certain jurisdictions where we lack the legal structure to issue the requisite guarantees required on certain projects.

Following the

Spin-Off,

which was completed pursuant to a Separation and Distribution Agreement (the “Separation and Distribution Agreement”), the Company has remaining performance guarantees on behalf of GE.

Under the Separation and Distribution Agreement, GE is obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of

non-fulfillment

PRODUCT WARRANTIES.

We provide warranty coverage to our customers as part of customary practices in the market to provide assurance that the products we sell comply with agreed-upon specifications. We provide estimated product warranty expenses when we sell the related products. Warranty accruals are estimates that are based on the best available information, mostly historical claims experience, therefore claims costs may differ from amounts provided. An analysis of changes in the liability for product warranties follows.

Product Warranties


	For the three months ended March 31
	2023			2022
Balance at beginning of period	$	193		$	161
Current-year provisions		49			55
Expenditures		(51	)		(45	)
Other changes		2			(1	)

Balance at end of period	$	193		$	170

Product warranties are recognized within All other current liabilities in the Condensed Consolidated and Combined Statements of Financial Position.

LEGAL MATTERS.

In the normal course of our business, we are involved from time to time in various arbitrations; class actions; commercial, intellectual property, and product liability litigation; government investigations; investigations by competition/antitrust authorities; and other legal, regulatory, or governmental actions, including the significant matter described below that could have a material impact on our results of operations. In many proceedings, including the specific matter described below, it is inherently difficult to determine whether any loss is probable or even reasonably possible or to estimate the size or range of the possible loss, and accruals for legal matters are not recorded until a loss for a particular matter is considered probable and reasonably estimable. Given the nature of legal matters and the complexities involved, it is often difficult to predict and determine a meaningful estimate of loss or range of loss until we know, among other factors, the particular claims involved, the likelihood of success of our defenses to those claims, the damages or other relief sought, how discovery or other procedural considerations will affect the outcome, the settlement posture of other parties, and other factors that may have a material effect on the outcome. For such matters, unless otherwise specified, we do not believe it is possible to provide a meaningful estimate of loss at this time. Moreover, it is not uncommon for legal matters to be resolved over many years, during which time relevant developments and new information must be continuously evaluated.

Contracts with Iraqi Ministry of Health

Anti-Terrorism

Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and

dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all of the judges on the U.S. Court of Appeals for the District of Columbia Circuit (“the D.C. Circuit”). On February 2, 2023, the D.C. Circuit denied this request. On February 10, 2023, defendants filed a motion for a temporary, partial stay of further district court proceedings until the Supreme Court issues its decision in a separate case, Twitter, Inc. v. Taamneh, which also involves the U.S. Anti-Terrorism Act. On March 1, 2023, the District Court granted the motion for a temporary, partial stay. Defendants also plan to petition the Supreme Court to review the D.C. Circuit’s decision.

NOTE 14. COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

Product Warranties


	2022			2021			2020
Balance at January 1	$	161		$	157		$	152
Current-year provisions		238			228			207
Expenditures		(199	)		(221	)		(205	)
Other changes		(7	)		(3	)		3

Balance as of December 31	$	193		$	161		$	157

Product warranties are classified as short-term or long-term in the Combined Statements of Financial Position based on the expected settlement date.

GUARANTEES.

The Company has

off-balance

sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 9, “Borrowings” for further information. In addition, GE has provided parent company guarantees in certain jurisdictions where we lack the legal structure to issue the requisite guarantees required on certain projects.

LEGAL MATTERS.

Contracts with Iraqi Ministry of Health

In 2017, a number of U.S. Service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia (the “District Court”) against a number of pharmaceutical and medical device companies, including GE HealthCare and certain affiliates, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all of the judges on the U.S. Court of Appeals for the District of Columbia Circuit (“the D.C. Circuit”). On February 2, 2023, the D.C. Circuit denied this request. On February 10, 2023, defendants filed a motion for a temporary, partial stay of further district court proceedings until the Supreme Court issues its decision in a separate case, Twitter, Inc. v. Taamneh, which also involves the U.S. Anti-Terrorism Act. Defendants also plan to petition the Supreme Court to review the D.C. Circuit’s decision.

ENVIRONMENTAL AND ASSET RETIREMENT OBLIGATIONS.

Our operations, like operations of other companies engaged in similar businesses, involve the use, disposal, and cleanup of substances regulated under environmental protection laws and nuclear decommissioning regulations. We have obligations for ongoing and future environmental remediation activities. Liabilities for environmental remediation and nuclear decommissioning exclude possible insurance recoveries. Due to uncertainties or changes regarding the status of laws, regulations, technology, and information related to individual sites and lawsuits, it is reasonably possible that our exposure will exceed amounts accrued, and amounts not currently reasonably estimable and/or probable may need to be accrued in future periods. Our environmental remediation liabilities, which are measured on an undiscounted basis, were $11 million and $9 million as of December 31, 2022 and 2021, respectively, and are recognized within All other current liabilities and All other liabilities in the Combined Statements of Financial Position.

We record asset retirement obligations, which primarily relate to nuclear decommissioning, associated with the retirement of tangible long-lived assets as a liability in the period in which the obligation is incurred and its fair value can be reasonably estimated. The liability is measured at the present value of the obligation when incurred and is adjusted in subsequent periods. Corresponding asset retirement costs are generally capitalized as part of the carrying value of the related long-lived assets and depreciated over the assets’ useful lives. Our asset retirement obligations were $274 million and $264 million at December 31, 2022 and 2021, respectively, and are recognized within All other current liabilities and All other liabilities in the Combined Statements of Financial Position. Changes in the liability balance were mainly due to settlement, accretion, and revisions in fair value, and were not material for the years ended December 31, 2022, 2021, and 2020.

OTHER CONTRACTUAL OBLIGATIONS.

We have future contractual obligations and other minimum commercial commitments which represent

take-or-pay

contracts as well as purchase orders for goods and services utilized in the normal course of business such as capital expenditures, inventory, and services under contracts.

Other Contractual Obligations


	2023		2024		2025		2026		2027		Thereafter		Total
Other Contractual Obligations	$	245	$	174	$	95	$	86	$	40	$	40	$	680

Segment and Geographical Information - Schedule of Revenues From External Customers and Long Lived Assets By Geographical Areas (Detail) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets - net	$ 2,314	$ 2,235
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets - net	860	839
China [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets - net	393	357
Norway [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets - net	249	228
Others [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets - net	$ 812	$ 811

Restructuring And Other Activities

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Restructuring and Related Activities [Abstract]

Restructuring And Other Activities

NOTE 14. RESTRUCTURING AND OTHER ACTIVITIES

Restructuring activities are essential to reflect the business operating model for GE HealthCare as a stand-alone company and mostly involve workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring and other charges primarily include facility exit costs, employee-related termination benefits associated with workforce reductions, asset write-downs, and

cease-use

costs. For segment reporting, restructuring, and other activities are not allocated.

As a result of committed restructuring initiatives, we recorded expenses of $12 million for both the three months ended March 31, 2023 and 2022. These restructuring initiatives are expected to result in additional expenses of approximately $71 million, to be incurred primarily in 2023, substantially related to employee-related termination benefits and facility exit costs. Restructuring expenses are recognized within Cost of products, Cost of services, or Selling, general, and administrative

(“SG&A”),

as appropriate, in the Condensed Consolidated and Combined Statements of Income.

Restructuring and Other Activities


	For the three months ended March 31
	2023		2022
Employee termination costs	$	10	$	9
Facility and other exit costs		1		3
Asset write-downs		1		—

Total restructuring and other activities	$	12	$	12

In connection with the

Spin-Off,

GE transferred employee termination obligations for services already rendered of $31 million to GE HealthCare. Liabilities related to restructuring are recognized within All other current liabilities and All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position and totaled $99 million and $75 million as of March 31, 2023 and December 31, 2022, respectively.

NOTE 15. RESTRUCTURING AND OTHER ACTIVITIES

In 2022, we initiated restructuring activities to reflect the business operating model for GE HealthCare as a stand-alone company mostly involving workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring and other charges primarily include facility exit costs, employee-related termination benefits associated with workforce reductions, asset write-downs, and

cease-use

costs. For segment reporting, restructuring and other activities are not allocated.

As a result of restructuring initiatives, we recorded expenses of $146 million, $155 million, and $134 million for the years ended December 31, 2022, 2021, and 2020, respectively. These restructuring initiatives are expected to result in additional expenses of approximately $82 million, to be incurred primarily in 2023, substantially related to employee-related separation and facility exit costs. Restructuring expenses are recognized within Cost of products, Cost of services, or Selling, general, and administrative, as appropriate, in the Combined Statements of Income.

Restructuring and Other Activities


	For the years ended December 31
	2022		2021		2020
Employee termination costs	$	74	$	127	$	108
Facility and other exit costs		46		20		11
Asset write-downs		26		8		15

Total restructuring and other activities	$	146	$	155	$	134

In connection with the Separation, GE transferred employee termination costs for services already rendered of $31 million to GE HealthCare. These amounts are not included in the Combined Statements of Financial Position as of December 31, 2022.

Liabilities related to restructuring are recognized within All other current liabilities and All other liabilities in the Combined Statements of Financial Position and totaled $75 million and $58 million as of December 31, 2022 and 2021, respectively.

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2022

Earnings Per Share [Abstract]

Summary of earnings per share

Earnings Per Share


	For the three months ended March 31
(In millions, except per share amounts)	2023			2022
Numerator:
Net income	$	383		$	402
Net income attributable to noncontrolling interests		(11	)		(13	)

Net income attributable to GE HealthCare		372			389
Deemed preferred stock dividend of redeemable noncontrolling interest		(183	)		—

Net income attributable to GE HealthCare common stockholders	$	189		$	389

Denominator:
Basic weighted-average shares outstanding		454			454
Dilutive effect of common stock equivalents		3			—

Diluted weighted-average shares outstanding		457			454

Basic Earnings Per Share	$	0.42		$	0.86
Diluted Earnings Per Share	$	0.41		$	0.86

Antidilutive securities (a)		4			—

(a)	Diluted EPS excludes certain shares issuable under stock based compensation plans because the effect would have been antidilutive.

Supplemental Financial Information - Summary of Other Current and Non-Current Liabilities (Details) - USD ($)
$ in Millions

Mar. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Other Liabilities Disclosure [Abstract]

Employee compensation and benefit liabilities

^[1]

$ 853

$ 884

Sales allowances, equipment projects, and other commercial liabilities

296

302

Uncertain and other income taxes and related liabilities

237

245

Product warranties

193

161

Accrued freight and utilities

150

118

Operating lease liabilities

104

Derivative instruments

Environmental and asset retirement obligations

All other current liabilities

^[2]

237

257

$ 3,037

2,190

2,162

Non-current contract liabilities

650

630

632

Operating lease liabilities

243

262

Environmental and asset retirement obligations

251

238

Uncertain and other income taxes and related liabilities

182

133

Finance lease obligations

Sales allowances, equipment projects, and other commercial liabilities

All other non-current liabilities

^[3]

222

155

$ 1,834

$ 1,603

$ 1,484

[1]	Employee compensation and benefit liabilities primarily consists of accrued payroll, commissions, employee compensation and benefits, and pension and other postretirement benefit obligations.
[2]	Current Other primarily consists of miscellaneous accrued costs and interest payable.
[3]	Non-current Other primarily consists of liabilities related to derivative instruments.

Postretirement Benefit Plans - Summary of Pre-tax Cost of Postretirement Benefit Plans and Changes in Other Comprehensive Income (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Amount Recognized In Net Periodic Benefit Cost And Other Comprehensive Income Loss Before Tax [Line Items]
Cost of postretirement benefit plans	$ 33	$ 31	$ 9	$ 25	$ 27
Changes in other comprehensive loss (income):
Net loss (gain) – current year	$ 372	$ 389	1,916	2,247	13,846
Postemployment Retirement Benefits [Member]
Schedule Of Amount Recognized In Net Periodic Benefit Cost And Other Comprehensive Income Loss Before Tax [Line Items]
Cost of postretirement benefit plans			9	23	29
Changes in other comprehensive loss (income):
Net loss (gain) – current year			(74)	(86)	10
Reclassifications out of AOCI:
Amortization of net loss			(5)	(16)	(18)
Amortization of prior service credit			5	4	4
Total changes in other comprehensive loss (income)			(74)	(98)	(4)
Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)			$ (65)	$ (75)	$ 25

Postretirement Benefit Plans - Summary of Expected Future Benefit Payments of Our Benefit Plans (Detail) $ in Millions	Dec. 31, 2022 USD ($)
Retirement Benefits [Abstract]
2023	$ 46
2024	50
2025	53
2026	51
2027	52
2028-2032	$ 256

Accumulated Other Comprehensive (Income) Loss - Net (Detail) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Mar. 31, 2023

Mar. 31, 2022

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Currency translation adjustments

Currency translation adjustments, Beginning balance

^[2]

$ (1,845)

^[1]

$ (969)

^[1]

$ (969)

^[1]

$ 643

$ 1,705

^[1]

(153)

^[1]

876

^[2]

326

^[2]

(374)

^[2]

Currency translation adjustments, Ending balance

^[1]

^[2]

(688)

^[2],[3]

(1,760)

^[1]

(1,122)

^[1]

(1,845)

^[1],[2]

(969)

^[1],[2]

643

^[2]

Benefit plans

Benefit plans, Beginning balance

(42)

(100)

180

310

(13)

(5)

(58)

(74)

Benefit plans, Ending balance

(52)

(6)

(136)

^[3]

1,865

(105)

(42)

(100)

180

Cash flow hedges, Beginning balance

(13)

(27)

(40)

Cash flow hedges, Ending balance

(26)

(11)

(8)

(27)

^[3]

(30)

Total AOCI, Beginning balance

(1,878)

(1,037)

(839)

(2,022)

(123)

791

212

(332)

Total AOCI, Ending balance

(78)

(11)

(14)

(851)

^[3]

$ (1,171)

$ (1,878)

$ (1,037)

$ (839)

Unrecognized gain transferred from GE pension taxes

^[4]

1,972

Currency translation adjustments Member

Unrecognized gain transferred from GE pension taxes

^[1],[4]

Benefit plans Member

Unrecognized gain transferred from GE pension taxes

^[4]

1,972

Cash flow hedges Member

Unrecognized gain transferred from GE pension taxes

^[4]

$ 0

[1]	The amount of foreign currency translation recognized in Other comprehensive income (loss) during the three months ended March 31, 2023 and 2022 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “Financial Instruments and Fair Value Measurements.”
[2]	The amount of foreign currency translation recognized in other comprehensive income during the years ended December 31, 2022, 2021, and 2020 included net gains (losses) relating to net investment hedges, as further discussed in Note 13, “Financial Instruments and Fair Value Measurements.”
[3]	The total reclassification from AOCI included $836 million related to the sale of our BioPharma business in 2020, including currency translation of $688 million, net of taxes.
[4]	Refer to Note 9, “Postretirement Benefit Plans” for further information on the unrecognized gain transferred from GE pension in connection with the Spin-Off.

Subsequent Events - Additional information (Details) $ / shares in Units, shares in Millions, $ in Millions				3 Months Ended
	Apr. 25, 2023 $ / shares	Feb. 01, 2023 USD ($) Employees shares	Jan. 03, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jan. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Subsequent Event [Line Items]
Deferred Compensation Arrangement with Individual, Recorded Liability						$ 0	$ 0
Derivative, Notional Amount				$ 8,971		8,488	10,786
Deferred Income Taxes Asset						1,691	1,508
Deferred Income Tax Liabilities, Net				64		$ 370	$ 385
Guarantor Obligations, Maximum Exposure, Undiscounted				164
Subsequent Event [Member]
Subsequent Event [Line Items]
Percentage Of Common Stock Outstanding			80.10%
Deferred Compensation Arrangement with Individual, Compensation Expense				525
Deferred Income Taxes Asset				2,200
Deferred Income Tax Liabilities, Net				516
Guarantor Obligations, Maximum Exposure, Undiscounted			$ 164
Proceeds From Funds To Pay Expenses			$ 75
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Value		$ 100
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEmployees \| Employees		8,200
Dividends Payable, Amount Per Share \| $ / shares	$ 0.03
Dividends Payable, Date to be Paid	Jun. 15, 2023
Dividends Payable, Date of Record	May 23, 2023
Subsequent Event [Member] \| GE HealthCare Technologies Inc [Member]
Subsequent Event [Line Items]
Deferred Income Taxes Asset				1,700
Subsequent Event [Member] \| Share-Based Payment Arrangement, Option [Member]
Subsequent Event [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant \| shares		1.5
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage		50.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date		Feb. 01, 2025
Subsequent Event [Member] \| Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant \| shares		0.8
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage		50.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date		Feb. 01, 2026
Subsequent Event [Member] \| Pension Plan [Member]
Subsequent Event [Line Items]
Deferred Income Taxes Asset				$ 958
Subsequent Event [Member] \| Not Designated as Hedging Instrument, Economic Hedge [Member]
Subsequent Event [Line Items]
Derivative, Notional Amount					$ 224

Income Taxes - Summary of Reconciliation of U.S. Federal Statutory Income Tax Rate to Actual Income Tax Rate (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income before taxes	$ 546	$ 533	$ 2,512	$ 2,875	$ 2,710
Tax expected at 21%			528	604	569
Foreign operations			47	(43)	42
U.S. tax on foreign operations			(36)	(23)	(45)
Uncertain tax positions			6	11	25
R&D benefits			(33)	(32)	(30)
State taxes, net of federal benefit			39	45	47
Valuation allowance			8	33	37
Other			4	5	7
Total	$ 163	$ 131	$ 563	$ 600	$ 652
Actual income tax rate	29.90%	24.60%	22.40%	20.90%	24.10%

Financial Instruments And Fair Value Measurements - Schedule of Pre-tax Gains (Losses) Recognized in OCI Related to Cash flow and Net Investment Hedges (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Financial Instruments and Fair Value Measurements Disclosure [Abstract]
Cash flow hedges	$ (17)	$ 41	$ 37	$ 40	$ (36)
Net investment hedges	$ 35	$ 0	$ (111)	$ 0	$ 0

Receivables - Schedule Of Current Customer Receivables Sold (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Receivables [Abstract]
Beginning balance	$ 15	$ 1,628
GE HealthCare sales to WCS and third parties	9	5,456
Collections and other activities	(18)	(7,076)
Reclassification from long-term customer receivables	1	7
Ending Balance	$ 7	$ 15

Borrowings - Additional Information (Detail) - USD ($) $ in Millions		3 Months Ended	12 Months Ended
	Nov. 22, 2022	Mar. 31, 2023	Dec. 31, 2022	Jan. 03, 2023	Nov. 30, 2022	Nov. 04, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Draw down of term loan		$ 10,283	$ 8,288					$ 37
Cash, cash equivalents, and restricted cash		2,334	1,451				$ 506	561	$ 1,012	$ 869
Unused letters of credit and bank guarantees and bonds		675	657					808
General Electric Company [Member]
Debt Instrument [Line Items]
Cash	$ 4,221
Debt Securities Payable [Member]
Debt Instrument [Line Items]
Residual value of guarantees on equipment sold		44	43					63
Liability related to guarantees		4	$ 4					$ 5
Senior Unsecured Debt [Member]
Debt Instrument [Line Items]
Debt instrument face amount	$ 8,250	8,250
Debt instrument Maturity date	the Company issued $8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2024 through 2052 (collectively, the “Notes”).		The Company’s long-term borrowings include $8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2024 through 2052 (collectively, the “Notes”).
Date of first interest payment	Mar. 31, 2023
Frequency of periodic payment	semi-annually
Percentage of aggregate principal amount of the notes repurchased	101.00%
Debt issuance costs	$ 37
Payments of debt issuance costs			$ 0
Maturity of debt			9 years
Average interest expense rate			5.97%
Interest expense for borrowing			$ 54
Accrued Interest expense for borrowing			52
Amortization of debt issuance costs			1
Senior Unsecured Debt [Member] \| General Electric Company [Member]
Debt Instrument [Line Items]
Debt instrument face amount	$ 4,000				$ 8,250
Five Year Senior Unsecured Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		2,500				$ 2,500
Three Hundred And Sixty Four Day Senior Unsecured Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		1,000				1,000
Three Year Senior Unsecured Term Loan Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		2,000				$ 2,000
Senior Unsecured Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Outstanding amounts under the Credit Facilities		$ 0	$ 0
Senior Unsecured Revolving Credit Facility [Member] \| Subsequent Event [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 10,250
Senior Unsecured Revolving Credit Facility [Member] \| Subsequent Event [Member] \| General Electric Company [Member]
Debt Instrument [Line Items]
Draw down of term loan				2,000
Cash, cash equivalents, and restricted cash				$ 1,800
Credit Facilities [Member]
Debt Instrument [Line Items]
Average interest rate		5.94%
Repayments of debt		$ 0

Borrowings

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Debt Disclosure [Abstract]

Borrowings

NOTE 8. BORROWINGS

The Company’s borrowings include the following senior unsecured notes and credit agreements:

Senior Unsecured Notes

The Company’s long-term borrowings include $8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2024 through 2052 (collectively, the “Notes”).

Credit Facilities

The Company has credit agreements providing for:

•

a five-year senior unsecured revolving credit facility in an aggregate committed amount of $2,500 million

;

•

364-day

senior unsecured revolving credit facility in an aggregate committed amount of $1,000 million

; and

•

a three-year senior unsecured term loan credit facility in an aggregate principal amount of $2,000 million (the “Term Loan Facility” and, together with the

five-year revolving credit facility

and the

364-

day revolving credit facility

, the “Credit Facilities”).

There were no outstanding amounts under the

five-year

revolving

credit facility and the 364-day revolving credit facility

as of March 31, 2023 or December 31, 2022. On January 3, 2023, the Company completed a $2,000 million drawdown of the Term Loan Facility in connection with the

Spin-Off

from GE.

The average interest rate for the Notes and our Credit Facilities for the three months ended March 31, 2023 was 5.94%. We had no principal debt repayments on the Notes or the Credit Facilities for the three months ended March 31, 2023.

Long-Term Borrowings Composition


	As of
	March 31, 2023		December 31, 2022
5.550% senior notes due November 15, 2024	$	1,000	$	1,000
5.600% senior notes due November 15, 2025		1,500		1,500
5.650% senior notes due November 15, 2027		1,750		1,750
5.857% senior notes due March 15, 2030		1,250		1,250
5.905% senior notes due November 22, 2032		1,750		1,750
6.377% senior notes due November 22, 2052		1,000		1,000
Term Loan Facility		2,000		—
Other		33		38

Total principal debt issued		10,283		8,288

Less: Unamortized debt issuance costs and discounts		44		47
Less: Current portion of long-term borrowings		5		7

Long-term borrowings, net of current portion	$	10,234	$	8,234

See Note 12, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated interest rate and cross-currency swaps.

LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS.

In addition to the Notes, which were guaranteed on a senior unsecured basis by GE through the completion of the

Spin-Off,

at which time GE was automatically and unconditionally released and discharged from all obligations under its guarantees, as of March 31, 2023 and December 31, 2022, the Company had unused letters of credit, bank guarantees, bid bonds, and surety bonds of approximately $675 million and $657 million, respectively, related to certain commercial contracts. Additionally, we have approximately $44 million and $43 million of guarantees as of March 31, 2023 and December 31, 2022, respectively, primarily related to residual value guarantees on equipment sold to third-party finance companies. Our Condensed Consolidated and Combined Statements of Financial Position reflects a liability of $4 million and $4 million as of March 31, 2023 and December 31, 2022, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to

off-balance

sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 13, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE.

NOTE 9. BORROWINGS

BORROWINGS.

Senior Unsecured Notes

On November 22, 2022, and in connection with the Separation, the Company issued $

8,250

million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2024 through 2052 (collectively, the “Notes”). Interest payments on the Notes are due semi-annually until maturity, with the first interest payment due in

March 2023

. In the event of a change in control and a related downgrade of the ratings of the Notes below investment grade, the indenture governing the Notes requires that the Company make an offer to each holder of the Notes to repurchase all or any part of that holder’s notes at a repurchase price equal to

101

% of the aggregate principal amount of the Notes repurchased, plus any accrued and unpaid interest. The indenture also includes a limitation on liens incurred by the Company and its wholly owned U.S. subsidiaries. The indenture does not restrict the Company or its subsidiaries from incurring indebtedness, nor does it require any financial covenants. All the covenants are subject to a number of exceptions, limitations, and qualifications.

Upon issuance, the Notes became guaranteed on a senior unsecured basis by GE. Following the completion of the Separation on January 3, 2023, GE was automatically and unconditionally released and discharged from all obligations under its guarantees. Of the $

8,250

million of the Notes, $

4,000

million of the indebtedness was issued directly to GE and net cash proceeds of $

4,221

million from the remaining indebtedness issued to third parties was distributed to GE. GE exchanged the $

4,000

million of indebtedness with third parties prior to December 31, 2022. As of December 31, 2022, all of the Notes were held by third parties.

We recorded $

million of debt issuance costs related to the Notes. Debt issuance costs are presented as a reduction of debt in the Combined Statements of Financial Position and are amortized as a component of interest expense over the term of the related debt using the effective interest method.

We had no debt payments on the Notes during the year ended December 31, 2022. The average maturity of the Company’s long-term debt as of December 31, 2022 is approximately 9 years and the average interest expense rate on our total borrowings for the year ended December 31, 2022 is approximately

5.97

%. Interest expense associated with long-term debt was $

million for the year ended December 31, 2022, and is included in Interest and other financial charges – net in the Combined Statements of Income. Interest expense for borrowings was not significant for the years ended December 31, 2021 and 2020. Included in interest expense on the Combined Statements of Income is accrued interest of $

million and amortization of debt issuance costs of $

million for the year ended December 31, 2022.

Credit Facilities

On November 4, 2022, the Company entered into credit agreements providing for:

•

a five-year senior unsecured revolving credit facility in an aggregate committed amount of $

2,500

million

(the

“5-Year

Revolving Credit Facility”);

•

364-day

senior unsecured revolving credit facility in an aggregate committed amount of $

1,000

million (the

“364-Day

Revolving Credit Facility”); and

•

a three-year senior unsecured term loan credit facility in an aggregate principal amount of $

2,000

million (the “Term Loan Facility” and, together with the

5-Year

Revolving Credit Facility and the

364-Day

Revolving Credit Facility, the “Credit Facilities”).

The Credit Facilities were not available to the Company or its subsidiaries until consummation of the Separation. As such, there were no outstanding amounts under the Credit Facilities as of December 31, 2022. On January 3, 2023, GE HealthCare completed a $

2,000

million drawdown of the Term Loan Facility in connection with the

Spin-Off

from GE, bringing total principal balance of borrowings to $

10,250

million. After settlement of all

Spin-Off

transactions with GE, we began operations as an independent company with approximately $1,800 million of cash, cash equivalents, and restricted cash.

The Company pays a facility fee to each lender, which accrues at a rate equal to an applicable margin specified in the revolving credit facility agreements on the daily commitments of the lenders. The Borrowings under the Credit Facilities will bear interest at variable interest rates equal to: (i) the alternate base rate or (ii) the Secured Overnight Funding Rate, in each case plus an applicable margin specified in the credit agreement. The Credit Facilities contain affirmative and negative covenants customary to financings of this type that, among other things, limit the Company and its subsidiaries’ ability to incur additional liens and to make certain fundamental changes. In addition, the Credit Facilities contain a financial covenant that requires the Company to not exceed a maximum consolidated net leverage ratio that will be tested beginning with the fiscal quarter ending on June 30, 2023. The Credit Facilities will be used for general corporate purposes.

Long-Term Borrowings Composition


	As of
	December 31, 2022		December 31, 2021
5.550% senior notes due November 15, 2024	$	1,000	$	—
5.600% senior notes due November 15, 2025		1,500		—
5.650% senior notes due November 15, 2027		1,750		—
5.857% senior notes due March 15, 2030		1,250		—
5.905% senior notes due November 22, 2032		1,750		—
6.377% senior notes due November 22, 2052		1,000		—
Other		38		37

Total principal debt issued		8,288		37

Less: Unamortized debt issuance costs and discounts		47		—
Less: Current portion of long-term borrowings		7		6

Long-term borrowings, net of current portion	$	8,234	$	31

Scheduled maturities of long-term debt, excluding amortization of discounts and debt issuance costs, are as follows:


2023	$	7
2024		1,025
2025		1,504
2026		2
2027		1,750
Thereafter		4,000

Total	$	8,288

See Note 13, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated interest rate and cross-currency swaps.

LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS.

In addition to the Notes, which were guaranteed on a senior unsecured basis by GE through the completion of the Separation, at which time GE has been automatically and unconditionally released and discharged from all obligations under its guarantees, as of December 31, 2022 and 2021, the Company had unused letters of credit, bank guarantees, bid bonds, and surety bonds of approximately $657 million and $808 million, respectively, related to certain commercial contracts. Additionally, we have approximately $43 million and $63 million of guarantees as of December 31, 2022 and 2021, respectively, primarily related to residual value guarantees on equipment sold to third-party finance companies. Our Combined Statements of Financial Position reflects a liability of $4 million and $5 million as of December 31, 2022 and 2021, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to

off-balance

sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Property, Plant and Equipment [Abstract]

Property, Plant, And Equipment And Operating Leases (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Schedule Of Property, Plant, and Equipment


	As of
	March 31, 2023			December 31, 2022
Original cost	$	5,060		$	4,989
Less accumulated depreciation and amortization		(3,039	)		(2,988	)
Right-of-use operating lease assets		306			313

Property, plant, and equipment — net	$	2,327		$	2,314

Property, Plant, and Equipment – Net


As of December 31	Depreciable lives (in years)	Original Cost				Accumulated Depreciation						Net Carrying Value
As of December 31	Depreciable lives (in years)	2022		2021		2022			2021			2022		2021
Land and improvements (a)	8	$	70	$	77	$	(1	)	$	(1	)	$	69	$	76
Buildings, structures and related equipment	8-40		1,889		1,756		(1,109	)		(1,006	)		780		750
Machinery and equipment (b)	4-20		2,541		2,466		(1,791	)		(1,746	)		750		720
Leasehold costs and manufacturing plants under construction	1-10		489		394		(87	)		(63	)		402		331

Property, plant, and equipment – net, exclusive of ROU operating lease assets		$	4,989	$	4,693	$	(2,988	)	$	(2,816	)	$	2,001	$	1,877

ROU operating lease assets (c)													313		358

Property, plant, and equipment – net												$	2,314	$	2,235

(a)	Depreciable lives exclude land.

(b)	Equipment leased to customers is classified as Machinery and equipment and is reported at cost less accumulated depreciation, and was $39 million and $40 million as of December 31, 2022 and 2021, respectively.

(c)	See Note 7, “Leases” for further information.

Supplemental Financial Information - Summary of Inventories (Details) - USD ($)
$ in Millions

Mar. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Inventory Disclosure [Abstract]

Raw materials

$ 1,097

$ 1,053

$ 900

Work in process

107

104

Finished goods

1,052

1,011

942

Inventories

$ 2,256

^[1]

$ 2,155

^[1],[2]

$ 1,946

^[2]

[1]	Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.
[2]	Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Combined Statements of Financial Position. See the supplemental table for “All Other Current and Non-Current Assets” for further information.

Financing Receivables - Schedule of Financing Receivables (Detail) - USD ($)
$ in Millions

Mar. 31, 2023

Dec. 31, 2022

Dec. 16, 2022

Dec. 31, 2021

Schedule of Financing Receivables [Line Items]

Financing Receivable, Allowance for Credit Loss, Current

$ (4)

^[1]

$ (3)

^[1]

Financing Receivable, after Allowance for Credit Loss, Current

100

^[2]

Financing Receivable, Allowance for Credit Loss, Noncurrent

(5)

(6)

^[1]

(4)

^[1]

Financing Receivable, after Allowance for Credit Loss, Noncurrent

196

^[2]

186

^[2]

Loans, Net Of Deferred Income [Member]

Schedule of Financing Receivables [Line Items]

Financing Receivable, before Allowance for Credit Loss, Current

Financing Receivable, before Allowance for Credit Loss, Noncurrent

Investment In Financing Leases, Net Of Deferred Income [Member]

Schedule of Financing Receivables [Line Items]

Financing Receivable, before Allowance for Credit Loss, Current

Financing Receivable, before Allowance for Credit Loss, Noncurrent

$ 157

$ 158

$ 149

[1]	Allowance for credit losses activity related to current and non-current financing receivables including write-offs, net of recoveries, was not material for the years ended December 31, 2022 and 2021.
[2]	Current financing receivables and non-current financing receivables are recognized within All other current assets and All other assets, respectively, in the Combined Statements of Financial Position.

Postretirement Benefit Plans

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Retirement Benefits [Abstract]

Postretirement Benefit Plans

NOTE 9. POSTRETIREMENT BENEFIT PLANS

PENSION BENEFITS AND RETIREE HEALTH AND LIFE BENEFITS SPONSORED BY GE, TRANSFERRED TO GE HEALTHCARE IN CONNECTION WITH THE SPIN-OFF.

Certain GE HealthCare employees were covered under various pension and retiree health and life plans sponsored by GE prior to the

Spin-Off,

including principal pension plans, other pension plans, and principal retiree benefit plans. A subset of these pension plans have been closed to new participants. For the three months ended March 31, 2022, relevant participation costs for these plans were allocated to the Company and recognized within the Condensed Combined Statement of Income. These included service costs for active employees in the U.S. GE Pension Plan, certain international pension plans, the U.S. GE Supplementary Pension Plan, and the U.S. retiree benefit plan. We did not record any liabilities associated with our participation in these plans in our Condensed Combined Statement of Financial Position as of December 31, 2022.

Expenses associated with our employees’ participation in the U.S. GE principal pension and principal retiree benefit plans, which represent the majority of related expense, were $24 million for the three months ended March 31, 2022. Expenses associated with our employees’ participation in GE’s

non-U.S.

based pension plans were $4 million for the three months ended March 31, 2022.

In connection with the

Spin-Off,

on January 1, 2023, these plans were separated and GE transferred certain liabilities and assets of these plans to GE HealthCare based upon measurements as of December 31, 2022. The amounts assumed by GE HealthCare on January 1, 2023, are shown in the tables below.

Accumulated Benefit Obligations and Unrecognized Gain


	As of January 1, 2023
	Defined benefit plans		Other postretirement plans		Total
Accumulated benefit obligations	$	21,696	$	1,210	$	22,906
Unrecognized gain to be recorded in AOCI		1,258		1,223		2,481

Net Benefit Liability


	As of January 1, 2023
	Defined benefit plans		Other postretirement plans		Total
Projected benefit obligations	$	21,743	$	1,210	$	22,953
Fair value of assets		18,908		—		18,908

Net liability	$	2,835	$	1,210	$	4,045

PENSION PLANS SPONSORED BY GE HEALTHCARE, INCLUDING THOSE TRANSFERRED BY GE.

As the pension plans were transferred by GE on January 1, 2023, there are no amounts included for these plans in the period ended March 31, 2022. Pension plans with pension assets or obligations less than

$50 million and $20 million as of March 31, 2023 and 2022, respectively, are not included in the results below.

Components of Expense (Income)


	Defined benefit plans						Other post-retirement plans
For the three months ended March 31	2023			2022			2023			2022
Service cost — Operating	$	14		$	5		$	2		$	—
Interest cost		292			4			15			—
Expected return on plan assets		(356	)		(7	)		—			—
Amortization of net loss (gain)		(29	)		2			(16	)		—
Amortization of prior service cost (credit)		(1	)		(1	)		(22	)		—

Non-operating	$	(94	)	$	(2	)	$	(23	)	$	—

Net periodic (income) expense	$	(80	)	$	3		$	(21	)	$	—

For the three months ended March 31, 2023, the Company made contributions for benefit payments totaling $48 million to the pension plans and $43 million to its postretirement plans. For the remainder of 2023, the Company expects to make future benefit payments of approximately $255 million to our defined benefit pension and postretirement plans for benefit payments. The Company does not have a required minimum cash pension contribution obligation for its U.S. plans in 2023. Future contributions will depend on market conditions, interest rates, and other factors.

Prior to the

Spin-Off,

we disclosed postretirement plans with assets or obligations that exceeded $20 million. As a result of the transferred liabilities and assets to GE HealthCare on January 1, 2023, we now present postretirement plans with assets or obligations that exceed $50 million. For the year, the Company expects to contribute approximately $11 million to postretirement plans that are no longer disclosed.

Defined Contribution Plan

As a result of the

Spin-Off,

GE HealthCare established a defined contribution plan for its eligible U.S. employees that was largely consistent with the plan they participated in while GE HealthCare operated as a business of GE. Expenses associated with our employees’ participation in GE HealthCare’s defined contribution plan in 2023 and GE’s defined contribution plan in 2022 represent the employer matching contributions for GE HealthCare employees and were $33 million and $31 million for the three months ended March 31, 2023 and 2022, respectively.

NOTE 10. POSTRETIREMENT BENEFIT PLANS

PENSION BENEFITS AND RETIREE HEALTH AND LIFE BENEFITS SPONSORED BY GE.

Certain GE HealthCare employees are covered under various pension and retiree health and life plans sponsored by GE, including principal pension plans, other pension plans, and principal retiree benefit plans. These plans are accounted for as multiemployer plans. Certain of these pension plans have been closed to new participants. Relevant participation costs for certain

GE-sponsored

employee benefit plans have been allocated to the Company and are recognized within the Combined Statements of Income. These include service costs for active employees in the U.S. GE Pension Plan, certain international pension plans, the U.S. GE Supplementary Pension Plan, and the U.S. retiree benefit plan. We have not recorded any liabilities associated with our participation in these plans in our Combined Statements of Financial Position as of December 31, 2022 and 2021. Expenses associated with our employees’ participation in the U.S. GE principal pension and principal retiree benefit plans, which represent the majority of related expense, were $73 million, $96 million, and $194 million for the years ended December 31, 2022, 2021, and 2020, respectively. Expenses associated with our employees’ participation in GE’s

non-U.S.

based pension plans were $11 million, $22 million, and $19 million for the years ended December 31, 2022, 2021, and 2020, respectively.

In connection with the Separation, on January 1, 2023, these plans were separated and GE transferred certain liabilities and assets of these plans to GE HealthCare. The amounts assumed by GE HealthCare are shown in the table below. These amounts are not included in the Combined Statements of Financial Position as of December 31, 2022 and 2021.

Accumulated Benefit Obligations and Unrecognized Gain


	As of January 1, 2023
	Defined benefit plans		Other post-retirement plans		Total
Accumulated benefit obligations	$	21,696	$	1,210	$	22,906
Unrecognized gain to be recorded in AOCI		1,258		1,223		2,481

Net Benefit Liability


	As of January 1, 2023
	Defined benefit plans		Other post-retirement plans		Total
Projected benefit obligations	$	21,743	$	1,210	$	22,953
Fair value of assets		18,908		—		18,908

Net liability	$	2,835	$	1,210	$	4,045

Defined Contribution Plan

Expenses associated with our employees’ participation in GE’s defined contribution plan represent the employer matching contributions for GE HealthCare employees and were $123 million, $119 million, and $83 million for the years ended December 31, 2022, 2021, and 2020, respectively.

PENSION PLANS SPONSORED BY GE HEALTHCARE.

In addition to these

GE-sponsored

plans, certain employees are covered by pension plans sponsored by the Company. Our pension plans in 2022 included 11 U.S. and

non-U.S.

pension plans with pension assets or obligations greater than $20 million. Smaller pension plans with pension assets or obligations less than $20 million are not presented in the following tables. We use a December 31

measurement date for these plans. These defined benefit plans generally provide benefits to employees based on formulas recognizing length of service and earnings. Certain of these pension plans have been closed to new participants.

Funding

The funding policy for our pension plans is to contribute amounts sufficient to meet minimum funding requirements as set forth in employee benefit and tax laws plus any additional amounts as we may determine to be appropriate. In 2022, we contributed $18 million to fund certain pension plans. In 2023, we expect to contribute approximately $19 million to our pension plans that were included in our Combined Statements of Financial Position as of December 31, 2022.

Plan Funded Status


	As of
	December 31, 2022			December 31, 2021
Change in projected benefit obligations
Balance at January 1	$	940		$	1,048
Service cost		19			24
Interest cost		17			15
Participant contributions		1			1
Actuarial loss (gain) – net		(193	)		(59	)
Benefits paid		(38	)		(44	)
Exchange rate adjustments		(43	)		(45	)

Balance at December 31	$	703		$	940

Change in plan assets
Balance at January 1		553			537
Actual gain (loss) on plan assets		(101	)		44
Employer contributions		18			20
Participant contributions		1			1
Benefits paid		(38	)		(44	)
Exchange rate adjustments		(8	)		(5	)

Balance at December 31	$	425		$	553

Funded status – surplus (deficit)	$	(278	)	$	(387	)

Amounts Recorded in Combined Statements of Financial Position


	As of
	December 31, 2022			December 31, 2021
Non-current assets – other	$	65		$	97
Current liabilities – other		(16	)		(18	)
Non-current liabilities – compensation and benefits		(327	)		(466	)

Net amount recorded	$	(278	)	$	(387	)

Amounts Recorded in AOCI


	As of
	December 31, 2022			December 31, 2021
Net loss (gain)	$	60		$	138
Prior service cost (credit)		(5	)		(9	)

Total recorded in AOCI	$	55		$	129

The accumulated benefit obligation represents the actuarial present value of benefits based on employee service and compensation as of the measurement date and does not include an assumption about future compensation levels. The table below summarizes the total accumulated benefit obligations, the accumulated benefit obligations in excess of plan assets, and the projected benefit obligation and fair value of plan assets for the defined benefit pension plans with projected benefit obligations in excess of plan assets.

Plan Obligations in Excess of Plan Assets


	As of
	December 31, 2022		December 31, 2021
Accumulated benefit obligation	$	687	$	912

Plans with accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation	$	390	$	528
Fair value of plan assets		63		71

Plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	$	406	$	555
Fair value of plan assets		63		71

Components of Expense (Income)


	For the years ended December 31
	2022			2021			2020
Service cost – Operating	$	19		$	24		$	23
Interest cost		17			15			17
Expected return on plan assets		(27	)		(27	)		(26	)
Amortization of net loss (gain)		5			17			18
Amortization of prior service cost (credit)		(5	)		(4	)		(4	)
Curtailment / settlement loss (gain)		—			—			(1	)

Non-operating	$	(10	)	$	1		$	4

Net periodic expense	$	9		$	25		$	27

Pre-tax

Cost of Postretirement Benefit Plans and Changes in Other Comprehensive Income


	For the years ended December 31
	2022			2021			2020
Cost of postretirement benefit plans	$	9		$	23		$	29

Changes in other comprehensive loss (income):
Net loss (gain) – current year		(74	)		(86	)		10
Reclassifications out of AOCI:
Amortization of net loss		(5	)		(16	)		(18	)
Amortization of prior service credit		5			4			4

Total changes in other comprehensive loss (income)	$	(74	)	$	(98	)	$	(4	)

Cost (income) of postretirement benefit plans and changes in other comprehensive loss (income)	$	(65	)	$	(75	)	$	25

Assumptions


	For the years ended December 31
	2022			2021			2020
Weighted-average benefit obligations assumptions
Discount rate		4.26	%		1.91	%		1.44	%
Compensation increases		2.99	%		2.81	%		2.65	%

Weighted-average benefit cost assumptions
Discount rate		1.91	%		1.44	%		1.80	%
Expected rate of return on plan assets		6.32	%		5.39	%		5.40	%

Assumptions Used in Calculations

Accounting requirements necessitate the use of assumptions to reflect the uncertainties and the length of time over which the pension obligations will be paid. The actual amount of future benefit payments will depend upon when participants retire, the amount of their benefit at retirement, and how long they live. To reflect the obligation in today’s U.S. dollars, we discount the future payments using a rate that matches the time frame over which the payments will be made. We also assume a long-term rate of return that will be earned on investments used to fund these payments.

We evaluate these assumptions annually. We periodically evaluate other assumptions, such as retirement age, mortality, and turnover, and update them as necessary to reflect our actual experience and expectations for the future.

We determine the discount rate using the weighted average yields on high-quality fixed-income securities that have maturities consistent with the timing of benefit payments. Lower discount rates increase the size of the benefit obligations and generally increase pension expense in the following year; higher discount rates reduce the size of the benefit obligation and generally reduce subsequent-year pension expense.

The expected return on plan assets is the estimated long-term rate of return that will be earned on the investments used to fund the pension obligations. To determine this rate, we consider the current and target composition of plan investments, our historical returns earned, and our expectations about the future.

The compensation assumption is used to estimate the annual rate at which compensation of active plan participants will grow. If the rate of growth assumed increases, the size of the pension obligations will increase, as will the amount recorded in AOCI in our Combined Statements of Financial Position and amortized to earnings in subsequent periods.

With respect to the pension balances included on our Combined Statements of Financial Position as of December 31, 2022, we estimate that we will amortize $3 million of net actuarial loss and $2 million of prior service credit from AOCI into pension expense during 2023.

Expected Future Benefit Payments of Our Benefit Plans


	2023		2024		2025		2026		2027		2028-2032
Estimated future benefit payments	$	46	$	50	$	53	$	51	$	52	$	256

COMPOSITION OF PLAN ASSETS.

The fair value of our pension plans’ investments is presented below. The inputs and valuation techniques used to measure the fair value of the assets are consistently applied and described in Note 2, “Summary of Significant Accounting Policies.”

Composition of Plan Assets


	As of
	December 31, 2022		December 31, 2021
Global equity securities	$	33	$	61
Debt securities		174		200
Real estate		12		20
Private equities and other investments		59		70

Plan assets measured at fair value		278		351
Global equity securities		34		83
Debt securities		31		47
Real estate		13		11
Private equities and other investments		69		61

Plan assets measured at net asset value		147		202

Total plan assets	$	425	$	553

Those investments that were measured at net asset value as a practical expedient were excluded from the fair value hierarchy. Investments with a fair value of $61 million and $76 million as of December 31, 2022 and 2021, respectively, were classified within Level 3 of the fair value hierarchy and primarily relate to private equities, insurance contracts, and real estate. The remaining investments were all considered Levels 1 and 2.

Weighted Average Asset Allocation of Pension Plans


	2022
	Target			Actual
Global equity securities		17	%		16	%
Debt securities (including cash equivalents)		44	%		48	%
Real estate		6	%		6	%
Private equities and other instruments		33	%		30	%

Plan fiduciaries of our pension plans set investment policies and strategies for the assets held in trust and oversee their investment allocations, which includes selecting investment managers, commissioning periodic asset-liability studies, and setting long-term strategic targets. Long-term strategic investment objectives take into consideration a number of factors, including the funded status of the plans, a balance between risk and return, and plans’ liquidity needs. The plans utilize a combination of long-dated corporate bonds, treasuries, and derivatives to implement its investment strategies as well as for hedging asset and liability risks. Target allocation percentages are established at an asset class level by plan fiduciaries. Target allocation ranges are guidelines, not limitations, and occasionally plan fiduciaries will approve allocations above or below a target range.

The entire disclosure for retirement benefits.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Contract and Other Deferred Assets [Abstract]

Revenue Recognition (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2023

Dec. 31, 2022

Summary of contract and other deferred assets

Contract and Other Deferred Assets


	As of
	March 31, 2023		December 31, 2022
Contract assets	$	593	$	584
Other deferred assets		390		405

Contract and other deferred assets		983		989
Non-current contract assets (a)		38		37
Non-current other deferred assets (a)		81		82

Total contract and other deferred assets	$	1,102	$	1,108

(a)	Non-current contract and other deferred assets are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Contract and Other Deferred Assets


	As of
	December 31, 2022		December 31, 2021
Contract assets	$	584	$	433
Other deferred assets		405		369

Contract and other deferred assets		989		802
Non-current contract assets (a)		37		19
Non-current other deferred assets (a)		82		77

Total contract and other deferred assets	$	1,108	$	898

(a)	Non-current contract and other deferred assets are recognized within All other assets in the Combined Statements of Financial Position.

Discontinued Operations - Summary Of Results of Discontinued Operations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Discontinued Operations [Line Items]
revenues			$ 830
Selling, general, and administrative			142
Research and development			44
Operating income of discontinued operations			386
Non-operating income (loss)			(7)
Gain on disposal	$ 6	$ 16	12,782
Income of discontinued operations, before income taxes	6	16	13,161
Benefit (provision) for income taxes	12	2	(1,317)
Income from discontinued operations, net of taxes	18	18	11,844
Less net (loss) attributable to noncontrolling interests			(5)
Income of discontinued operations, net of taxes and amounts attributable to noncontrolling interests	$ 18	$ 18	11,839
Product [Member]
Discontinued Operations [Line Items]
revenues			785
Operation costs			230
Service [Member]
Discontinued Operations [Line Items]
revenues			45
Operation costs			$ 28

Supplemental Financial Information - Summary of Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Noncontrolling Interest [Abstract]
Balance at beginning of period	$ 230	$ 220	$ 220	$ 223	$ 217
Net income attributable to redeemable noncontrolling interests	10	9	47	39	48
Distributions to and exercise of redeemable noncontrolling interests			(37)	(42)	(42)
Redemption value adjustments	183	0
Exercise of redeemable noncontrolling interests	(222)	0
Balance at end of period	$ 201	$ 229	$ 230	$ 220	$ 223

Postretirement Benefit Plans - Summary of Accumulated Benefit Obligations and Unrecognized Gain (Detail) - USD ($) $ in Millions	Jan. 01, 2023	Dec. 31, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligations	$ 22,906	$ 687	$ 912
Unrecognized gain to be recorded in AOCI	2,481
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligations	21,696
Unrecognized gain to be recorded in AOCI	1,258
Other Postretirement Benefits Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligations	1,210
Unrecognized gain to be recorded in AOCI	$ 1,223

Condensed Consolidated and Combined Statements of Financial Position - USD ($)
$ in Millions

Mar. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Statement of Financial Position [Abstract]

Cash, cash equivalents, and restricted cash

$ 2,327

$ 1,445

$ 556

Receivables – net of allowances of $91 and $107

3,373

3,295

3,227

Due from related parties

Inventories

2,256

^[1]

2,155

^[1],[2]

1,946

^[2]

Contract and other deferred assets

983

989

802

All other current assets

634

417

437

Current assets

9,604

8,318

7,000

Property, plant, and equipment – net

2,327

2,314

2,235

Goodwill

12,924

12,813

12,892

Other intangible assets – net

1,494

1,520

1,847

Deferred income taxes

4,336

1,550

1,287

All other assets

1,952

1,024

1,047

Total assets

32,637

27,539

26,308

Short-term borrowings

Accounts payable

2,977

2,944

2,540

Due to related parties

186

146

189

Contract liabilities

2,031

1,896

1,864

All other current liabilities

3,037

2,190

2,162

Current liabilities

8,236

7,191

6,761

Long-term borrowings

10,234

8,234

Compensation and benefits

5,372

549

751

Deferred income taxes

370

385

All other liabilities

1,834

1,603

1,484

Total liabilities

25,740

17,947

9,412

Commitments and contingencies

Redeemable noncontrolling interests

201

230

220

Common stock, par value $0.01 per share, 100,000 shares authorized, 100 shares issued and outstanding as of 2022; none issued and outstanding as of 2021

Additional paid-in capital

6,425

Retained earnings

185

Net parent investment

11,235

17,692

Accumulated other comprehensive income (loss) – net

(1,878)

(1,037)

Total equity attributable to GE HealthCare

6,690

9,357

16,655

Noncontrolling interests

Total equity

6,696

9,362

16,676

Total liabilities, redeemable noncontrolling interests, and equity

$ 32,637

$ 27,539

$ 26,308

[1]	Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.
[2]	Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Combined Statements of Financial Position. See the supplemental table for “All Other Current and Non-Current Assets” for further information.

Supplemental Financial Information - Summary of Redeemable Noncontrolling Interests (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Noncontrolling Interest [Abstract]
Redemption value adjustments	$ 183	$ 0
Exercise of redeemable noncontrolling interests	$ (222)	$ 0

Supplemental Financial Information - Summary of Other Current and Non-Current Assets (Details) - USD ($)
$ in Millions

Mar. 31, 2023

Dec. 31, 2022

Dec. 16, 2022

^[1]

Dec. 31, 2021

Other Assets [Abstract]

Prepaid expenses and deferred costs

$ 163

Financing receivables – net

$ 100

$ 97

^[1]

Derivative instruments

Equity method and other investments

^[2]

All other current assets

634

417

437

322

341

Financing receivables – net

196

$ 196

186

^[1]

Long-term receivables – net

145

138

Long-term inventories

104

123

Long-term contract and other deferred assets

119